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Abstract  
Periodontitis is a multi-factorial disease characterised by the loss of connective tissue 
and underlying alveolar bone leading to the loss of teeth. Porphyromonas gingivalis (P. 
gingivalis) is a gram-negative black pigmented anaerobe associated with chronic 
periodontitis. Porphyromonas gingivalis possesses a range of virulence factors 
including gingipains, lipopolysaccharide (LPS) and fimbriae. Receptor activator of 
nuclear factor-κB ligand (RANKL) induces bone resorption whilst osteoprotegerin 
(OPG) blocks this process by binding to RANKL and acting as a decoy receptor. 
Cyclooxygenase-2 (COX-2) is an enzyme responsible for the synthesis of prostaglandin 
E2 (PGE2), a potent inflammatory mediator of bone resorption. Mitogen-activated 
protein kinases (MAPK) are intra-cellular signaling proteins that control fundamental 
cellular events, with implications in inflammation and bone metabolism.  
 
This thesis aimed to investigate the effect of P. gingivalis on bone marrow stromal cells, 
primarily on the regulation of molecular mechanisms involved in bone resorption, using 
gene and protein expression assays, and secondarily on changes in their global 
transcriptional profile, using microarray technology.  
 
It was determined that P. gingivalis upregulated RANKL and downregulated OPG gene 
and protein expression, resulting in an increased RANKL/OPG expression ratio. These 
regulations were partly attributed to its LPS and an unidentified synergistic factor. 
PGE2 was a key mediator in this regulation of RANKL expression. Further to this, P. 
gingivalis was shown to signal through p38 MAPK, contributing to the PGE2-mediated 
RANKL induction. The extension of this work using microarray technology 
demonstrated that in the present experimental system P. gingivalis positively regulates a 
broad spectrum of genes involved in promoting inflammation and bone destruction. 
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This thesis shows that P. gingivalis can exert its virulence on bone marrow stromal 
cells. An interplay of bacterial and host factors leads to the activation of molecular 
mechanisms of bone resorption, which may be implicated in initiating periodontal 
disease. Moreover, the identified mediators of bone resorption may serve as potential 
targets for treating P. gingivalis-associated periodontitis. 
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1. Literature Review 
1.1 Periodontitis 
Periodontitis is an inflammatory multi-factorial disease that is characterised by the loss 
of periodontal connective tissue and underlying alveolar bone, eventually resulting in 
the loss of teeth. The aetiology of periodontitis is complex with multiple factors 
contributing to the initiation and progression of disease. Such factors include the 
prevalence of specific gram negative bacteria, a genetic predisposition and poor oral 
hygiene. 
A shift in the predominance of 
subgingival microflora from 
gram positive to gram 
negative anaerobic bacteria 
can predispose to disease 
(Marsh 1994). There are 
several theories explaining the 
role of plaque bacteria in 
disease. The “specific plaque 
hypothesis” by Loesche states 
that out of a diverse number of 
bacteria present within the 
plaque microflora only a small 
number of bacteria are 
involved in causing disease (Loesche 1976). Conversely the “non-specific plaque 
hypothesis” proposed by Theilade explains that many bacteria present within the 
biofilm are able to contribute to disease regardless of plaque composition (Theilade 
Fig. 1. Structure of the tooth and supporting tissues in 
health and disease. 
In health there are normal levels of bone and gingival tissue. 
Gingival detachment and loss of alveolar bone leads to 
periodontal bone loss. 
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1986). A modified hypothesis presented by Marsh suggests that an ecological shift in 
subgingival microflora may result from triggers in changes of the micro-environmental 
conditions, such as high pH and low redox potential, which may favour the growth of 
anaerobic organisms (Marsh 2003). 
1.1.1 Risk factors for periodontitis 
It may not be sufficient for individuals who only harbour periodontal pathogens to 
develop periodontitis as a combination of additional factors is necessary. Environmental 
risk factors associated with periodontal disease include poor oral hygiene, smoking and 
psychological stress. Poor oral hygiene leads to an accumulation of dental plaque and 
has been shown to positively correlate with periodontal disease progression (Stabholz, 
Soskolne et al. 2010). Although the precise mechanisms are unclear, there a several 
possible reasons why smoking may affect periodontal disease. It has been suggested that 
smokers may harbour more pathogenic microbial flora compared to non-smokers, have 
an impaired local immune response and reduced healing potential of periodontal tissue 
(Kinane and Chestnutt 2000). Individuals who are under psychological stress are also 
more likely to develop clinical attachment and tooth loss where the host response may 
be compromised (Van Dyke and Sheilesh 2005). Since aggressive periodontitis shows 
familial aggregation, some risk factors of disease development may be conferred by 
genetic elements (Stabholz, Soskolne et al. 2010). 
 
A number of diseases can predispose or exacerbate underlying periodontal disease. In 
the 1999 classification of periodontal diseases and conditions (Armitage 1999), if a 
systemic disease profoundly affects the development or progression of periodontitis, the 
disease category is classed as ‘Periodontitis as Manifestation of Systemic Diseases’. 
Such diseases include diabetes mellitus, osteoporosis, obesity and rheumatoid arthritis 
(Stabholz, Soskolne et al. 2010).  
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1.1.2 Disease initiation and progression 
The disease is initiated through oral pathogenic bacteria which attach onto tooth 
surfaces and form complex “biofilm” communities. Within the dental biofilm, bacterial 
virulence factors elicit inflammation-mediated damage to the underlying periodontal 
tissues. A pathological space between the teeth and gums is then formed, which is called 
a periodontal pocket (Fig. 1). Dental biofilms accumulate in these pockets leading to 
further destruction of soft tissue and bone. At least 500 different bacterial species 
associated with dental biofilms have been isolated from periodontal pockets, including 
Aggregatibacter actinomycetemcomitans (A. Actinomycetemcomitans), Tanerella 
forsythia (T. forsythia), Campylobacter rectus, Prevotella intermedia and 
Porphyromonas gingivalis (P. gingivalis) (Colombo, Silva et al. 2006). The two 
periopathogens that have been best characterised are A. actinomycetemcomitans and P. 
gingivalis, which are frequently associated with localised aggressive periodontitis 
(Zambon, Christersson et al. 1983) and chronic periodontitis (Van Winkelhoff, Loos et 
al. 2002; Yang, Huang et al. 2004), respectively. 
 
Aggressive periodontitis predominantly affects younger individuals where there is a 
rapid rate of progression of disease. In localised aggressive periodontitis, there are often 
lower levels of inflammation, thinner biofilm formation and fewer teeth affected. In 
generalised aggressive periodontitis often mostly the first permanent incisors and molars 
are affected. In chronic periodontitis, the disease progresses at a much slower rate and 
tends to affect older patients. There are also generalised and localised versions of 
chronic periodontitis differentiated by the number of teeth affected. In both forms of 
chronic periodontitis there tends to be moderate to heavy deposits of plaque and 
calculus. Another key difference between aggressive and chronic periodontitis is that 
the composition of the microbiota is different in each disease. Both types of disease, if 
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left untreated, result in periodontal tissue damage and eventual loss of teeth. Anti-
infective treatment such as scaling, root planing and the use of antiseptics and 
antibiotics is effective in managing both forms of the disease (Armitage and Cullinan 
2010; Armitage, Cullinan et al. 2010). 
1.2 Bone 
1.2.1 Bone as a tissue 
Bone is a type of connective tissue forming the main part of the skeletal system. There 
are two main types of bone, cancellous and cortical bone. Cancellous bone is defined as 
the inner layer that contains the bone marrow, whereas the denser cortical bone forms 
the outer part. Bone serves four main functions; to support the body and provide the site 
of attachment for muscles and tendons; to protect the internal organs and the bone 
marrow; and to provide calcium and phosphate reservoirs for the body for which bone 
plays a metabolic function. There are four main cell types in bone including 
osteoprogenitor cells, 
osteoblasts, osteocytes 
and osteoclasts. 
Physiologically, there is a 
tight balance between 
bone resorption and bone 
formation in the adult 
skeleton that determines 
the levels of bone mass. 
The two principle cells 
types involved in bone metabolism are osteoblasts and osteoclasts (Fig. 2.). Osteoblasts 
are bone forming cells that are derived from mesenchymal stromal cells, whereas 
Fig. 2. The different stages of bone remodelling.  
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osteoclasts are bone resorbing cells that are derived from haematopoietic bone marrow 
cells (Long 2012). Osteocytes, which are former osteoblasts, are embedded in the bone 
matrix and behave as mechanosensory cells prior to osteoclastic bone resorption, among 
other functions. Cells from the bone marrow have the potential to differentiate into 
multiple cell types under appropriate stimulation. For example, bone marrow stromal 
osteoprogenitor cells possess the potential to differentiate into osteoblasts, adipocytes 
and chondrocytes (Gregory, Prockop et al. 2005).  
 
The extracellular matrix (ECM) of bone is composed of two parts. The organic ECM 
consists mainly of type I collagen, which composes about 90% of the ECM with the 
remainder composed of ground substance including proteoglycans, glycoproteins, 
hylaronic acid and water and the inorganic matrix, consisting of hydroxyapatite. When 
there is a physiological need for replacement of bone or when bone is damaged, 
osteocytes and locally recruited inflammatory cells release cytokines and chemotactic 
signals that attract multi-nucleated osteoclasts to the site requiring resorption (Clarke 
2008). The multi-nucleated osteoclasts then attach to the bone surface and release 
proteolytic enzymes such as cathepsin K that digests the bone matrix. Following bone 
resorption, osteoclasts depart from the resorbed area (also known as “Howship’s 
lacuna”), and osteoblasts are recruited to the site and express genes required for the 
synthesis of the ECM. First the soft “osteoid” organic matrix is synthesised and 
secreted, which is subsequently mineralised with hydroxyapatite, as the bone maturates. 
 
Other important molecules of osteoblastic function include the expression of alkaline 
phosphatase and the production of matrix bone proteins such as osteonectin, osteopontin 
and osteocalcin, which is a bone specific protein (Hughes, Turner et al. 2006). The key 
transcription factors that are involved in osteoblast differentiation include core binding 
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factor 1 (Cbfa-1), (Ducy, Zhang et al. 1997) and osterix (Osx) (Nakashima, Zhou et al. 
2002) and in Cbfa-1 and Osx knockout mice no bone was synthesised (Komori 2000; 
Nakashima, Zhou et al. 2002). In Osx-knockout mice Cbfa-1 was expressed whilst in 
Cbfa-1 null mice Osx was not expressed, indicating Osx is downstream of Cbfa-1 
(Nakashima, Zhou et al. 2002). Cbfa-1 has also been reported to interact with the 
osteocalcin promoter inducing its expression (Ducy, Zhang et al. 1997), contribute to 
the expression of osteoprotegerin (OPG), (an osteclastogenesis inhibitor) 
(Thirunavukkarasu, Halladay et al. 2000) and also positively regulate type I collagen 
(Kern, Shen et al. 2001)  
 
There are a variety of families of growth factors and cytokines that can regulate 
osteoblastic differentiation including transforming growth factor β (TGF-β), fibroblast 
growth factor (FGF) and insulin-like growth factors (Hughes, Turner et al. 2006). Bone 
morphogenic proteins (BMPs) are members of the TGF-β family and are secreted 
signalling molecules that can induce bone formation (Wang, Rosen et al. 1990). Bone 
marrow stromal cells are known to respond to recombinant BMP2 by expressing 
osteoblastic markers including alkaline phosphatase and osteocalcin (Thies, Bauduy et 
al. 1992). Glucocorticoids such as dexamethasone are also inducers of osteoblastic 
differentiation, upregulating markers such as alkaline phosphatase, and bone 
mineralisation (Cheng, Yang et al. 1994). Conversely glucocorticoids can also suppress 
osteoblast formation inducing osteoporosis (Canalis, Mazziotti et al. 2007). 
1.2.2 Bone resorption 
Bone resorption is the process of degradation of bone by osteoclasts, which is required 
for the physiological replacement of bone. In the bone remodelling cycle bone 
formation and resorption are coupled meaning that resorbed bone is always being 
replaced by newly synthesised bone. When bone formation and bone resorption are 
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uncoupled this can lead to pathological conditions including osteoporosis, osteopetrosis, 
periodontal disease and rheumatoid arthritis (Teitelbaum and Ross 2003). The 
molecular mechanisms responsible for controlling rates of bone resorption are 
dependent on the interplay of receptor activator of nuclear factor-κB ligand (RANKL) 
and osteoprotegerin (OPG). The interaction between membrane bound or soluble 
RANKL binding to its receptor RANK induces osteoclastogenesis (Fig.3). The decoy 
receptor OPG can bind to RANKL preventing this interaction, effectively inhibiting 
osteoclastogenesis and bone resorption. Ultimately it is the ratio of RANKL to OPG 
that controls the rate of bone resorption and an increase in RANKL relative to OPG will 
increase bone resorption.  
1.2.3 Receptor activator of nuclear factor-κB ligand (RANKL) 
RANKL is a 40 kilodalton (kDa) member of the tumor necrosis factor (TNF) ligand 
family. It is classified as a type II membrane-bound protein composed of a large 
extracellular receptor and a membrane-bound domain. Several groups discovered 
RANKL and identified it as the ligand that binds OPG (Wong, Rho et al. 1997; Lacey, 
Timms et al. 1998; Yasuda, Shima et al. 1998; Kong, Yoshida et al. 1999). Apart from 
its role in bone resorption, RANKL has also been reported to be involved in mammary 
gland development during pregnancy, cancer metastasis and fever control (Hanada, 
Hanada et al. 2011). 
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Physiologically, RANKL is required for normal skeletal and lymph node development. 
In RANKL knockout mice, osteoclast formation is absent, teeth fail to erupt and mice 
display severe forms of osteopetrosis. They also exhibit impaired differentiation of B 
and T lymphocytes and lack all lymph nodes (Kong, Yoshida et al. 1999).  
 
 
 
 
1. Macrophage colony stimulating 
factor (M-CSF) is secreted by 
stromal cells and osteoblasts and 
binds to its receptor cFMS on 
haematopoietic cells.  
 
2. Thus stimulated, haematopoietic 
cells proliferate and differentiate 
into early osteoclast cells.  
 
3. RANK, present on pre-osteoclast 
cells, binds to RANKL, pre-
osteoclasts are committed to 
osteoclastogenesis.  
 
4. They then fuse and differentiate 
further into latent, multi-nucleated 
osteoclasts, which are recruited to 
the site requiring bone absorbtion.  
 
5. As a result of the RANKL/RANK 
interaction, signal transduction is 
initiated which triggers the export of 
hydrogen ions, expression of 
tartrate-resistant acid phosphatase 
(TRAP) and release of cathepsin K, 
(a cysteine protease). These events 
are followed by degradation of 
underlying bone.  
 
Alternatively,  OPG is a soluble 
decoy receptor (also secreted by a 
variety of cells) that can bind to 
RANKL inhibiting its interaction 
with RANK effectively preventing 
osteoclastogenesis. 
Fig. 3. Interactions between RANKL, RANK and OPG in osteoclastogenesis.  
RANKL mainly exists as a membrane bound protein and is found on the cell surface of 
osteoblasts and stromal cells (Udagawa, Takahashi et al. 1999), but can be cleaved by 
proteases, such as TNF-α convertase rendering RANKL a soluble protein (Lum, Wong 
et al. 1999). The expression of RANKL is controlled by various stimuli. (Lum, Wong et 
al. 1999). Hormones, such as parathyroid hormone, 1,25-dihydroxy vitamin D3, and 
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prostaglandin E2 (PGE2) (Udagawa, Takahashi et al. 1999), and cytokines, such as 
TNF- α, Interleukin (IL)-1β, and IL-6, all have the potential to induce the expression of 
RANKL (Nakashima, Kobayashi et al. 2000). RANKL has been shown to be expressed 
in abundance on activated T-cells (Wong, Rho et al. 1997) and has been demonstrated 
to cause bone loss in vivo mediated by RANKL in a rat adjuvant arthritis model (Kong, 
Feige et al. 1999). RANKL is also expressed in periodontal tissues, including 
periodontal ligament (PDL) cells (Hasegawa, Yoshimura et al. 2002), as well as skin 
fibroblasts upon stimulation (Quinn, Horwood et al. 2000). Conversely, dental pulp and 
PDL cells have been demonstrated to constitutively express RANKL in vitro in the 
absence of stimulants (Uchiyama, Nakamichi et al. 2009). More recently it has emerged 
that osteocytes are the main source of RANKL involved during growth and bone 
remodelling (Nakashima, Hayashi et al. 2011; Xiong, Onal et al. 2011).  
 
Several periodontal bacterial species, including A. actinomycetemcomitans and P. 
gingivalis have also been shown to induce RANKL expression in osteoblasts (Okahashi, 
Inaba et al. 2004), gingival fibroblasts, PDL cells (Belibasakis, Johansson et al. 2005) 
and T cells (Belibasakis, Reddi et al. 2011). Moreover A. actinomycetemcomitans LPS 
stimulates RANKL induction in human PDL cells (Tiranathanagul, Yongchaitrakul et 
al. 2004; Kajiya, Giro et al. 2010). 
1.2.4 Receptor activator of nuclear factor-κB (RANK) 
RANK is a type II transmembrane protein receptor, member of the TNF receptor family 
and is mainly expressed in osteoclast progenitor cells, osteoclasts and B- and T- 
lymphocytes (Anderson, Maraskovsky et al. 1997). It is now known that RANK is the 
receptor for RANKL and binding of RANK results in osteoclastogenesis (Hsu, Lacey et 
al. 1999). Similarly to RANKL deficient mice, RANK knockout mice also show an 
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osteopetrotic phenotype, a deficiency in B cells and a lack of peripheral lymph nodes 
(Dougall, Glaccum et al. 1999).  
1.2.5 Osteoprotegerin (OPG) 
OPG is a secreted, 60 kDa protein, also a member of the TNF receptor family that 
effectively acts as a decoy receptor for RANKL, which inhibits bone resorption by 
binding to RANKL, and blocking it from interacting with its receptor RANK (Simonet, 
Lacey et al. 1997; Yasuda, Shima et al. 1998). OPG, unlike RANKL, is widely 
expressed at high levels in osteoblasts, stromal cells, endothelial cells and fibroblasts 
(Lerner 2004). Mice that are deficient in OPG show signs of an osteoporotic phenotype 
with a decrease in trabecular and cortical bone density (Bucay, Sarosi et al. 1998).  
1.2.6 Regulation of the RANKL-OPG system 
The regulation of OPG and RANKL is critical for normal bone metabolism and is 
controlled by a wide range of factors. Cytokines such as IL-1β, IL-6 and IL-11 decrease 
OPG expression, whereas IL-13, INF-γ and TGF-β1 increase OPG and, additionally, 
suppress RANKL (Nakashima, Kobayashi et al. 2000). When the RANKL/OPG ratio is 
increased, this would suggest an increase in osteoclastogenesis. Both RANKL and OPG 
expression can be increased by IL-1, IL-6, IL-11, oncostatin M and TNF-α. (Hughes, 
Turner et al. 2006). It has been reported that OPG can suppress the shedding of RANKL 
from murine osteoblasts (Nakamichi, Udagawa et al. 2007). The stage of osteoblast 
differentiation is also thought to have an effect on the RANKL/OPG ratio. It has been 
reported that the basal mRNA level of RANKL was consistent at all stages of osteoblast 
differentiation but increased upon stimulation of 1,25-dihydroxy vitamin D3. In contrast, 
OPG levels were unaffected by 1,25-dihydroxy vitamin D3 stimulation, but levels of 
OPG were increased after mineralisation suggesting that the stage of differentiation of 
osteoblasts can affect rates of osteoclastogenesis (Thomas, Baker et al. 2001).  
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1.2.7 The RANKL-OPG system in periodontal disease 
It has been established that the RANKL/OPG expression ratio is higher in chronic 
periodontitis sufferers compared to healthy subjects (Liu, Xu et al. 2003). Gingival 
crevicular fluid (GCF) is a serum exudate located in the gingival crevice that contains 
antibodies, leukocytes and inflammatory mediators (Uitto 2003) and can serve as a 
useful biological media for periodontal disease progression. Accordingly, GCF tested 
from chronic periodontitis patients shows that RANKL is upregulated and OPG is 
downregulated compared to healthy patients (Mogi, Otogoto et al. 2004; Bostanci, 
Ilgenli et al. 2007). In addition, in gingival tissue taken from patients with both 
aggressive and chronic periodontitis, the RANKL/OPG mRNA expression ratio was 
increased compared to healthy controls, and RANKL mRNA expression was higher in 
aggressive compared with chronic periodontitis (Bostancı, İlgenli et al. 2007). These 
studies provide a sound basis to use the RANKL/OPG ratio to be a potential biomarker 
for diagnosis and disease progression. Interestingly, after periodontal treatment in 
patients with aggressive and chronic periodontitis, the RANKL/OPG ratio remained the 
same even though a clinical improvement was observed (Bostanci, Saygan et al. 2011). 
Therefore the RANKL/OPG ratio may serve as a good biomarker for periodontitis it 
may not necessarily be an effective prognostic factor of the disease, or an indicator of 
clinical improvement (Belibasakis and Bostanci 2012). 
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1.2.8 COX-2/PGE2 involvement in periodontal disease 
Prostaglandins are short-lived bioactive lipid messengers derived from the breakdown 
of arachidonic acid. It has been shown that PGE2 is the most abundant prostanoid in 
humans and has fundamental biological roles in the immune system, the central nervous 
system and in the regulation of bone formation and healing (Legler, Bruckner et al. 
2010). Cyclooxygenase-2 (COX-2) is the enzyme responsible for the breakdown of 
arachidonic acid into its metabolite PGE2 and is inducible under inflammatory 
conditions. Several cytokines and growth factors can induce COX-2 expression, such as 
IL-1α, IL-1β and TGF-β (Morita 2002). Over-expression of PGE2 can lead to chronic 
pathologic conditions and diseases including various types of cancer and neurological 
disorders (Legler, Bruckner et al. 2010). Furthermore, there is evidence to suggest that 
PGE2 is involved in the pathogenesis of periodontitis. COX-2 expression and PGE2 
levels have been shown to be elevated in chronic periodontitis compared to health 
(Ohm, Albers et al. 1984; Zhang, Engebretson et al. 2003; Mesa, Aguilar et al. 2010). 
Prostaglandin-2 is proposed to be an inflammatory mediator of tissue destruction since 
levels of PGE2 increased in GCF of periodontitis patients, and was linked with severity 
disease (Offenbacher, Odle et al. 1984), indicating that PGE2 levels in GCF may prove 
to be a useful biomarker of disease progression. Moreover, COX-2 expression has been 
show to be linked to alveolar bone loss in a rat model of periodontitis (Lohinai, 
Stachlewitz et al. 2001). These studies implicate COX-2 and PGE2 as important 
inflammatory mediators in tissue and bone destruction during periodontitis. 
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1.3 Microbiology of periodontal diseases 
There are over 500 different microbial species exist within the periodontium (Moore 
and Moore 1994). When there is a shift in gram positive bacteria to gram negative 
bacteria (Marsh 1994) accompanied by a deregulated immune system, this can lead to 
the pathological condition periodontitis.  
 
Gram positive bacteria are associated with supragingival (above the gingival margin, or 
“gumline”) plaque whilst gram negative anaerobic bacteria tend to be associated with 
subgingival (below the “gumline”) plaque (Listgarten 1994). In health, the plaque 
biofilm mainly consists of gram-positive species such as Streptococcus and 
Actinomyces, whereas in patients who present with periodontitis the main predominant 
species consists of gram-negative bacteria such as the Preponema species, Prevotella 
intermedia and P. gingivalis (Listgarten 1994). The initial formation of plaque biofilm 
occurs when bacteria adhere to the salivary pellicle (a thin layer consisting of saliva and 
gingival crevicular fluid) that are present on teeth and gingival epithelial tissue. The 
early colonisers such as Streptococcus gordini (S. gordini), S. mitis and S. oralis bind to 
salivary receptors which then permits sequential binding and coaggregation of bacteria 
forming the plaque biofilm (Kolenbrander, Palmer et al. 2010). For example, P. 
gingivalis, which is a secondary or late coloniser, has been demonstrated to bind to the 
early colonisers S. mitis and S. oralis (Lamont, Hersey et al. 1992). Studies 
investigating the architecture of the bacterial oral biofilm determined that P. gingivalis 
appears in micro-colonies within the outer layer of the biofilm (Zijnge, van Leeuwen et 
al. 2010). 
 
A key study investigating the bacterial profile of diseased periodontal tissue identified 
five distinct bacterial complexes within subgingival plaque. The designated ‘red 
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complex’ of bacteria, consisting of P. gingivalis, Treponema denticola and T. forsythia, 
was the main complex associated with periodontitis since they were linked to clinical 
parameters such as increasing pocket depth and bleeding upon probing. A further four 
bacterial complexes were described associated to various degrees with diseased 
locations named the orange, yellow, green and purple complexes with the purple being 
the least associated with diseased sites (Socransky, Haffajee et al. 1998). 
 
A. actinomycetemcomitans is gram-negative bacterium associated with localised 
aggressive periodontitis (Slots and Ting 1999). Its main distinguishing virulence factor 
is a leukotoxin that lyses host neutrophils and monocytes (Tsai, McArthur et al. 1979). 
The JP2 clone of A. actinomycetemcomitans has a 530 base pair deletion in the 
promoter region of the leukotoxin gene operon, leading to increased leukotoxin activity 
contributing to its virulence potential (Brogan, Lally et al. 1994). In a longitudinal study 
it was discovered that individuals who carried the JP2 clone compared to non-JP2 
clones had an increased risk of developing periodontal attachment loss (Haubek, Ennibi 
et al. 2008).  
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1.4 Porphyromonas gingivalis 
Porphyromonas gingivalis is a gram-negative black pigmented anaerobe. It has been 
isolated from the oral cavity and periodontal pockets of periodontitis patients and is 
strongly associated with chronic periodontitis (Zambon, Reynolds et al. 1981). In 
addition, P. gingivalis challenge in animal models has been demonstrated to induce 
periodontitis resulting in clinical bone loss (Roeterink, van Steenbergen et al. 1984; 
Evans, Klausen et al. 1992). 
 
Bacterial virulence factors are molecules expressed by pathogenic bacteria that act alone 
or synergistically, to cause disease by interfering in normal host cell processes. There 
are specific virulence factors of P. gingivalis, including lipopolysaccharide (LPS), 
gingipains, fimbriae and haemaglutinins that are have been implicated in contributing to 
tissue and bone destruction in periodontitis (Malek, Fisher et al. 1994; Reife, Shapiro et 
al. 1995). Recently it has been demonstrated that the P. gingivalis capsule may be an 
important virulence factor. It can evade the host immune system and therefore persist by 
reducing phagocytosis leading to bacterial survival. There is an increased virulence 
compared with non-capsulated strains in the mouse abscess model (Hajishengallis 2009; 
Singh, Wyant et al. 2011). 
1.4.1 P. gingivalis LPS 
Porphyromonas gingivalis LPS is considered an important virulence factor that can 
contribute to the establishment and development of periodontal disease by this species 
(Wang and Ohura 2002). It is a potent inducer of an inflammatory response, elevating 
levels of TNF-α, IL-1 and IL-1β. P. gingivalis LPS contributes to bone loss and has also 
been shown to inhibit osteoblastic differentiation (Kadono, Kido et al. 1999). 
 34
1.4.2 Structure of LPS 
Lipopolysaccharide is a major component of the gram-negative cell wall and is essential 
for cell survival and stability. It also plays a pivotal role in the evasion of the host 
immune response (Erridge, Bennett-Guerrero et al. 2002). LPS consists of three main 
components; the O antigen, core polysaccharide and lipid A (Fig.4). The O antigen is 
the outermost part of the molecule and consists of repeating units between one and eight 
glycosyl residues.  
 
 
 
Fig. 4. The general structure of lipopolysaccharide. 
Breaking down the components of LPS:  
the O- polysaccharide, the core polysaccharide and lipid A. 
Lipopolysaccharide is recognised by the innate immune response and is highly variable 
with hundreds of serotypes being identified. The core polysaccharide is comprised of 
hexose sugars such as glucose, galactose, N-acetyl galactosamine and N-acetyl 
glucosamine and is more conserved compared to the O antigen. The core polysaccharide 
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is attached to lipid A through a specific sugar called 2-keto-3-deoxyoctulosonic acid 
(KDO). Lipid A is the most conserved part of LPS and is responsible for the majority of 
endotoxic activity, although KDO and the polysaccharide component can also 
contribute to the induction of cytokines (Rietschel, Brade et al. 1987; Haeffner-
Cavaillon, Caroff et al. 1989).  
 
Lipid A is composed of a β-D-GlcN-(1-6)-α-D-GlcN disaccharide that carries two 
phosphoryl- groups at position 1 and 6 of the two sugars. To this a number of acyl- 
chains can be attached. It is now known that the number and length of the acyl chains 
present and phosphorylation state of the disaccharide backbone heavily influences 
endotoxic activity. It has been shown that full endotoxic activity has been reached by E. 
coli lipid A, which is diphosphorylated and is hexa-acylated. It has been shown that E. 
.coli LPS elicited a stronger immune response and higher biological activity compared 
to P. gingivalis LPS (Reife, Shapiro et al. 1995). One group has investigated whether 
the three-dimensional shape of lipid A affects its bioactivity (Schromm, Brandenburg et 
al. 2000; Seydel, Oikawa et al. 2000). E. coli, which is hexa-acylated, has a conical 
shape and is highly endotoxic, whereas tri-acylated cylindrical shapes such as in 
Rhodobacter capsulatum do not induce production of potent inflammatory mediators, 
such as IL-6 (Erridge, Bennett-Guerrero et al. 2002). 
1.4.3 P. gingivalis lipid A 
Porphyromonas gingivalis is unusual compared to other gram-negative species in that it 
contains lipid A heterogeneity which differs in the number and length of acyl- chains 
present and also varies in the number of phosphate groups attached. P. gingivalis LPS 
was initially thought to have very little endotoxic activity compared to E. coli LPS, but 
studies have reported that the former can also induce inflammatory mediators in 
hyporesponsive LPS mice (Kirikae, Nitta et al. 1999). The main P. gingivalis lipid A 
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structures that have been characterised include tri-, tetra- and penta-acylated (Ogawa 
1993; Kumada, Haishima et al. 1995). Additionally, a degree of heterogeneity in fatty 
acid chain length and phosphorylation of the disaccharide backbone was discovered 
(Kumada, Haishima et al. 1995; Darveau, Pham et al. 2004; Dixon and Darveau 2005).  
1.4.4 LPS and Toll-like receptors 
The activation of signal transduction following recognition of LPS by toll-like receptors 
(TLRs) is an important part of the innate host immune response to infection by gram-
negative bacteria. It has been shown by various groups that P. gingivalis LPS is 
recognised by TLRs present on host cells (Hirschfeld, Weis et al. 2001; Darveau, Pham 
et al. 2004), initiating signal transduction and leading to the upregulation of 
inflammatory cytokines, which promote bacterial killing or bacterial clearance in the 
host. When LPS is shed, either by cell division or cell lysis, it becomes bound to serum 
circulating LPS binding protein (LBP) and is brought to either soluble or membrane-
bound cluster of differentiation factor 14 (CD14) (Hailman, Lichenstein et al. 1994), 
which is commonly expressed by monocytes and macrophages (Goyert, Ferrero et al. 
1988). Other cells such as gingival fibroblasts and B cells are also known to express 
CD14 (Ziegler-Heitbrock, Pechumer et al. 1994). This LPS-LPB complex binds to 
CD14. Subsequently, CD14 transfers the LPS to myeloid differentiation protein-2  
(MD-2), which is bound to the ectodomain of TLR. Thereafter, upon binding of LPS to 
MD-2, TLR receptor is rearranged and dimerises, inducing a number of signal 
transduction pathways that upregulate cytokine production (Medzhitov, Preston-
Hurlburt et al. 1997). 
 
Porphyromonas gingivalis LPS has been demonstrated to signal through both TLR-2 
and TLR-4 (Darveau, Pham et al. 2004). Tetra- and penta-acylated P. gingivalis LPS 
can interact with TLR-4 differently since, although both types of lipid A interact with 
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TLR-4, penta-acylated lipid A was found to be an agonist of E-selectin expression, 
whilst tetra-acylated lipid A failed to induce E-selectin (Reife, Coats et al. 2006). It has 
also been shown that synthetic penta-acylated and tri-acylated P. gingivalis lipid A both 
activate TLR-4/MD-2 complex but fail to activate TLR-2, like synthetic E. coli lipid A 
(Sawada, Ogawa et al. 2007). Cementoblasts also express TLR-2, TLR-4, MD-2 and 
CD14. When cementoblasts are challenged with P. gingivalis LPS, they are activated 
partially through TLR-2/MD-2 (Nociti, Foster et al. 2004). One study compared penta- 
and tetra-acylated P. gingivalis lipid A in murine cementoblasts and determined that the 
transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) was significantly induced and was activated through TLR-2 (Nemoto, Darveau et 
al. 2006). In addition, human gingival epithelial (HGE) cells are activated through TLR-
2 when challenged with P. gingivalis fimbriae (Asai, Ohyama et al. 2001). More 
recently it has been discovered that alternate lipid A structures of P. gingivalis can 
differentially regulate host cytokines, since penta-acylated lipid A was able to 
significantly upregulate IL-6 and IL-8 in human gingival fibroblasts (HGFs) compared 
to tetra-acylated lipid A indicating that P. gingivalis can use its lipid A heterogeneity to 
evade the host immune system (Herath, Wang et al. 2011).  
1.4.5 P. gingivalis gingipains 
The proteases involved in the destruction of periodontal tissue are collagenases (Geiger 
and Harper 1980), aminopeptidases (Kumagai, Yagishita et al. 2005) and trypsin-like 
enzymes (Kesavalu, Holt et al. 1996). P. gingivalis also produces proteases that are 
suggested to play a role in the virulence properties of this species, facilitating tissue 
invasion and destruction and altering the hosts immune response (Lamont and 
Jenkinson 1998). Table 1 describes some functions of P. gingivalis proteases within the 
host environment. 
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The proteases that cleave at amino-acids arginine and lysine are specific and have 
received much attention over the years for their potential as virulence factors. These 
proteases are from a family of Arg-X and Lys-X cysteine proteases, commonly called 
gingipains. There are two genes that encode Arg-specific gingipains, rgpA and rgpB. 
The major difference between rgpA and rgpB is the absence of a 
haemagglutinin/adhesion domain on rgpB. A double rgpA and rgpB mutant has been 
developed since disruption in both genes are required to fully abolish Arg-X proteases 
(Nakayama, Kadowaki et al. 1995; Aduse-Opoku, Davies et al. 2000). Lys-X gingipain 
is only encoded by one gene, named kgp. In kgp mutants the Lys-X activity is abrogated 
(Okamoto, Nakayama et al. 1998; Aduse-Opoku, Davies et al. 2000). P. gingivalis 
gingipains can potentially cause periodontal destruction through the upregulation of pro-
inflammatory cytokines, for example inducing IL-6 and IL-8 in monocytic cells 
(Uehara, Imamura et al. 2008) and upregulating TNF-α and IL-8 production in 
macrophages (Grenier and Tanabe 2010).  
 
Tissue damage Interference in host 
immune response 
Bacterial function 
Upregulation of pro-
inflammatory cytokines 
facilitating tissue and bone 
destruction 
Degradation of 
immunoglobulins 
Release of hemin and iron from 
host proteins for bacterial 
growth requirements 
 
Degradation of ECM proteins 
and hydrolysis of collagens 
Degradation of complement 
components or complement 
system activation 
 
Involvement in intracellular 
invasion 
 
Activation of matrix 
metalloproteinases 
Destruction of cytokines and 
chemokines 
 
Post-translational modification 
of fimbrillin and proteases 
Degradation of fibrinogen and 
fimbrin enhancing bleeding 
potential 
 
Cleavage of leukocyte surface 
receptors 
 
 
Inactivation of plasma 
proteinase inhibitors 
  
Activation of the kallikrein/kinin 
cascade releasing bradykin and 
increasing vascular permeability 
enhancement 
  
 Table 1. Summary of P. gingivalis protease functions within the host.  
Adapted from Lamont and Jenkinson 1998.  
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1.4.6 P. gingivalis fimbriae 
Fimbriae are thin, hair-like structures present on the surfaces of gram negative bacteria 
that mediate bacterial attachment to cells. The major fimbriae of P. gingivalis are 
constructed from fimbrillin encoded by the fim A gene (Lamont and Jenkinson 1998). 
FimA fimbriae bind to proteins such as collagen, laminin and fibronectin (Hamada, 
Amano et al. 1998). Studies show that P. gingivalis fimbria can attach to saliva coated 
surfaces and highlights the importance of fimbriae in establishing infection in the oral 
cavity (Lee, Sojar et al. 1992). The role of P. gingivalis fimbriae in periodontitis 
remains to be established but evidence suggests that they can upregulate inflammatory 
cytokines such as IL-6 and TNF-α and stimulate bone resorption in vitro (Kawata, 
Hanazawa et al. 1994). Furthermore P. gingivalis fimbriae have been shown to 
stimulate bone resorption in vivo as demonstrated by deactivating the fim A gene 
rendering P. gingivalis unable to produce fimbrillin (Malek, Fisher et al. 1994). 
1.4.7 P. gingivalis and the regulation of RANKL, OPG and PGE2 
Prostaglandin E2 is involved in the regulation of RANKL stimulated by P. gingivalis. 
Sonicates of three periodontopathogenic bacterial species, P. gingivalis, Treponema 
denticola and Treponema socranskii, induced RANKL and suppressed OPG expression 
in primary murine osteoblasts, and PGE2 was shown to be partly involved in these 
events (Choi, Moon et al. 2005). More recently, it has been shown that P. gingivalis 
culture supernatants induced RANKL and PGE2 production in Jurkat T-cells, 
suggesting that PGE2 may be involved in contributing to the induction of RANKL in 
these cells (Belibasakis, Reddi et al. 2011). 
 
Cementoblasts share similar characteristics with osteoblasts. It has been reported that 
PGE2 activates cementoclastogenesis by inducing RANKL via a specific EP4 receptor 
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pathway in murine bone marrow stromal cells and also downregulated the expression of 
OPG (Oka, Miyauchi et al. 2007). Recently it has been shown that a formalin-killed P. 
gingivalis strain used as a vaccine in non-human primates with induced periodontitis 
resulted in decreased PGE2 levels and reduction of alveolar bone loss (Roberts, Houston 
et al. 2004). These findings suggest that P. gingivalis can regulate RANKL, OPG and 
PGE2 expression, and these virulence properties may have potential implications in 
bone destruction occurring in periodontitis.  
1.5 Intracellular pathways involved in P. gingivalis  
Mitogen-activated protein kinases (MAPK) are a family of serine/threonine specific 
protein kinases that regulate many cellular processes including those involved in cell 
differentiation, proliferation, stress response and cell death. Dysregulation of MAPK 
signaling pathways can lead to a host of severe pathological conditions including 
cancer, diabetes and inflammatory disorders (Plotnikov, Zehorai et al. 2011). There are 
three main MAPK signaling pathways, including extracellular signal-related kinases 
ERK1/2 (also known as p44/ p42 MAPK), c-Jun N-terminal kinases or stress-activated 
protein kinases (JNK/SAPK) and p38. MAPK are activated through phosphorylation of 
tyrosine/threonine residues in signal transduction cascades ultimately culminating in 
gene expression and post-translational protein modifications.  
 
The reported effects of P. gingivalis on MAPK signalling are cell type specific. It has 
been shown that viable P. gingivalis reduces the phosphorylation of p44/42 MAPK in 
gingival epithelial cells and also activate JNK MAPK, indicating that P. gingivalis is 
capable of activating one MAPK pathway whilst downregulating another (Watanabe, 
Yilmaz et al. 2001). Acknowledging this, another study showed that purified P. 
gingivalis LPS was not able to activate p44/p42 MAPK in human endothelial cells 
(Darveau, Arbabi et al. 2002). P. gingivalis has also been shown to activate p38 MAPK 
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in endothelial cells (Walter, Zahlten et al. 2004; Zhang, Zheng et al. 2011). Conversely, 
purified P. gingivalis LPS did not activate p38 MAPK in endothelial cells, but could 
activate p38 MAPK in human monocytes. It has been demonstrated that P. gingivalis 
LPS may serve as an antagonist for E. coli LPS induced p38 MAPK activation, where 
E. coli LPS induced p38 MAPK activation was abrogated with the addition of P. 
gingivalis LPS in endothelial cells (Darveau, Arbabi et al. 2002). In addition, it has been 
shown that P. gingivalis Arg- and Lys- gingipains can induce the phosphorylation of 
MAPK P38α in human macrophage cells (Grenier and Tanabe 2010).  
 
The NF-κB transcription factor pathway is involved in the expression of genes involved 
in immunity and inflammation and dysregulation of this pathway can lead to 
pathological conditions such as autoimmune diseases, cancer and diabetes (Hayden and 
Ghosh 2012). There is evidence that P. gingivalis does not activate the transcription 
factor NF-κβ in gingival epithelial cells (Watanabe, Yilmaz et al. 2001), whereas NF-κβ 
activation has been demonstrated with P. gingivalis challenge in endothelial cells 
(Walter, Zahlten et al. 2004; Zhang, Zheng et al. 2011). The activating protein-1 (AP-1) 
transcription factor complex is composed of homo- or heterodimers of Jun, Fos or 
activation of transcription factor components and is important in regulating an array of 
cellular processes including cellular proliferation, differentiation and apoptosis 
(Shaulian and Karin 2002). Viable P. gingivalis has also been demonstrated to activate 
the AP-1 complex in primary osteoblast cells (Okahashi, Inaba et al. 2004). Together 
these studies suggest that the activation of various intracellular mechanisms through 
which P. gingivalis can signal are complex, and this varies according to the whether 
cells are challenged with whole P. gingivalis cells or purified P. gingivalis virulence 
components in the different cell types used. 
 
 42
Conclusion 
There is no single etiological factor in periodontitis but a combination of factors which 
contribute to disease, such as the microenvironment of bacteria species, the 
susceptibility of the periodontal host environment, a deregulated immune system and 
the effect of surrounding environmental conditions. These factors together can create an 
optimal environment for the colonization and growth establishment of bacteria that can 
favour the destruction of periodontal tissue and bone resorption. This literature review 
has been an introduction into the background of periodontitis including the 
microbiological aetiology, in particular P. gingivalis and its associated virulence 
properties. The main clinical aspect/feature of periodontitis is the loss of alveolar bone, 
characterised by changes in the balanced molecular expression of RANKL and OPG, 
which are the master regulators of bone resorption. So the emphasis of the following 
work was to investigate P. gingivalis, its effect on these bone resorption mediators and 
its overall virulence potential, aiming to shed light to pathogenic mechanisms that could 
aid the development of future therapeutic targets. 
 43
Chapter 2. 
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2. Aims and Objectives 
P. gingivalis is part of the ‘red complex’ of bacteria and is considered a bona fide 
periodontal pathogen with distinguished virulence factors contributing to disease 
progression. To investigate if P. gingivalis can affect cells with bone regenerative 
potential an established murine bone marrow stromal cell line W20-17 will be used in 
this study. The relationship between bacteria and the host needs to be investigated to 
understand the underlying mechanisms behind bone loss in periodontitis. 
 
This study will be conducted in two parts. 
 
Primary Objectives: 
 To establish an in vitro experimental model with bone marrow stromal cells 
possessing osteogenic properties and their response to P. gingivalis. 
 To use this optimised model to investigate the regulation of RANKL and OPG.  
 To investigate the role of the inflammatory mediator PGE2 in this model, and its 
involvement in the regulation of the RANKL-OPG system.  
 To explore the role of putative virulence factors of P. gingivalis, such as the 
gingipains and LPS, in regulation of the expression of RANKL, OPG and 
PGE2. 
 To determine the intracellular pathways involved in the regulation of RANKL, 
OPG and PGE2. 
Secondary Objectives  
 To investigate the overall virulence of P. gingivalis with osteogenic bone 
marrow stromal cells by the employing gene microarray technology. 
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Chapter 3. 
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3. Materials and Methods 
3.1 Summary of main experimental steps  
 
P. gingivalis challenge in W20-17 cell to determine RANKL and OPG expression 
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P. gingivalis challenge in W20-17 cells to determine COX-2/ PGE2 involvement 
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3.2 P. gingivalis 
3.2.1 Preparation and growth of P. gingivalis W50, K1A and E8 strains 
Porphyromonas gingivalis wild-type W50 strain and mutant K1A (Lys-X specific 
gingipain mutant) and E8 (Arg-X specific gingipain mutant) strains were provided by 
the Centre of Infectious Disease (Institute of Cellular and Molecular Science, Barts and 
the London School of Medicine and Dentistry). Cultures of W50, K1A and E8 strains 
were grown on blood agar plates supplemented with 5% horse blood in an anaerobic 
environment containing 80% nitrogen, 10% hydrogen and 10% carbon dioxide at 37°C 
for 3 days. Each strain was then subcultured into 10 millilitres (ml) of media consisting 
of brain heart infusion broth supplemented with 5 micrograms (µg)/ml of hemin. The 
following day, the 10 ml culture was inoculated into 90ml of fresh media. This was 
considered day 0 of the culture. Optical density (OD) for each culture was measured in 
duplicate at A540 on days 0, 3 and 6. At day 6, W50, K1A and E8 strain cultures were 
centrifuged at 8500 rotations per minute (rpm) for 45 minutes (mins) at 4ºC. The 
bacterial supernatant was removed, aliquotted and stored at -80ºC for further use. This 
protocol was followed from Aduse-Opoku (Aduse-Opoku, Davies et al. 2000). 
3.2.2 Determining Arg-X and Lys-X protease activity in W50, K1A and 
E8 strains 
The protease activity of gingipains was characterised in the 6-day culture supernatants 
of strains W50, K1A and E8. Arg-X protease activity was measured in assay buffer 
(Appendix 1) and 500 millimolar (mM) N-benzoyl-DL-arginine-p-nitroanilide as the 
substrate. Lys-X protease activity was measured with assay buffer (Appendix 1) and 
250mM a-acetyl-L-lysine-p-nitroanilide. Both enzyme activities were measured in 
duplicate at 30°C, pH 8.1. The enzyme activity was detected by measuring absorption at 
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405 nanometres (nm) and expressed in units per ml of supernatant. One enzyme unit 
represents the amount of enzyme that causes an increase in the absorption of 1.0 min-1 at 
30 °C. Protocol followed was from Aduse-Opoku (Aduse-Opoku, Davies et al. 2000). 
3.2.3 Levels of bacterial endotoxin in P. gingivalis W50, K1A and E8 
strains  
To determine the level of Gram-negative bacterial endotoxin activity present in P. 
gingivalis strains W50, K1A and E8, a Limulus Ameobocyte Lysate (LAL) assay 
(Cambrex Bio Science, Walkersville, MD) was performed according to manufacturer’s 
instructions. Briefly, endotoxin present in the sample activates the pro-enzyme present 
in the LAL, releasing peptide nucleic acid from colourless substrate for measurement. 
Supernatants were measured in triplicate against a standard curve composed of serial 
dilutions of E. coli endotoxin. A range from 1.0 endotoxin units (EU)/ml to 0.125 
EU/ml was used. Absorption was read at 405nm. Blank values were subtracted from 
sample values and a linear standard curve was used to read EU/ml. 
3.2.4 Determining total bacterial protein concentration in W50, K1A 
and E8 strains 
To determine total bacterial protein concentration in the culture supernatants of W50, 
K1A and E8 strains, the Bio-Rad Protein Assay was used. This assay detects basic and 
aromatic amino acid residues, especially arginine, present in the sample which bind to 
the Coomassie blue dye. It is therefore a dye-binding assay in which a differential 
colour change of a dye occurs in response to various concentrations of protein. The 
procedure followed the manufacturer’s instructions. Samples were measured in 
triplicate against a bovine serum albumin standard in a 96 well plate. The range of 
standards used was between 1480 µg/ml to 0.7 µg/ml. Absorption was read at 595nm. 
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Background values were subtracted from sample values and a 4-point polynomial curve 
fit to standard values was used to deduce unknown protein concentrations.  
3.2.5 Removal of P. gingivalis endotoxin from culture supernatant 
A detoxi-gel endotoxin removing column (Pierce) was used to remove endotoxin from 
the W50 strain culture supernatant. The detoxi-gel endotoxin-removing column is 
coated with immobilised antibiotic, polymyxin B. When the sample is run through the 
column, polymyxin B binds to the lipid A part of bacterial LPS, removing it from the 
sample, and allows for the rest of the components to flow through. Although polymyxin 
B inactivates endotoxin it may not completely eliminate the presence of all forms of 
lipid A. Briefly 1% percent of sodium deoxycholate was used to wash the column and 
washed a further 3 times with autoclaved dH20. Bacterial culture supernatant was 
incubated in the column for 1 h at 4°C and flow-through collected. To ensure maximal 
removal of endotoxin, the column was washed again as previously described and the 
collected flow-through culture supernatant was put through the column once more and 
incubated for 30 min at 4°C. This experiment was repeated three independent times. 
3.2.6 Inhibition of gingipain (cysteine protease) activity of W50 
To investigate whether the expression of the studied molecules are affected by P. 
gingivalis gingipains, the chemical inhibitor Nα-Tosyl-L-lysine chloromethyl ketone 
hydrochloride (TLCK) (Sigma), was used to treat P. gingivalis culture supernatant. 
TLCK inhibits cysteine proteases and serine proteases, by making a covalent bond with 
a histidine residue present in the active site of the protease thereby inactivating it. The 
treatment of P. gingivalis W50 culture supernatant was performed by incubation with 1 
mM TLCK and for 1 h at 4°C. The TLCK-treated P. gingivalis supernatant was then 
used to challenge the cell cultures, as described above, and the effects were compared to 
those induced by the un-treated wild-type P. gingivalis culture supernatant. A TLCK-
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only control group was also used, to investigate the putative cytotoxic and other effects 
of this inhibitor to the cells. This experiment was repeated three independent times. 
 
An additional approach used to investigate the role of proteinaceous components, 
including gingipains, in the observed effects was to heat-treat the wild-type P. gingivalis 
W50 strain bacterial supernatant. The heat-inactivation process included heating of the 
culture supernatant (5 µg/ml protein concentration) to 70°C for 1 h to destroy the 
protein content. This heat-treated supernatant was thereafter used to challenge the cell 
cultures for 24 h and 48 h, and the effects were compared to those of the un-treated 
wild-type P. gingivalis W50 strain. This experiment was repeated three independent 
times. 
3.2.7 Purification of P. gingivalis LPS through Tri-reagent 
Porphyromonas gingivalis W50 was cultured and grown as described in section 3.1.1. 
However, the cells were collected and centrifuged after only one day of growth. To 
isolate P. gingivalis LPS from the bacterial cells, the culture supernatant was decanted 
and discarded. The cell pellet was then resuspended in 10 ml of sterile 1 x phosphate 
buffered solution (PBS). The resuspended cell pellet was then freeze-dried using 
isopropanol and dry ice and then further dried overnight.  
 
Ten milligrams (mg) of dried P. gingivalis cells were measured and suspended in 200µl 
of TRI-reagent (contains phenol and homogenises cells) (Sigma). This was incubated at 
room temperature for 10 min for complete cell homogenisation. Twenty microlitres (μl) 
of chlorofilm per mg of cell weight was added to create a phase separation. To isolate 
the aqueous part of the solution from the organic phase, samples were vigorously 
vortexed and incubated at room temperature for 10 min. They were centrifuged at 13000 
rpm for 10 min at 4ºC where the aqueous part was removed and stored. To further 
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isolate the remaining aqueous solution from the mixture, 100 μl of distilled water was 
added to the solution containing aqueous and organic parts and vigorously vortexed. 
This was then incubated at room temperature for 10 min and centrifuged as described 
earlier, where the aqueous part was removed and pooled. This process was repeated a 
further three times. Finally, the organic part was discarded and the aqueous part was 
freeze-dried.  
 
The following day, the freeze-dried (aqueous) part of the solution were dissolved in 500 
μl 0.375 molar (M) MgCl2 (made in 95% ethanol), vortexed and stored at -20°C for 1 h. 
Samples were then centrifuged at 13000 rpm for 15min at +4°C where supernatant was 
decanted. Five hundred microlitres of 95% ethanol was added to each sample, vortexed 
and centrifuged at 13000 rpm for 15 min at +4°C where supernatant was discarded. The 
protocol of Tri-Reagent LPS extraction was adapted from Yi and Hackett (Yi and 
Hackett 2000). 
 
Samples were then air-dried in the fume cupboard for 3 hrs. P. gingivalis LPS was then 
re-suspended in 200 μl of LAL endotoxin free water (Cambrex Bio Science, 
Walkersville, MD) and vortexed for 25 min. The resulting LPS samples were then 
pooled together and endotoxin units were measured as section 3.1.3. They were then 
stored at -80ºC.  
3.3 Cell Culture 
3.3.1 Eukaryotic cell culture  
An established murine bone marrow stromal cell line derived from endochrondral bone, 
W20-17 (Thies, Bauduy et al. 1992), and a more differentiated murine pre-osteoblastic 
calvarial cell line derived from intramembranous bone, MC3T3-E1 (Sudo, Kodama et 
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al. 1983), were used in this experimental system. Cell culture was carried out in alpha 
minimum essential medium (Gibco-BRL) supplemented with 10% v/v foetal calf serum, 
50 Units/ml penicillin, 50 µg/ml streptomycin (Gibco-BRL) and 50 µg/ml of ascorbic 
acid (Sigma). The cell cultures were incubated at 37 °C in an atmosphere of 5% CO2. 
For sub-culturing, the cells were detached from the bottom of the culture flask with 
0.1% Trypsin/EDTA (Gibco) and centrifuged at 1000 rpm for 5 min at room 
temperature. The supernatant was discarded and the cell pellet was re-suspended in 10 
ml of culture medium. For the experiments, after trypsinisation the cells were counted 
using a haemocytometer and seeded in appropriate cell culture wells at a density of 2 x 
104 cells/cm2, and left to attach for at least 18 h before being challenged with the 
indicated bacterial stimulants. 
3.3.2 Bacterial challenge of the cell cultures using W50, K1A and E8 
strains and P. gingivalis LPS  
For the experiments, the aliquoted bacterial supernatant was thawed and filter-sterilized 
using a 0.2 µm filter. The cells were challenged with bacterial protein of 5 µg/ml and a 
series of 2-fold serial dilutions down to 0.625 µg/ml. In separate experiments, cells were 
challenged with purified P. gingivalis LPS of 5000 EU/ml, 2500 EU/ml and 1250 
EU/ml. Untreated cell cultures served as controls in all experiments. Each group was 
represented in duplicate wells, for each experiment. After the addition of any of the 
bacterial challenges to the attached cells, the cultures were incubated at 37°C in the 
presence of 5% CO2 for 6 h, 24 h, or 48 h. These experiments were repeated three 
independent times. 
3.3.3 Treatment of indomethacin to block PGE2 
To investigate the effects that PGE2 may have on RANKL and OPG, the chemical 
inhibitor indomethacin was use to block the production of PGE2. Indomethacin is a non-
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selective inhibitor of COX-1 and COX-2 enzymes. COX-2 enzyme is involved in the 
breakdown of arachidonic acid to PGE2. Prior to challenge with P. gingivalis, the cells 
were pre-treated with indomethacin at a concentration of 10-5 M for 3 h. The culture 
medium was then replenished with one containing P. gingivalis culture supernatant and 
indomethacin at a concentrations of 5 µg/ml and 10-5 M, respectively. An indomethacin 
only (10-5 M) control group was also used to test for cytotoxic or other effects to the 
cells. The cells were incubated for a further 24 h and 48 h. This experiment was 
repeated three independent times. 
3.3.4 Treatment of SB2390063 inhibitor to block MAPK p38 
The chemical p38 inhibitor SB203580 blocks the catalytic activity of p38 MAPK by 
binding to its ATP-binding site. For investigations involving the inhibition of p38, cells 
were pre-incubated for 1 h with 10 µM of SB203580 (Promega), prior to challenge with 
P. gingivalis for 24 h. This experiment was repeated three independent times. 
3.3.5 Cytotoxicity assay for P. gingivalis-challenged cells. 
Lactate dehydrogenase (LDH) is a cytosolic enzyme that is released upon cell lysis. Its 
increased extracellular presence in a cell culture can therefore serve as a good indicator 
of cell lysis. For the experiments investigating cytotoxicity, the cells were seeded at a 
cell density of 2.5 x 103/cm2. Bacterial culture supernatants were used at 2-fold serial 
dilutions, from 20 µg/ml down to 0.625 µg/ml to challenge the cells. Each group was 
represented in triplicate cultures, including an untreated control. After the addition of 
the bacterial challenge, the cell cultures were incubated further for 6 h, 24 h, and 48 h. 
At each experimental time-point, cell culture supernatant was collected. Then, the 
attached cell monolayers were washed once with 1 x PBS and then 0.1% Triton X-100 
detergent was used to lyse cells for 1 minute. The cell lysate was then centrifuged at 
12000 rpm for 5 min before being tested on a 96-well plate (Nunc). The cell lysate was 
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collected in order to determine the total LDH content in the cultures, which allows for 
the evaluation of the percentage of the extracellularly released LDH, indicative of cell 
death. The CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) was used to 
measure levels of LDH. Substrate provided by the Promega kit was added to samples 
and incubated in the dark for 30 min. Stop solution was then added and absorption was 
read at 490 nm. The OD values were used to assess levels of LDH, and background 
values were subtracted from all sample values. This procedure was performed with both 
the W20-17 and the MC3T3-E1 cell line. This experiment was performed once for each 
cell-line with triplicate cultures. 
3.4 Analysis of mRNA expression 
3.4.1 Extraction of total RNA and synthesis of cDNA 
For the investigation of regulation of gene expression in the cells in response to P. 
gingivalis, total RNA was collected and reverse-transcribed (RT) into cDNA, before 
being assayed by quantitative real-time Polymerase Chain Reaction (qPCR). For each 
studied time-point, duplicate cell cultures were used. The cell culture supernatant was 
removed and the cell monolayers were washed with 1 x PBS. Total RNA was extracted 
from cells using RNeasy kit (Qiagen) according to the manufacturer’s instructions. The 
cell lysis buffer RLT, included in the kit, was prepared by the addition of 1% of 14.2 M 
β-mercaptoethanol. This solution was then added onto the washed monolayers to lyse 
cells. The cell lysates from duplicate group wells were pooled together. Samples were 
stored at -80°C until further processing. Cell lysates were thawed and homogenized 
using a QIAshredder column (Qiagen). Thereafter, equal volume (1:1) of 70% ethanol 
was added to the cell lysates, a process that promotes binding of RNA to the silica 
matrix of the RNeasy Mini Spin column. The sample was then added to this column, 
and processed according to the manufacturer’s instructions. Finally, the collected total 
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RNA was eluted with RNase free water, and was quantified using a Nanodrop 
spectrophotrometer. Then, 1 µg of this total RNA was reversed transcribed into cDNA. 
Firstly, it was incubated with 0.5 µg/ml of oligo dT primer (Promega) at 70°C for 5 min 
and cooled on ice. Then master mix (Promega) was added to this samples, comprising 
of dH20, 1 x M-MLV RT Buffer, 10 mM dNTPs, and 200 units of moloney murine 
leukemia virus RT enzyme. Finally, for cDNA synthesis this mixture was incubated at 
40°C for 60 min, 70°C for 15 min and +4°C to cool down. The resulting cDNA samples 
were stored at -20°C, until further use. 
3.4.2 Quantitative real-time PCR (qPCR) 
To quantify the mRNA expression levels, qPCR was performed on the prepared cDNA 
samples. TaqMan® Gene Expression Assays were used from Applied Biosystems 
(ABI) and the qPCR analyses were performed in a ABI Prism 7900HT Sequence 
Detection System. To be able to normalise the obtained target gene Ct values, a 
housekeeping gene screen was performed. This entailed using a series of 12 murine 
housekeeping genes and assaying a random set of samples. The aim was to deduce two 
housekeeping genes that were the most stable and consistent, which would be further 
used to normalise data. The housekeeping gene screen performed for the W20-17 cell 
line indicated that the eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2) 
and cytochrome 1 (CYC1) gene expressions were the most stable among all samples, 
and were used to normalise the data in all further experiments. For each sample, the 
relative target gene expression was determined as the ΔCt value, which is the difference 
between the target gene Ct and the average Ct of the selected two housekeeping genes. 
The TaqMan® Gene Expression Assays IDs for the studied target genes were as 
follows: EIF4A2: Mm00834357_g1, CYC1: Mm00470540_g1, TNFSF11 (RANKL): 
Mm00441908_m1, TNFRSF11B (OPG): Mm00435452_m1, COX-2: Mm00478377_g1, 
TLR-2: Mm00442346_m1, TLR-4: Mm00445273_m1, SAA3: Mm00441203_m1, and 
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LCN2: Mm01324470_m1. ROX mastermix was used in combination with the 
TaqMan® Gene Expression Assays. The amplification conditions in the ABI Prism 
7900HT Sequence Detection System were 10 min at 95 °C, followed by 40 cycles at 95 
°C for 15 sec and 60 °C for 1 min.  
3.5 Protein analysis 
3.5.1 Protein collection from cells challenged with W50  
In order to investigate if the gene expression levels reflected the protein levels, cell 
culture supernatants were collected for the measurement of secreted proteins, whereas 
cell lysates were collected for evaluating the cell-associated protein levels. For the 
latter, chilled radio-immunoprecipitation assay (RIPA) buffer (Appendix 1) was used to 
extract intracellular and membrane-associated proteins. Of note, the ionic detergents 
SDS and NP-40 contained in this lysis buffer are efficient in disrupting the nuclear 
membrane in order to remove cell-associated protein. In particular, after completion of 
the experiments, the cell culture plates were removed from the incubator, and cooled by 
placing on ice. Culture supernatant was collected and maintained temporarily on ice, 
until the cell lysates were also collected. Cells were washed with cold 1 x PBS, and then 
chilled RIPA buffer including 1:100 Protease Inhibitor Cocktail (Sigma) was added on 
the cell monolayers and incubated for 20 min on ice at 4°C , to lyse the cells. The cell 
monolayers were then scraped using a cell scraper, and the cell lysate was collected and 
stored on ice. Once all cell lysates were collected, all samples were centrifuged at 1500 
rpm for 20 min at +4°C to spin down cell debris. Cell debris-free lysates were then 
removed and stored at -80°C.  
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3.5.2 Enzyme Linked Immunosorbent Assay (ELISA) for RANKL and 
OPG 
To quantitatively evaluate levels of RANKL and OPG protein present in samples, 
sandwich ELISAs for RANKL and OPG (R&D Systems) were performed according to 
the manufacturer’s instructions. The 96-well ELISA plates (Nunc) were coated with 
0.04 µg/100µl per well of monoclonal capture antibody (Ab) and incubated at room 
temperature overnight. The following day the capture Ab was aspirated and washed 
three times with PBS-Tween wash buffer (Appendix 1). Reagent diluent (Appendix 1) 
was then added to the wells and incubated for 1 h at room temperature, to block 
unspecific binding. The wells were washed again three times, followed by the addition 
of the experimental samples, as well as the pre-determined protein standards, and 
incubated at room temperature for 2 h. Cell lysates and culture supernatants were used 
undiluted for the detection of RANKL, but diluted 1:20 when testing for OPG. 
Standards for RANKL and OPG were included in the ELISA kit (R&D Systems), with a 
concentration range between 4000 picograms (pg)/ml and 62.5 pg/ml. The wells were 
washed again and then 2 nanograms (ng)/100µl per well of detection Ab was added and 
incubated for a further 2 h at room temperature. Thereafter, and following once again 
washing, 100μl of streptavidin-conjugated horseradish peroxidase was added to the 
wells and incubated in the dark for 20 min. After a further round of washes, 100μl of 
TMB liquid substrate (Calbiochem) was added to the wells and incubated in the dark for 
another 20 min. Then, a 2N H2SO4 was added to the wells to stop the reaction. 
Absorption was then read at 570 nm, subtracting readings at 450 nm. The corresponding 
background values (i.e. culture media) were also subtracted from the obtained sample 
and standard values. A 4 point polynomial equation was used to produce a standard 
curve and used to determine the levels of RANKL and OPG protein in samples. 
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3.5.3 Prostaglandin E2 (PGE2) ELISA  
A competitive ELISA Assay (Parameter, R&D Systems) was used to determine PGE2 
levels in culture supernatant from cells challenged with P. gingivalis. In this assay PGE2 
in the sample competes with binding sites on the primary antibodies, with the addition 
of PGE2 conjugated to HRP. The established protocol followed the manufacturer’s 
instructions. The 96-well microplates were pre-coated with 50 µl/well of goat anti-
mouse polyclonal antibody against PGE2. One hundred micro-litres of standard and 
sample were then added to the plate. A standard curve was created, with upper and 
lower limits of 1250 pg/ml and 19.6 pg/ml, respectively. All samples were diluted 1:5. 
Mouse monoclonal antibody to PGE2 and PGE2 conjugate were then added to the wells, 
and the plates were incubated at +4°C for 16 h to 20 h. The following day the wells 
were aspirated and washed four times with wash buffer provided by the manufacturer. 
Then substrate (also provided in the kit) was added to the wells and incubated for 20 
min, protected from light. To stop the reaction, 2N H2SO4 was added. Absorption was 
read at 570 nm, extracting values at 450 nm. The corresponding background values 
were also subtracted from samples and standards. A 4-point polynomial equation was 
used to produce a standard curve, and was used to determine levels of PGE2 in samples. 
3.5.4 Griess Reaction for the detection of Nitric Oxide (NO) production 
The Griess reaction can be used to measure levels of NO by detecting nitrite production, 
one of two breakdown components of NO. Sulfanilamide and N-1-
napthylethylenediamine dihydrochloride (NED) is used to covert nitric oxide into a 
compound that can be measured spectrophotometrically. Sample and standards were 
added in duplicate to a 96-well plate. A range of standards between 100 micromolar 
(µM) to 1.56 µM of nitrite (Appendix 1) was used. Sulfanilamide solution (Appendix 1) 
was added and incubated at room temperature in the dark for 5-10 min. NED solution 
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(Appendix 1) was added and incubated at room temperature in the dark for 5-10 min. 
Absorption was measured at 520 nm – 550 nm. This experiment was performed once. 
3.5.5 Extraction of intracellular protein from cell lysates for western 
immunoblotting 
After 15 min, 30 min and 60 min challenge with P. gingivalis supernatants, the cell 
monolayers were washed with cold 1 x PBS and then lysed using chilled RIPA buffer 
(Appendix 1) and 1:100 Protease Inhibitor Cocktail (Sigma). Just prior to addition to the 
cell monolayers, 10-1 M sodium orthovanadate (Sigma) and 10-2 x 5 M sodium fluoride 
(Sigma) were added to the buffer. To obtain the cell lysates, the cell monolayers were 
incubated in RIPA buffer for 20 min at 4 ºC. Lysates were then collected and 
centrifuged at 1500 rpm for 20 min at 4 ºC, and the pelleted cell debris was discarded. 
To achieve complete homogenisation, these cell lysates were passaged through a 21G 
needle. Total protein concentration was then determined colorimetrically, using the 
Pierce BCA Kit, according to the manufacturers instructions.  
3.5.6 Western immunoblotting 
Western immunoblotting was used to evaluate the total and phosphorylated levels of the 
three studied MAPK, namely p38, p44/42, and SAPK/JNK at early time-points of 15 
min, 30 min and 60 min post P. gingivalis supernatant challenge. The MAPK pathways 
can be activated early upon stimulus and therefore early time-points were chosen 
instead of the later time-points of 6 h, 24 h and 48 h used previously in this work to 
investigate RANKL, OPG and COX-2/PGE2 expression.  
 
Six μg of total protein from each lysate at indicated time-points was used. The samples 
were denatured for 5 min at 100°C and separated on a 4% - 12% Bis-Tris-HCl 
polyacrylamide gradient gel (Invitrogen), at 100 V for 2 h. The separated protein 
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content was electrotransferred from the gel onto a polyvinylidene fluoride membrane, at 
100 V for 1 h. The membranes were then blocked (1 x Tris-buffered-saline, including 
5% milk and 0.05% Tween) for 1 h at room temperature, and then incubated overnight 
at 4°C with appropriate primary antibodies, purchased from Cell Signalling 
Technologies (phospho-p44/42 rabbit antibody - Cat. No. 4370, phospho-p38 rabbit 
antibody - Cat. No. 9211, phospho-SAPK/JNK rabbit antibody - Cat. No. 4668, total 
p44/42 rabbit antibody - Cat No. 4695, total p38 antibody - Cat. No. 9212, total 
SAPK/JNK antibody - Cat. No. 9258). These primary antibodies were detected by using 
an anti-rabbit IgG horse radish peroxide-conjugated secondary antibody (Cat. No. 7074, 
Cell Signalling Technology). The protein bands were finally visualised by short 
incubation of the membrane in ECL chemiluminescent substrate (GE Healthcare), 
followed by exposure of the membrane onto a photographic film, where the signal was 
developed. This experiment was performed two independent times. 
3.6 Gene Microarray Analysis 
3.6.1 Experimental technology and protocol 
To investigate the gene expression profile of bone marrow stromal cells challenged with 
P. gingivalis, the Illumina Whole-Genome Expression Assay was used (MouseRef-8 
v2.0 Expression BeadChips). The Illumina technology consists of oligonucleotides 
immobilised to beads in microwells contained in the array that bind to complimentary 
sequences contained in the target template. Cells were challenged with 5 μg/ml P. 
gingivalis culture supernatant protein for 6 h and 24 h. RNA was then extracted and 
collected as described in the qPCR section. However, the resulting RNA in this case 
was used in the Illumina Whole-Genome Expression Array. Two hundred and fifty 
nanograms of high quality total RNA was biotin-labelled with a single round 
amplification using the Illumina total preparation kit (LifeTech). Spike RNA controls 
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were also included within samples prior to amplification to control for the success of the 
reaction. The biotin-labelled cRNA was then quantified using a Nanodrop spectrometer. 
To assess the quality of the RNA, fragment size distribution of ribosomal RNA was 
checked for by electrophoresis on a RNA nano chip on the Bioanalyser (Agilent). Seven 
hundred and fifty nanograms of cRNA was then hybridised to the MouseRef-8 v2 array 
(Illumina) according to the manufacturers instructions and data was visualised on the 
Bead Array Reader (Illumina). This assay was performed at the core facilities of the 
Genome Centre of Barts and The London School of Medicine and Dentistry. 
3.6.2 Data analysis 
Intensity data from the Bead Array Reader was imported into the BeadStudio software 
(Illumina) to be analysed. Quality control checks were performed based on spiked-in 
controls. Data fulfilling the quality criteria were then quantile normalised before 
grouping replicates and performing group differential analysis using Beadstudio. 
Further to this, a Bonferonni statistical test was performed to adjust for a large number 
of p values. These p values were then converted to differential (diff) scores, a number 
that takes into account both the p value and the difference between the average signal of 
the reference and comparison group, in this case the control group versus the P. 
gingivalis-challenged (test) group. A p value of 0.001 is equivalent to a diff score of ± 
33. To be stringent an arbitrary cut-off diff score of ±65 was chosen.  
 
The list of genes together with fold changes was uploaded into the Ingenuity software 
(Ingenuity Systems®, http://www.ingenuity.com). The Ingenuity program was then used 
to sort the list of genes into broad cellular categories such as cancer, inflammatory and 
bone metabolism genes. 
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3.7 Statistical Analyses 
A one-way or two-way analysis of variance (ANOVA) test was employed to determine 
if the mean of more than two experimental groups involving gene or protein expression 
data varied. A one-way ANOVA was used when there was one variable i.e. one time-
point and in instances with more than one time-point a two-way ANOVA was used. 
Following this, a Bonferroni post-test determined statistical differences between 
experimental groups to control or wild-type P. gingivalis. Student’s t test was used 
when only two experimental groups were compared. 
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Chapter 4. 
 
Results 
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4. Results  
4.1 Bacterial growth of P. gingivalis and characterisation of proteolytic 
and endotoxic activities in culture supernatants 
Porphyromonas gingivalis wild-type W50 and its knock-out mutant strains K1A and E8 
were grown for a total of 6 days, when their culture supernatant was collected. P. 
gingivalis K1A and E8 are genetically modified, lacking the genes responsible for their 
specific Arg-X and Lys-X gingipain activity. Hence, K1A is a mutant that with a 
deletion of the Kgp gene, whilst E8 is a mutant with a double RgpA and RgpB gene 
deletion (Aduse-Opoku, Davies et al. 2000). 
 
The growth of these strains was assessed by measuring the optical density of the 
cultures at baseline and after 3 and 6 days (Fig. 5). The peak of growth in all three 
strains was at day 3. After this point growth of W50 and E8 decline steadily at a similar 
rate, whereas K1A growth declined at a more rapid rate. To ensure that the protease 
activity in K1A and E8 strains was diminished compared to W50 strain, their respective 
enzyme activities was measured in the culture supernatants. Strain K1A was confirmed 
to have a 92% reduction of Lys-X activity, whereas E8 exhibited a 98% decrease in 
Arg-X activity compared to wild-type W50 strain (Fig. 6A). In addition, enzyme 
activity was also measured in culture supernatants of the W50 strain treated with TLCK 
or polymyxin B, or heat inactivated. Protease activity was reduced by all treatments and 
completely abolished by heat inactivation compared to parental W50 strain (Fig. 6B). 
To determine the total level of bacterial endotoxin present in the culture supernatants of 
the three strains, the LAL assay was used. The obtained values (expressed in endotoxin 
units/ml) were calibrated against the protein concentration in each culture supernatant 
(Table 2). Although the absolute levels of endotoxin varied between the culture 
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supernatants of the different strains, when calibrated for bacterial protein concentration 
(endotoxin units/µg of protein), these proved to be similar.  
 
To investigate the potential effects of LPS, culture supernatants of wild-type P. 
gingivalis W50 were passed through a polymyxin B column, that binds and removes the 
lipid A component of LPS from the mixture. It was indeed confirmed that 89% of 
endotoxic activity was successfully removed by this approach. 
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Fig. 6. Growth of P. gingivalis strains W50, E8 and K1A 
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Fig. 6. Optical density of wild-type P. gingivalis W50, and mutant E8 and K1A strains at day 0 and after 
3 and 6 days of bacterial culture. 
 
 
 
Fig. 7A. Gingipain activity in P. gingivalis culture supernatants 
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Fig. 7B. Gingipain activity in treated P. gingivalis culture supernatants 
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Fig.7. (A) Arg- X and Lys-X protease activity in culture supernatant of wild-type P. gingivalis W50 and 
mutants E8 and K1A at day 6. (B) Arg- X and Lys-X protease activity in culture supernatant of wild-type 
P. gingivalis W50, treated with TLCK, heat inactivated and polymyxin B-treated. 
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Table 2. Endotoxin and protein levels in P. gingivalis culture supernatants 
 
Strain Endotoxin  
(units/ml) 
Bacterial protein 
(µg/ml) 
Endotoxin units/µg 
of protein 
W50 342.1 84 ± 0.0047 4.1 
E8 278.7 53 ± 0.0049 5.3 
K1A 791.5 176 ± 0.0111 4.5 
 
 
4.2 Determination of cytotoxic effects of P. gingivalis  
The bacterial culture supernatants of the different strains were assayed for their ability 
to induce cell death, in order to establish the range of sub-toxic concentrations suitable 
for further study. Wild-type P. gingivalis W50 strain culture supernatant was used to 
challenge W20-17 bone marrow stromal cells in ascending concentrations of total 
bacterial protein, for 6 h, 24 h and 48 h. Intracellular and extracellular levels of LDH 
were measured, in order to define the percentage of extracellularly released LDH, 
indicative of cell lysis. Ten µg/ml and 20 µg/ml of bacterial protein induced 
significantly higher levels of extracellular LDH release compared to the control, at 24 h 
and 48 h (Fig. 7A), indicating increased toxicity. Although 0.625 µg/ml to 5 µg/ml 
concentrations increased LDH release at 48 h, this was no more than 10% compared to 
control, whereas 10 µg/ml and 20 µg/ml induced over 40% LDH release. Based on 
these observations, it was deduced that 10 µg/ml and 20 µg/ml of P. gingivalis protein 
concentrations were particularly toxic to cells, inducing a high percentage of cell death. 
Hence, concentrations between 0.625 µg/ml and 5 µg/ml were used in subsequent 
experiments. 
 
The MC3T3-E1 pre-osteoblastic cell line was also tested for cytotoxicity in response P. 
gingivalis challenge (Fig. 7B). Here, 20 µg/ml of bacterial supernatant significantly 
enhanced LDH release compared to the control at 24 h and 48 h. From the results of this 
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cytotoxicity assay, it was deduced ascending P. gingivalis concentrations between 0.625 
µg/ml and 10 µg/ml, should be used for further experiments.  
 
In subsequent experiments, P. gingivalis mutant strains K1A and E8, or treatment of P. 
gingivalis W50 with indomethacin, or TLCK have been used. To examine if these 
treatment groups would induce cytotoxicity, W20-17 cells were challenged again with 5 
µg/ml of bacterial protein from the corresponding supernatants. Also, the cytotoxic 
effects of treatment with 10-5 M indomethacin, or 1 mM TLCK, were tested for 24 h 
(Fig. 8). Although statistical difference was found between groups compared to control 
which may indicate an increase in cell death, this difference was numerically not greater 
than 7 %. 
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Fig. 8A. Cytotoxic effects of P. gingivalis W50 on W20-17 cells  
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Fig. 8B. Cytotoxic effects of P. gingivalis W50 on MC3T3-E1 cells 
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Fig. 8. Cytotoxic effects in response to ascending concentrations of P. gingivalis W50 protein at 6 h, 24 h 
and 48h. (A) W20-17 bone marrow stromal cells. (B) MC3T3-E1 calvarial cells. Percentage of 
extracellular LDH calibrated against total LDH is plotted to show induced cell death. Bars represent 
standard error of mean (SEM) from one experiment with three replicates. A two-way ANOVA with 
Bonferroni post-hoc test was used to compare experimental groups to untreated control. ** p < 0.01,*** p 
<0.001. 
 
 
 
Fig. 9. Cytotoxic effects of P. gingivalis strains and treatment groups on W20-17    
cells 
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Fig. 9. Cytotoxic effects in W20-17 cells in response to 5 µg/ml of P. gingivalis strains W50, K1A, E8 
and treatment groups of P. gingivalis W50, including indomethacin and TLCK at, 24 h. Percentage of 
extracellular LDH against total LDH is plotted to show induced cell death. Bars represent SEM from one 
experiment with three replicates. A one-way ANOVA, Bonferroni test was used to compare groups to 
untreated control. * p <0.001, *** p <0.001.  
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4.3 Effects of P. gingivalis on regulators of bone resorption 
4.3.1 Effects of P. gingivalis on RANKL, OPG, COX-2, PGE2 and 
iNOS 
W20-17 bone marrow stromal cells were challenged with ascending concentrations of 
P. gingivalis W50 over 6 h, 24 h and 48 h. RANKL mRNA expression was investigated 
by qPCR. It was demonstrated that this expression was upregulated with increasing 
bacterial concentration and over time (Fig. 9A). In particular, 2.5 µg/ml and 5 µg/ml of 
bacterial challenge proved to significantly enhance RANKL expression compared to 
control at 48 h. Moreover, the levels of total RANKL protein production by the cells 
was measured by ELISA. Total amount included both cell-associated and secreted 
RANKL into the culture supernatants. The results showed an upregulation trend 
consistent with RANKL mRNA expression, with 2.5 µg/ml and 5 µg/ml of P. gingivalis 
concentration causing a statistically significant increase compared to the control, after 
oth 24 h and 48 h (Fig. 9B).  
G protein expression remained 
uppressed with increasing P. gingivalis concentration. 
b
 
Unlike RANKL, OPG mRNA and protein levels displayed different expression patterns 
in response to P. gingivalis. In fact, OPG mRNA was highly expressed in the untreated 
control, but downregulated with 5 µg/ml of bacterial concentration at 24 h (Fig. 9C). All 
tested P. gingivalis concentrations, except 0.625 µg/ml, significantly downregulated 
OPG protein levels, at 24 h which was sustained at 48 h (Fig. 9D). However, although 
OPG mRNA returned to control levels at 48 h, OP
s
 
The effect of P. gingivalis on COX-2 mRNA expression and PGE2 production was also 
investigated. There was a concentration-dependent increase of COX-2 mRNA 
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expression at 6 h, 24 h and 48 h compared to the control. Statistically, the upregulation 
of COX-2 expression was significant compared to the unchallenged control, after 48 h 
of challenge with 5 µg/ml P. gingivalis W50 (Fig. 9E). Since COX-2 is involved in 
PGE2 synthesis, the levels of secreted PGE2 were also investigated. It was found that 
increasing concentrations of P. gingivalis caused a concentration-dependent increase of 
PGE2 secreted levels over time, in line with the trend of COX-2 expression (Fig. 9F). In 
is case, a significant increase of PGE2 secretion was already evident at 6 h post-
 
roduction was measured by the Griess reaction. However, nitrite production was not 
t was concluded that this cell line was not suitable 
to investigate the RANKL-OPG system in the context of the present work, and therefore 
not selected for further experiments. 
th
challenge with P. gingivalis. 
 
The potential regulation of iNOS gene expression by P. gingivalis was also investigated. 
Unchallenged cells did not express iNOS. However, its expression was upregulated by 
P. gingivalis in a concentration- and time-dependent manner, which proved to be 
statistically significant at 48 h, by 5 µg/ml P. gingivalis (Fig. 9G). To investigate if 
iNOS mRNA expression levels correspond to NO levels in the culture, nitrite
p
detected at any time-point or by any P. gingivalis concentration used (data not shown).  
 
The effect of P. gingivalis on the potential regulation of the RANKL-OPG system was 
also tested in the MC3T3-E1 cell line. It was found that neither RANKL mRNA nor 
protein expression were detected under any of the present experimental conditions, 
whereas OPG mRNA and protein were expressed in abundance (data not included). In 
the absence of RANKL expression, i
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Fig. 10A. RANKL gene expression 
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Fig. 10A. RANKL gene expression in W20-17 cells challenged with ascending concentrations of P. 
gingivalis W50 bacterial protein at 6 h, 24 h and 48 h. Bars represent mean ± SEM from three 
independent experiments. The gene expression levels were measured by qPCR, and calibrated against the 
expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to control. ** p < 0.01.  
 
 
 
 
 
Fig. 10B. RANKL protein expression 
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Fig. 10B. RANKL total protein in W20-17 cells challenged with ascending concentrations of P. 
gingivalis W50 bacterial protein at 6 h, 24 h and 48 h. Bars represent mean ± SEM from three 
independent experiments. Total protein levels (intracellular + extracellular) were measured by 
commercially available ELISA kits. A Bonferroni two-way (ANOVA) post-hoc test was used to compare 
experimental groups to control. *p<0.05, ** p < 0.01, *** p <0.001. 
 73
Fig. 10C. OPG gene expression 
6 24 48
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9 Control
0.625µg/ml
1.25µg/ml
2.5µg/ml
5µg/ml
*
Time (hours)
R
el
at
iv
e 
ex
pr
es
si
on
 
Fig. 10C. OPG gene expression in W20-17 cells challenged with ascending concentrations of P. 
gingivalis W50 bacterial protein at 6 h, 24 h and 48 h. Bars represent mean ±SEM from three independent 
experiments. The gene expression levels were measured by qPCR, and calibrated against the expression 
of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to 
compare experimental groups to control. *p <0.05. 
 
 
 
 
 
Fig. 10D. OPG protein expression  
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Fig. 10D. OPG total protein in W20-17 cells challenged with ascending concentrations of P. gingivalis 
W50 bacterial protein at 6 h, 24 h and 48 h. Bars represent mean ±SEM from three independent 
experiments. Total protein levels (intracellular + extracellular) were measured by commercially available 
ELISA kits. A Bonferroni two-way (ANOVA) post-hoc test was used to compare experimental groups to 
control. *p <0.05, ** p < 0.01, *** p <0.001. 
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Fig. 10E. COX-2 gene expression 
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Fig. 10E. COX-2 gene expression in W20-17 cells challenged with ascending concentrations of P. 
gingivalis W50 bacterial protein at 6 h, 24 h and 48 h. Bars represent mean ± SEM from three 
independent experiments. The gene expression levels were measured by qPCR, and calibrated against the 
expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to control. ** p < 0.01. 
 
 
 
 
Fig. 10F PGE2 protein expression 
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Fig. 10F. Secreted PGE2 protein from W20-17 cells challenged with ascending concentrations of P. 
gingivalis W50 bacterial protein at 6 h, 24 h and 48 h. Bars represent mean ±SEM from three independent 
experiments. Secreted protein levels were detected by commercially available ELISA kits. A Bonferroni 
two-way (ANOVA) post-hoc test was used to compare experimental groups to control. *p <0.05, *** p 
<0.001. 
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Fig. 10G. iNOS gene expression 
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Fig. 10G. iNOS gene expression in W20-17 cells challenged with ascending concentrations of P. 
gingivalis W50 bacterial protein at 6 h, 24 h and 48 h. Bars represent mean ± SEM from three 
independent experiments. The gene expression levels were measured by qPCR, and calibrated against the 
expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to control. ** p < 0.01, *** p <0.001. 
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4.4 Investigation of degradation of RANKL and OPG protein by P. 
gingivalis 
 
Porphyromonas gingivalis proteases are known to degrade host molecules such as 
collagen, fibrinogen and other extracellular matrix proteins, as well as immunoglobulins 
and complement factors. In this study the effect of P. gingivalis culture supernatant on 
purified RANKL and OPG protein degradation was investigated. To test this 
hypothesis, 1000 pg/ml of recombinant mouse (rm) RANKL and 2000 pg/ml of rm 
OPG standard from the ELISA kits used in this study (R&D Systems) were spiked with 
5 µg/ml of P. gingivalis W50 culture supernatant protein concentration and incubated 
for 48h. The resulting protein concentration was then determined by the respective 
ELISA kits. A significant reduction of detection by 39% was observed when RANKL 
was mixed with P. gingivalis W50 compared to a matched untreated control, both 
incubated at 37˚C for 48h (Fig. 10A). In contrast, in a similar experimental procedure, 
OPG detection levels were significantly increased by 36% when co-incubated with P. 
gingivalis W50, compared to OPG alone (Fig. 10B). 
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Fig. 11A. RANKL spiking with W50 
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Fig. 11B. OPG spiking with W50 
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Fig. 11. (A) Five µg/ml of P. gingivalis W50 protein concentration were used to spike 1000 pg/ml of 
rmRANKL protein standard (RnD systems) and incubated for 48h. (B) Five µg/ml of P. gingivalis W50 
protein concentration were used to spike 2000 pg/ml of rmOPG protein standard (RnD systems) and 
incubated at 48h. Bars represent mean ± SEM from triplicate determinations. Protein levels were detected 
by commercially available ELISA kits A one-way ANOVA with Bonferroni post hoc test was used to 
compare RANKL or OPG alone, to the respective groups incubated in presence of P. gingivalis W50. *** 
p <0.001 
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4.5 Investigation of PGE2 involvement in RANKL and OPG expression 
and production 
The involvement of PGE2 in the induction of RANKL was further investigated by the 
use of indomethacin, a non-selective COX-1 and COX-2 inhibitor. The cell cultures 
were pre-treated for 3 h with indomethacin before being challenged with indomethacin 
and 5 μg/ml P. gingivalis W50 for 24 h and 48 h. Indomethacin partially blocked COX-
2 mRNA expression by 37 % and 44 % at 24 h and 48 h, respectively, compared to P. 
gingivalis W50 challenge alone (Fig. 11A). The synthesis of PGE2 when induced by P. 
gingivalis W50, was successfully blocked to control levels at 24 h and 48 h (Fig. 11B). 
Indomethacin treatment also significantly inhibited RANKL mRNA expression (Fig. 
10C) and completely abolished RANKL protein production (Fig. 11D). Moreover, this 
treatment also significantly rescued P. gingivalis-induced downregulation of OPG 
mRNA at 48 h (Fig. 11E) but OPG protein production remained unaffected (Fig. 11F).  
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Fig. 12A. COX-2 gene expression 
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Fig. 12A. COX-2 gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 
bacterial protein and 5 µg/ml of W50 co-incubated with indomethacin for 24h and 48h. Bars represent 
mean ±SEM from three independent experiments. The gene expression levels were measured by qPCR, 
and calibrated against the expression of corresponding housekeeping genes. A Bonferroni two-way 
(ANOVA) post-hoc test was used to compare experimental groups to W50 alone. *p <0.05, *** p <0.001. 
 
 
 
 
 
Fig. 12B. PGE2 production 
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Fig. 12B. PGE2 secreted protein in W20-17 cells challenged with 5µg/ml of P. gingivalis W50 bacterial 
protein and 5µg/ml of W50 co-incubated with indomethacin for 24h and 48h. Bars represent mean ± SEM 
from three independent experiments. Secreted protein levels were measured by commercially available 
ELISA kits. A Bonferroni two-way (ANOVA) post-hoc test was used to compare experimental groups to 
W50 alone. *** p <0.001. 
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Fig. 12C. RANKL gene expression 
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Fig. 12C. RANKL gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 
bacterial protein and 5µg/ml of W50 co-incubated with indomethacin for 24h and 48h. Bars represent 
mean ± SEM from three independent experiments. The gene expression levels were detected by qPCR, 
and calibrated against the expression of corresponding housekeeping genes. A Bonferroni two-way 
(ANOVA) post-hoc test was used to compare experimental groups to W50 alone. *** p <0.001. 
 
 
 
 
 
Fig. 12D. RANKL protein expression 
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Fig. 12D. RANKL total protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 bacterial 
protein and 5µg/ml of W50 co-incubated with indomethacin for 24h and 48h. Bars represent mean ± SEM 
from three independent experiments. Total protein levels (intracellular + extracellular) were measured by 
commercially available ELISA kits. A Bonferroni two-way (ANOVA) post-hoc test was used to compare 
experimental groups to W50 alone. *** p <0.001. 
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Fig. 12E. OPG gene expression 
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Fig. 12E. OPG gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 bacterial 
protein and 5µg/ml of W50 co-incubated with indomethacin for 24h and 48h. Bars represent mean ± SEM 
from three independent experiments. The gene expression levels were measured by qPCR, and calibrated 
against the expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc 
test was used to compare experimental groups to W50 alone. *p <0.05, *** p <0.001. 
 
 
 
 
 
Fig. 12F. OPG protein expression 
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Fig. 12F. OPG total protein expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 
bacterial protein and 5µg/ml of W50 co-incubated with indomethacin for 24h and 48h. Bars represent 
mean ± SEM from three independent experiments. Total protein levels (intracellular + extracellular) were 
measured by commercially available ELISA kits. A Bonferroni one-way (ANOVA) post-hoc test was 
used to compare experimental groups to W50 alone. *p <0.05. 
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4.6 Effects of P. gingivalis virulence factors on RANKL, OPG and 
PGE2 
4.6.1 Effects of TLCK and heat inactivated P. gingivalis supernatant on 
RANKL, OPG and PGE2 
The next stage of these investigations was to identify possible virulence factors of P. 
gingivalis that may be responsible for the induction of RANKL and the downregulation 
of OPG. The wild-type P. gingivalis W50 strain was either treated with TLCK to 
remove gingipain activity or heat-inactivated to destroy the proteinaceous component in 
the culture supernatant. A TLCK-only control was also used. It was evident that neither 
TLCK treatment nor heat-inactivation of P. gingivalis W50 supernatant affected 
RANKL mRNA expression (Fig. 12A) or protein production (Fig. 12B), compared to 
un-treated P. gingivalis. Accordingly, these treatments did not rescue the reduction of 
the inhibition of OPG mRNA expression (Fig. 12C) or OPG protein production (Fig. 
12D), elicited by P. gingivalis W50 supernatants. Furthermore, a significant reduction 
in COX-2 mRNA expression was observed by heat-inactivated P. gingivalis W50 (Fig. 
12E), which however was not accompanied by a reduction in PGE2 production. (Fig. 
12F). Treatment of the cells with TLCK alone did not affect the expression of these 
factors, with the exception of OPG at 48h, which was upregulated compared to the 
untreated control.  
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Fig.13A. RANKL gene expression  
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Fig. 13A. RANKL gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 
bacterial protein, TLCK treated and heat inactivated P. gingivalis W50 for 24 h and 48 h. Bars represent 
mean ± SEM from three independent experiments. The gene expression levels were measured by qPCR, 
and calibrated against the expression of corresponding housekeeping genes. A Bonferroni two-way 
(ANOVA) post-hoc test was used to compare experimental groups to W50 alone. ** p < 0.01, *** p 
<0.001. 
 
 
 
 
 
Fig. 13B. RANKL protein expression 
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Fig. 13B. RANKL total protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 bacterial 
protein, TLCK treated and heat inactivated P. gingivalis W50 for 24 h and 48 h. Bars represent mean ± 
SEM from three independent experiments. Total protein levels (intracellular + extracellular) were 
measured by commercially available ELISA kits. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to W50 alone. *** p <0.001. 
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Fig. 13C. OPG gene expression 
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Fig. 13C. OPG gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 bacterial 
protein, TLCK treated and heat inactivated P. gingivalis W50 for 24 h and 48 h. Bars represent mean ± 
SEM from three independent experiments. The gene expression levels were measured by qPCR, and 
calibrated against the expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) 
post-hoc test was used to compare experimental groups to W50 alone. *** p <0.001. 
 
 
 
 
 
Fig. 13D. OPG protein expression 
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Fig. 13D. OPG total protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 bacterial 
protein, TLCK treated and heat inactivated P. gingivalis W50 for 24 h and 48 h. Bars represent mean ± 
SEM from three independent experiments. Total protein levels (intracellular + extracellular) were 
measured by commercially available ELISA kits. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to W50 alone. ** p < 0.01. 
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Fig. 13E. COX-2 gene expression 
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Fig. 13E. COX-2 gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 
bacterial protein, TLCK treated and heat inactivated P. gingivalis W50 for 24 h and 48 h. Bars represent 
mean ± SEM from three independent experiments. The gene expression levels were measured by qPCR, 
and calibrated against the expression of corresponding housekeeping genes. A Bonferroni two-way 
(ANOVA) post-hoc test was used to compare experimental groups to W50 alone. *p <0.05, *** p <0.001. 
 
 
 
 
 
Fig. 13F. PGE2 production  
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Fig. 13F. PGE2 secreted protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 bacterial 
protein, TLCK treated and heat inactivated P. gingivalis W50 for 24 h and 48 h. Secreted protein levels 
were measured by commercially available ELISA kits. Bars represent mean ± SEM from three 
independent experiments. A Bonferroni two-way (ANOVA) post-hoc test was used to compare 
experimental groups to W50 alone.  
 86
4.6.2 Effects of P. gingivalis gingipain mutants, K1A and E8 on 
RANKL, OPG and PGE2 
The potential involvement of P. gingivalis gingipains in the regulation of RANKL, 
OPG and PGE2 was also investigated by the use of gingipain knock-out mutant strains, 
namely kgp mutant strain K1A (lysine gingipain mutant), and the rgpArgpB mutant 
strain E8, (arginine gingipain double mutant). P. gingivalis K1A strain proved to induce 
significantly lower levels of RANKL mRNA and protein expression, compared to its 
parental wild-type W50 strain, after 48 h of challenge (Fig. 13A and 13B). There was no 
significant difference in RANKL inducing capacity between P. gingivalis E8 mutant 
and W50 wild-type strains. When OPG levels were investigated, P. gingivalis W50 
wild-type and K1A mutant strain suppressed OPG mRNA expression (Fig. 13C) and 
protein production (Fig. 13D) to a similar extent. Of note, the P. gingivalis E8 mutant 
strain caused a more pronounced inhibition of OPG mRNA expression, but not protein 
production, which proved to be significant only after 48 h. Finally, COX-2 mRNA 
expression and PGE2 production were investigated in response to the two gingipain 
mutant strains. It was found that, compared to the P. gingivalis wild-type W50 strain, 
the E8 mutant strain significantly increased COX-2 mRNA expression at 24 h and 48 h, 
whereas the K1A mutant strain significantly decreased this at 48 h (Fig. 13E). On the 
contrary, the levels of secreted PGE2 were not found to be significantly different 
between either of the P. gingivalis mutant groups and the wild-type group (Fig. 13F). 
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Fig. 14A. RANKL gene expression 
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Fig. 14A. RANKL gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50, K1A 
and E8 for 24 h and 48 h. Bars represent mean ± SEM from three independent experiments. The gene 
expression levels were measured by qPCR, and calibrated against the expression of corresponding 
housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to compare experimental 
groups to W50 alone. ** p < 0.01, *** p <0.001. 
 
 
 
 
 
Fig. 14B. RANKL protein production 
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Fig. 14B. RANKL total protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50, K1A and 
E8 for 24 h and 48 h. Bars represent mean ± SEM from three independent experiments. Total protein 
levels (intracellular + extracellular) were measured by commercially available ELISA kits. A Bonferroni 
two-way (ANOVA) post-hoc test was used to compare experimental groups to W50 alone. * p <0.05, *** 
p <0.001. 
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Fig. 14C. OPG gene expression 
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Fig. 14C. OPG gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50, K1A and 
E8 for 24h and 48h. Bars represent mean ± SEM from three independent experiments. The gene 
expression levels were measured by qPCR, and calibrated against the expression of corresponding 
housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to compare experimental 
groups to W50 alone. ** p < 0.01, *** p <0.001. 
 
 
 
 
 
Fig. 14D. OPG protein expression 
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Fig. 14D. OPG total protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50, K1A and E8 
for 24h and 48h. Bars represent mean ± SEM from three independent experiments. Total protein levels 
(intracellular + extracellular) were measured by commercially available ELISA kits. A Bonferroni two-
way (ANOVA) post-hoc test was used to compare experimental groups to W50 alone. ** p < 0.01. 
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Fig. 14E. COX-2 gene expression 
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Fig. 14E. COX-2 gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50, K1A 
and E8 for 24h and 48h. Bars represent mean ± SEM from three independent experiments. The gene 
expression levels were measured by qPCR, and calibrated against the expression of corresponding 
housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to compare experimental 
groups to W50 alone. ** p < 0.01, *** p <0.001. 
 
 
 
 
 
Fig. 14F. PGE2 production 
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Fig. 14F. PGE2 secreted protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50, K1A and 
E8 for 24h and 48h. Bars represent mean ± SEM from three independent experiments. Secreted protein 
levels were measured by commercially available ELISA kits. A Bonferroni two-way (ANOVA) post-hoc 
test was used to compare experimental groups to W50 alone.  
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4.6.3 Investigation of the role of P. gingivalis LPS in the regulation of 
RANKL, OPG and PGE2 
To investigate the putative involvement of P. gingivalis LPS in the upregulation of 
RANKL and PGE2, as well as downregulation of OPG, polymyxin B treatment of the P. 
gingivalis culture supernatants was used. This antibiotic binds to and removes lipid A 
from P. gingivalis W50 bacterial culture supernatant. This treated P. gingivalis 
supernatant was added to the cells and its effects were compared to those of the 
corresponding untreated supernatant. It was demonstrated that the RANKL mRNA-
inducing capacity of the LPS-depleted P. gingivalis culture supernatant was reduced by 
50%, compared to the untreated one, although this did not prove to be significant (Fig. 
14A). Interestingly, the corresponding results regarding RANKL protein production 
demonstrate that depletion of LPS from the P. gingivalis culture supernatant resulted in 
significant reduction of RANKL production levels of the control (Fig. 14B). 
 
In the case of OPG, LPS depletion by polymyxin B did not significantly affect the 
downregulation of OPG mRNA expression by P. gingivalis culture supernatants (Fig. 
14C), but it significantly rescued the downregulation of OPG protein production 
compared to the untreated P. gingivalis W50 culture supernatant at 48 h. With regards 
to COX-2 mRNA expression and PGE2 production, both were significantly lower by 
the polymyxin B-treated P. gingivalis culture supernatants, compared to the untreated 
ones (Fig. 14E & 14F). 
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Fig. 15A. RANKL gene expression 
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Fig. 15A. RANKL gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
polymyxin B treated W50 at 24 h and 48 h. Bars represent mean ± SEM from three independent 
experiments. The gene expression levels were measured by qPCR, and calibrated against the expression 
of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to 
compare experimental groups to W50 alone. ** p < 0.01. 
 
 
 
 
 
Fig. 15B RANKL protein expression 
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Fig. 15B. RANKL protein expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
polymyxin B treated W50 at 24h and 48h. Bars represent mean ± SEM from three independent 
experiments. The gene expression levels were measured by qPCR, and calibrated against the expression 
of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to 
compare experimental groups to W50 alone. *** p <0.001. 
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Fig. 15C. OPG gene expression 
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Fig. 15C. OPG gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
polymyxin B treated W50 at 24 h and 48 h. Bars represent mean ± SEM from three independent 
experiments. The gene expression levels were measured by qPCR, and calibrated against the expression 
of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to 
compare experimental groups to W50 alone. *p <0.05, ** p < 0.01. 
 
 
 
 
Fig. 15D. OPG protein expression 
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Fig. 15D. OPG gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
polymyxin B treated W50 at 24 h and 48 h. Bars represent mean ± SEM from three independent 
experiments. The gene expression levels were measured by qPCR, and calibrated against the expression 
of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to 
compare experimental groups to W50 alone. *p <0.05, ** p < 0.01, *** p <0.001. 
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Fig. 15E. COX-2 gene expression 
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Fig. 15E. COX-2 gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
polymyxin B treated W50 at 24 h and 48 h. Bars represent mean ± SEM from three independent 
experiments. The gene expression levels were measured by qPCR, and calibrated against the expression 
of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to 
compare experimental groups to W50 alone. ** p < 0.01, *** p <0.001. 
 
 
 
 
 
Fig. 15F PGE2 production 
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Fig. 15F. PGE2 secreted protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
polymyxin B treated W50 at 24 h and 48 h. Bars represent mean ± SEM from three independent 
experiments. The gene expression levels were measured by qPCR, and calibrated against the expression 
of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was used to 
compare experimental groups to W50 alone. ** p < 0.01, *** p <0.001. 
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4.6.4 Investigation of the role of purified P. gingivalis LPS in the 
regulation of TLR-2 and TLR-4 
To further investigate the role of P. gingivalis LPS on RANKL, OPG and PGE2 
regulation, LPS was purified from P. gingivalis W50 strain freeze-dried cells. To 
initially establish whether W20-17 cells could be responsive to P. gingivalis LPS, the 
gene expressions of LPS-signaling receptors TLR-2 and TLR-4, were measured and 
confirmed (Fig. 15A). Using the LAL assay, the levels of LPS in W50 culture 
supernatant was determined as 1670 EU/ml. It was therefore reasonable to employ 
purified LPS within this range of concentrations, in further experiment. Ascending 
concentrations of P. gingivalis LPS, starting from 1250 EU/ml to 5000 EU/ml were 
used. TLR-2 gene expression was significantly upregulated in P. gingivalis W50 culture 
supernatant compared to the untreated control (Fig. 15A), and purified P. gingivalis 
LPS also upregulated this expression (Fig. 15A). In contrast, P. gingivalis W50 culture 
supernatant did not significantly affect TLR-4 expression compared to the untreated 
control, at any time-point (Fig. 15B). However, with an LPS concentration of 2500 
EU/ml, the expression of TLR-4 was significantly upregulated at 6 h and 48 h, 
compared to the untreated control. Also, LPS concentration of 5000 EU/ml significantly 
enhanced TLR-4 expression compared to the untreated control at 6 h, but this 
enhancement was not sustained at further time-points. 
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Fig. 16A. TLR-2 gene expression 
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Fig. 16A. TLR-2 gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
ascending concentrations of P. gingivalis LPS at 6 h, 24 h and 48 h. Bars represent mean ± SEM from 
three experiments. The gene expression levels were measured by qPCR, and calibrated against the 
expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to control. *p <0.05, *** p <0.001. 
 
 
 
 
 
Fig. 16B. TLR-4 gene expression 
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Fig. 16B. TLR-4 gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
ascending concentrations of P. gingivalis LPS at 6 h, 24 h and 48 h. Bars represent mean ± SEM from 
three experiments. The gene expression levels were measured by qPCR, and calibrated against the 
expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to control. *p <0.05, ***p <0.001. 
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4.6.5 Investigation of the role of purified P. gingivalis LPS in the 
regulation of RANKL, OPG and PGE2 
The next step was to examine if the purified P. gingivalis LPS affects RANKL, OPG 
and PGE2 expression and production levels by W20-17 cells. Although P. gingivalis 
W50 did significantly induce RANKL mRNA levels, the present data shows that P. 
gingivalis LPS did not induce RANKL expression compared to the untreated control 
(Fig. 16A). P. gingivalis W50 downregulated levels of OPG at 6 h, resuming control 
levels at 24 h and 48 h (Fig. 16B). However, purified P. gingivalis LPS at a 
concentration of 5000 EU/ml significantly downregulated OPG expression in a 
sustained manner, over 48 h. Finally, P. gingivalis LPS also downregulated OPG 
expression at concentration of 1250 EU/ml at 24 h, and also at concentration of 2500 
EU/ml at 24 h and 48 h.  
 
In the case of COX-2 gene expression, this was upregulated upon challenge of P. 
gingivalis W50 at 6 h and 24 h. This induction was accompanied by an upregulation of 
PGE2 at 24 h and 48 h, compared to the control (Fig 16C, Fig. 16D). Purified P. 
gingivalis LPS significantly induced the expression of COX-2 at 1250 EU/ml at 48 h, 
and 2500 EU/ml and 5000 EU/ml at 24 h and 48 h. However, this induction was not 
followed by a concomitant induction of PGE2 at any time-point measured (Fig 16C, Fig. 
6D). 
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Fig. 17A. RANKL gene expression 
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Fig. 17A. RANKL gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
ascending concentrations of P. gingivalis LPS at 6 h, 24 h and 48 h. Bars represent mean ± SEM from 
three experiments. The gene expression levels were measured by qPCR, and calibrated against the 
expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to control. ***p <0.001. 
 
 
 
 
 
Fig. 17B. OPG gene expression 
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Fig. 17B. OPG gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
ascending concentrations of P. gingivalis LPS at 6 h, 24 h and 48 h. Bars represent mean ± SEM from 
three experiments. The gene expression levels were measured by qPCR, and calibrated against the 
expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to control. *p <0.05, ** p < 0.01, *** p <0.001. 
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Fig. 17C. COX-2 gene expression 
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Fig. 17C. COX-2 gene expression in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
ascending concentrations of P. gingivalis LPS at 6 h, 24 h and 48 h. Bars represent mean ± SEM from 
three experiments. The gene expression levels were measured by qPCR, and calibrated against the 
expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc test was 
used to compare experimental groups to control. *p <0.05, ** p < 0.01, ***p <0.001. 
 
 
 
 
 
Fig. 17D. PGE2 production 
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Fig. 17D. PGE2 secreted protein in W20-17 cells challenged with 5 µg/ml of P. gingivalis W50 and 
ascending concentrations of P. gingivalis LPS at 6 h , 24 h and 48 h. Bars represent mean ± error of mean 
(SEM) from three experiments. The gene expression levels were measured by qPCR, and calibrated 
against the expression of corresponding housekeeping genes. A Bonferroni two-way (ANOVA) post-hoc 
test was used to compare experimental groups to control. ***p <0.001. 
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4.7 Intracellular pathways regulated by P. gingivalis 
The next part of these studies was to investigate possible intracellular signalling 
pathways that may be regulated by P. gingivalis, and their potential association with the 
previously demonstrated regulations of the RANKL-OPG system and COX-2/PGE2. In 
these investigations, the focus was placed on the MAPK family, including p44/42, 
SAPK/JNK, p38 and their phosphorylation. 
 
4.7.1 Effects of P. gingivalis on MAPK signalling proteins p44/42, 
SAPK/JNK and p38. 
To investigate the effect of P. gingivalis on the three MAPK, the cells were cultured in 
the presence or absence of 5 µg/ml P. gingivalis W50 culture supernatants for up to 60 
min. Both total and phosphorylated levels of MAPK were investigated by Western 
immunoblotting after 0 min, 15 min, 30 min and 60 min of challenge with P. gingivalis. 
The phosphorylation of all three SAPK/JNK, p44/42, and p38 proteins was upregulated 
after 15 min in both P. gingivalis-challenged and unchallenged cell cultures, while the 
total level of these proteins remained unchanged (Fig. 18). Differences in 
phosphorylation of these proteins between the P. gingivalis-challenged and 
unchallenged groups were further considered. In the case of p44/p42, there was no 
obvious change in phosphorylation levels in the P. gingivalis-challenged compared to 
the control, at any time-point (Fig. 18A). When phosphorylation of JNK was 
investigated, no differences were evident up to 30 min, but there appeared to be a slight 
further upregulation in cells challenged with P. gingivalis, with a 1.5 fold increase after 
60 min compared to the control, as measured by densitometry (Fig. 18B). In contrast, a 
strong phosphorylation of p38 was evident at 30 min in P. gingivalis-challenged cells 
compared to the control, which was further increased by 2.1 fold at 60 min (Fig. 18C). 
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Collectively, these findings indicate that p38 is the MAPK most affected by P. 
gingivalis. 
 
Fig. 18. p44/42, SAPK/JNK & p38 protein expression 
 
 
 
Fig. 18. Western immunoblotting of phosphorylated and total p44/42, SAPK/JNK and p38. In these 
experiments, W20-17 bone marrow stromal cells were cultured in the presence or absence of 5µg/ml P. 
gingivalis W50 culture supernatants. Cell lysates were obtained at 0, 15 min, 30 min and 60 min from the 
P. gingivalis-challenged cultures and the corresponding unchallenged controls. Western immunoblotting 
was then performed to determine the total and phosphorylated levels of p44/42 (A), SAPK/JNK (B), and 
p38 (C). 
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4.7.2 Effects of p38 inhibition on RANKL, OPG and COX-2 gene 
expression 
To investigate the involvement of p38 in the regulation of RANKL, OPG and COX-2 
gene expression, a chemical inhibitor of p38 (SB203580) was used. W20-17 bone 
marrow stromal cells were pre-incubated with the inhibitor (10 µM) for 1 h, and then 
challenged with P. gingivalis (5µg/ml) for 24 h. RANKL gene expression was 
significantly upregulated in P. gingivalis–challenged cells compared to the 
unchallenged control at 24 h (Fig. 19A). When the cells were pre-treated with the p38 
inhibitor, a significant decrease was observed in the capacity of P. gingivalis to induce 
RANKL expression (Fig. 19A), accounting for an 83% reduction compared to non-pre-
treated cells.  
 
With regard to OPG gene expression, this was downregulated in response to P. 
gingivalis, after 24 h (Fig. 19B). However, pre-treatment with the p38 inhibitor did not 
rescue this downregulation of OPG expression by P. gingivalis, and in fact, this caused 
a further downregulation, which did not prove to be significant (Fig. 19B). In the 
absence of P. gingivalis, pre-treatment of the cells with the p38 inhibitor alone caused a 
downregulation in OPG expression relative to the control but this was not significant.  
 
Finally, the gene expression of COX-2, was also investigated. P. gingivalis culture 
supernatants significantly enhanced COX-2 expression after 24 h of challenge (Fig. 
19C), but, interestingly, the p38 inhibitor significantly reduced this effect by 76 %, in a 
trend similar to that of RANKL inhibition (Fig. 19C). 
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Fig. 19A. RANKL gene expression 
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Fig. 19A. Effect of p38 inhibitor on RANKL expression in response to P. gingivalis. W20-17 cells were 
either pre-treated or non-treated with the p38 inhibitor SB203580 (10-5 M) for 1 h. The cells were then 
challenged with 5 µg/ml P. gingivalis W50 culture supernatants for 24 h. The gene expression levels of 
RANKL were measured by qPCR analysis, and the results are expressed as the 2-ΔCT formula, normalised 
against the average housekeeping gene expression in each sample. Bars represent mean values ± SEM 
from three independent experiments. A one way (ANOVA) and Bonferroni post-hoc test were used to 
compare differences between the P. gingivalis-challenged group and the other groups. *p < 0.05. 
 
 
 
 
 
Fig. 19B. OPG gene expression 
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Fig. 19B. Effect of p38 inhibitor on OPG expression in response to P. gingivalis. W20-17 cells were 
either pre-treated or non-treated with the p38 inhibitor SB203580 (10-5 M) for 1 h. The cells were then 
challenged with 5 µg/ml P. gingivalis W50 culture supernatants for 24 h. The gene expression levels of 
OPG were measured by qPCR analysis, and the results are expressed as the 2-ΔCT formula, normalised 
against the average housekeeping gene expression in each sample. Bars represent mean values ± SEM 
from three independent experiments. A one way (ANOVA) and Bonferroni post-hoc test were used to 
compare differences between the P. gingivalis-challenged group and the other groups.  
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Fig. 19C. COX-2 gene expression 
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Fig. 19C. Effect of p38 inhibitor on COX-2 expression in response to P. gingivalis. W20-17 cells were 
either pre-treated or non-treated with the p38 inhibitor SB203580 (10-5 M) for 1 h. The cells were then 
challenged with 5 µg/ml P. gingivalis W50 culture supernatants for 24 h. The gene expression levels of 
OPG were measured by qPCR analysis, and the results are expressed as the 2-ΔCT formula, normalised 
against the average housekeeping gene expression in each sample. Bars represent mean values ± SEM 
from three independent experiments. A one way (ANOVA) and Bonferroni post-hoc test were used to 
compare differences between the P. gingivalis-challenged group and the other groups. *p < 0.05. 
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4.8 Gene microarray analysis of cells challenged with P. gingivalis  
To determine the overall transcriptional effect of P. gingivalis on bone marrow stromal 
cells, global gene expression was measured using an Illumina bead microarray 
(MouseRef-8 v2.0 Expression BeadChips). W20-17 bone marrow cells were challenged 
with 5 μg/ml of P. gingivalis W50 culture supernatant, over a 6 or 24 h time period. The 
specific changes in gene transcript levels induced by P. gingivalis were determined by 
normalising against unchallenged control samples. Over 24,000 transcripts were 
assayed and to narrow the frame of reference a cut off of 2-fold was chosen. A small 
number of genes with lower than 2-fold regulation were also included, since these were 
of specific interest in the earlier parts of this thesis. The purpose for this inclusion was 
to make a comparative validation of earlier results.  
 
The collective data indicates that 480 genes were identified with > 2-fold up- or 
downregulation at 6 h, and 364 genes were identified as up- or downregulated at 24 h. 
In particular, after 6 h of P. gingivalis challenge, 271 genes were upregulated whilst 209 
genes were downregulated (Appendix 2). Further on, after 24 h of P. gingivalis 
challenge, 259 genes were upregulated whilst 109 genes were downregulated (Appendix 
3). 
 
To categorise genes according to their known function, Ingenuity Pathway Analysis was 
used (Ingenuity Systems®, http://www.ingenuity.com). Hence, genes that were over 2-
fold regulated (up- or down-) were classified into cellular categories. The top five 
cellular functions, along with corresponding percentages of up and downregulated genes 
at 6 h and 24 h, are displayed (Table 3A and 3B). This data demonstrates two stages of 
response at 6 h and 24 h post-P. gingivalis challenge. An early 6 h-response to P. 
gingivalis was characterised by regulation of genes associated with cell movement, 
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growth, proliferation and signalling (Table 3A). However, by 24 h, genes that are linked 
to the immune response are upregulated, as shown by the predominance of these 
categories, including immunological disease, antigen presentation, cell-mediated and 
humoral immunity (Table 3B). Common to both time-points is the high level of genes 
up and downregulated categorised as associated with cancer. This may not be surprising 
and does not imply that P. gingivalis is involved in carcinogenesis. The likely 
explanation is that this is generally a broad category that contains genes important for 
initiation of cell growth, including regulators of cell cycle, apoptosis and genes involved 
in cellular proliferation. Overall, it is evident that P. gingivalis is affecting the 
transcriptional expression of a wide array of genes linked to several categories. 
 
Due to the theme of the previous studies of this thesis, genes affected by P. gingivalis 
challenge that are associated with bone metabolism and inflammatory processes were of 
particular interest (Table 4). The Ingenuity software did not distinguish between skeletal 
and muscle categories, since many of the genes have roles in both skeletal and muscle 
metabolism. Therefore genes for both groups were included. Categories were then 
further subdivided by broad cellular function, for example inflammation and immune 
related genes, and each gene was accompanied by the fold changes at 6 h and 24 h time-
points (Table 4).  
 
In response to P. gingivalis challenge, the transcription of apoptotic genes, including 
caspase 4 (CASP4), tumor necrosis factor receptor superfamily member 6 (FAS) and 
engulfment adaptor PTB domain containing 1 (GULP1), were upregulated at 6 h and 24 
h (Table 4, apoptosis related genes). The expression of negative regulation cell cycle 
genes p16 and p21 was also upregulated by 2.0- and 5.3-fold, respectively, at 6 h. 
Conversely another inhibitor of the cell cycle, p18, was downregulated at both 6 h and 
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24 h by 2.0- and 2.3-fold respectively. Cyclin D1, the only positive regulator of the cell 
cycle to be affected, was downregulated by 3.1-fold after 24 h (Table 4, Cell cycle 
genes). Collectively, these results indicate an overall negative effect on cell cycle 
progression, by P. gingivalis in the present experimental system.  
 
The regulation of inflammatory chemokines and cytokines groups by P. gingivalis 
challenge was further investigated. In particular, the expression of LPS-induced CXC 
chemokine (also named CXCL5) was upregulated at 24 h by a marked 112.0-fold. 
Chemokine C-C motif ligand 5 (CCL5) was upregulated by 9.0- and 86.8-fold, and 
chemokine C-X-C motif ligand 9 (CXCL9) by 10.5- and 35.0-fold, at 6 h and 24 h, 
respectively. Other chemokines of interest that were upregulated at 6 h and 24 h include 
CCL17, CCL2, CCL3, CCL7, CCL9, CXCL1, CXCL10 and CXCL2. Of the 
interleukins, IL-1α and IL-6 were increased at 24 h by 6.5- and 23.2-fold respectively. 
However, IL-15, a cytokine that regulates T- and natural killer cell activation and 
proliferation, was downregulated by 2.3-fold at 24 h. Macrophage stimulating factor 
(MCS-F) 1 and MCS-F 2 expression levels were also increased by 2.7- and 2.4-fold at 
6h. Additionally, RANKL expression was upregulated at 24 h by 1.9-fold, confirming 
results of the earlier parts of this thesis (Table 4, Chemokine and cytokines). All these 
regulations are in support of the enhancement of a pro-inflammatory phenotype of the 
cells induced by P. gingivalis at the later time-point of 24 h. 
 
Inflammatory genes were, in the main, upregulated in response to P. gingivalis 
challenge. Some of the key genes responsible for prostaglandin synthesis, COX-2 and 
prostaglandin E synthase (PTGES) were upregulated. COX-2 mRNA expression was 
increased by 3.2- and 2.3-fold at 6 h and 24 h respectively, whilst PTGES expression 
was only increased at 6 h by 3.2-fold. Haptoglobin (Hp) is a protein that binds 
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haemoglobin and can be induced in acute phase response. It was upregulated by 2.6 and 
7.5-fold at 6 h and 24 h respectively. Additionally, the transcript level of hemopexin 
(Hpx), the protein that binds heme was upregulated by 7-fold at 24 h. The expression of 
superoxide dismutase 2 (SOD2), a gene that encodes a mitochondrial protein that 
destroys superoxide anion radicals was upregulated at 6 h and 24 h. The gene transcript 
levels of the major LPS-interacting cellular component LBP, was upregulated by 2.4-
fold at 24 h, whereas the expression of MD-2, was downregulated by 2.3-fold at 6 h. 
Interestingly, within this category of inflammation-related genes were also the ones 
exhibiting the highest change in levels of mRNA expression. These were namely 
lipocalin 2 (LCN2) and serum amyloid A3 (SAA3). LCN2 was markedly increased at 6 
h and 24 h, with a fold change of 33.6 and 354.8 respectively. SAA3 was also strongly 
upregulated at 6 h and 24 h, with a fold increase of 144.8 and 143.9, respectively (Table 
4, Inflammation genes). 
 
P. gingivalis challenge also stimulated the expression of a number of immune related 
genes by the cells. The mRNA expression of cathelicidin antimicrobial peptide 
(CAMP), a protein that exhibits antibacterial activity, was upregulated at 24 h with a 
9.4-fold increase. Genes encoding complement proteins namely complement component 
1s (C1s), complement component 3 (C3), complement component 4B (C4B) and 
complement factor B (CFB) were upregulated at 24 h. Transcripts for macrophage 
antigen CD68 were also increased by 2.0-fold at 24 h. Pentraxin 3 (PTX3), another gene 
linked with innate immunity was upregulated at both 6 h and 24 h. Genes encoding for 
proteins associated with the major histocompatibility complex (MHC) were also 
upregulated at 6 h and 24 h (Table 4, Immune related genes). 
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The transcription of some growth factors was also affected by P. gingivalis challenge. 
In particular, a downregulation was evident in the expression of BMP4. BMP4 is a key 
gene in the process of stimulating osteoblastic differentiation, and this was 
downregulated by 2.2-fold at 6 h. Otherwise, vascular endothelial growth factor (VEGF) 
was upregulated by 2.1- and 2.8-fold at 6 h and 24 h, respectively, whereas hepatocyte 
growth factor (HGF) expression was increased by 2.3-fold at 24 h (Table 4, Growth 
factors genes).  
 
The regulation of genes encoding for some proteases and other functionally similar 
proteins was also affected. There were two differentially expressed A Disintegrin And 
Metalloproteinases (ADAM) proteases. One, ADAM domain 12 (ADAM12), was 
downregulated at 6 h by -2.4-fold, whereas the other, ADAM with thrombospondin 
(ADAMTS7) was upregulated at 24 h by 2.1-fold (Table 4, Protease and related genes). 
The expression levels of cysteine and serine proteases were also affected, with cysteine 
protease cathepsin L (CTSL) upregulated at 6 h whilst elastase 1 (ELA1), a serine 
protease, downregulated at both 6 h and 24 h. In addition, proteasome subunit beta type 
8 (PSMB8), a multicatalytic proteinase was upregulated at 6 h. Interestingly, the 
expression of secretory leukocyte peptidase inhibitor (SLPI), a proteinase inhibitor, was 
increased at 6 h and 24 h by 4.9- and 19.5-fold respectively (Table 4, Protease and 
related genes). The serine protease inhibitor (SERPIN) gene family, comprising several 
serine and selected cysteine proteinase inhibitors, were all upregulated. Serpin b6 and 
Serpin b9 expressions were increased at 24 h, whereas Serpin 3f and Serpin 3g 
expressions were increased at both 6 h and 24 h (Table 4, Proteases and related genes). 
Within the protease category, there was also evidence of elevated transcript levels of 
matrix metalloproteinases (MMPs), with MMP17 being upregulated at 6 h, whereas 
MMP12, MMP3 and MMP9 being upregulated at 24 h. In particular, MMP3 was 
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increased by 35.8-fold at 24 h, whereas MMP13 was upregulated at both 6 h and 24 h, 
by 9.3- and 8.4-fold, respectively. The only MMP downregulated was MMP-14, by 2.2-
fold at 6 h. An MMP inhibitor, Tissue inhibitor of metalloproteinase 1 (TIMP1) was 
upregulated at 6 h by 2.1-fold (Table 4, Protease and related genes). 
 
The transcription of a number of receptors was increased in response to P. gingivalis 
challenge. Cluster of differentiation 14 (CD14), a major receptor required for the 
activation of toll-like receptor complexes in response to LPS, was upregulated at 24 h 
by 2.1-fold. It was also found that the expression of TLR-2 itself was upregulated at 6 h 
and 24 h by 3.7- and 12.6-fold respectively. Interestingly, this is the major signalling 
receptor of P. gingivalis LPS. Genes encoding proteins that are associated with 
activation of Signal transducer and activator of transcription (STAT) pathway including 
interferon receptor 2 (IFNAR2) and interleukin 10 receptor beta (IL10RB) were also 
increased at 24 h. Also, IL-13 receptor, alpha (IL-13RA)1 and IL-13RA2 were 
upregulated at 24 h by 4.1- and 11.0-fold respectively. IL-1 receptor antagonist (IL1RN) 
was decreased at 6 h by 3.9-fold. The expression of OPG crucial negative regulator of 
bone resorption was also downregulated by 4.0-fold at 6 h. (Table 4, Receptor genes).  
 
Over the course of P. gingivalis challenge, transcripts for genes involved in signal 
transduction were mainly increased. Growth arrest and DNA-damage-inducible, beta 
(GADD45B), a protein normally involved in growth and apoptosis, was upregulated at 
24 h by 2.6-fold, whereas immediate early response 3 (IER3), a protein that protects 
against apoptosis, was also upregulated at 6 h and 24 h by 4.9- and 5.5-fold 
respectively. Janus kinase 2 (JAK2) is a protein tyrosine kinase, and was upregulated at 
24 h by 6.9-fold whereas suppressor of cytokine signalling 3 (SOCS3), a negative 
regulator of cytokines that signal through the JAK/STAT pathways, was increased at 6 h 
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and 24 h by 2.3- and 4.5-fold respectively. Serine, threonine kinases, mitogen-activated 
protein kinase kinase kinase 8 (MAP3K8) and receptor-interacting serine-threonine 
kinase 2 (RIPK2) transcripts are increased at both 6 h and 24 h. The expression of 
WNT1 inducible signalling pathway protein 2 (WISP2), a downstream gene of the 
WNT pathway was decreased at 6 h by 2.6-fold. Transcripts for myeloid differentiation 
primary response gene (88) (MYD88), an adaptor molecule involved in TLR signalling 
was increased at 24 h. The expressions of NF-κB inhibitors NF-κBIA, NF-κBIE, NF-
κBIZ, TNF α-induced protein 3 (TNFAIP3) and TNFAIP3 interacting protein 1 
(TNIP1) were all upregulated at 6 h and 24 h. NF-κBIZ in particular was upregulated at 
6 h and 24 h by 11.2- and 9.6-fold, respectively. B-cell lymphoma 3-encoded protein 
(BCL3), also a NF-κB inhibitor, was also upregulated at 24 h. Interestingly kinases that 
phosphorylate components of the NF-κB complex, inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase epsilon (IκBKE) and gamma (IκBKG) were also 
upregulated at 24 h. (Table 4, Signal transduction genes).  
 
The regulation of a number of transcription factors was also affected in response P. 
gingivalis challenge. Components of the NF-κB complex, NF-κB 1, NF-κB 2, v-rel 
reticuloendotheliosis viral oncogene homolog (REL) A and REL-B were all upregulated 
at 24 h (Table 4, transcription factor genes). Hairy-related transcription factor 1 
(HEY1), a transcription factor normally downstream of notch signalling, was increased 
at 6 h. A number of transcription factors were upregulated at 6 h and 24 h including 
CCAAT/enhancer-binding protein beta (CEBPβ) and STAT3. Components of the AP-1 
complex jun B proto-oncogene (JUNB) and FBJ murine osteosarcoma viral oncogene 
homolog (c-Fos) were also increased at 6 h and 24 h. Transcription factor genes sex 
determining region Y box 9 (SOX9) and odd-skipped related 2 (OSR2) were both 
downregulated at 24 h. (Table 4, Transcription factor genes). 
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Finally other genes that were considerably affected by P. gingivalis challenge included 
Guanosine triphosphate enzymes (GTPases), structural, and extracellular matrix genes 
(Table 4). GTPase genes were generally upregulated by P. gingivalis infection at 6 h 
and 24 h with guanylate binding protein 2 (GBP2) being especially upregulated at 6 h 
and 24 h by 4.4- and 16.3-fold (Table 4, GTPase proteins).  
 
Claudin 15 (CLDN15), a gene which encodes a component of tight junctions, was 
downregulated at 6 h and 24 h by 2.9 and 3.2 respectively. Other structural genes that 
were downregulated at 24 h include caveolin 1 (CAV1) and vimentin (VIM) (Table 4, 
Structural genes). Interestingly, the extracellular Matrix GLA protein (MGP) normally 
associated with bone and cartilage was downregulated by -2.9-fold at 24 h (Table 4, 
extracellular matrix gene). Angiopoietin-like 4 (ANGPTL4) is the only a hormone in 
this experimental system to be regulated over the 2.0-fold threshold, which was 
precisely 2.0-fold at 6 h and 3.5-fold at 24 h (Table 4, Hormones).  
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Table 3. Top five regulated gene categories according to cellular function.  
 
Table 3A. Genes regulated after 6 h 
 
 
Cellular function 
 
Upregulated Downregulated 
Cancer  
 33 %  22 % 
Cellular Movement 
 16 % 10% 
Cellular growth and 
proliferation 
 
24 %  20 % 
Cell-to-cell signalling 
 14 %  9 % 
Haematological system 
(development and function) 
 
17 % 6 % 
 
Table 3B. Genes regulated after 24 h 
 
 
Cellular function 
 
Upregulated Downregulated 
Cancer  
 36 % 33 % 
Immunological disease 
 25 % 9 % 
Antigen presentation 
 29 % 7 % 
Cell-mediated immune 
response 
 
28 % 10 %  
Humoral immune response 
 26 %  7 % 
 
Table 3. (A) Top five cellular categories of genes at 6 h (B) Top five cellular categories of genes at 24 h. 
The percentage of genes regulated within each category of processes is provided. 
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Table 4. Genes associated with Skeletal, Muscle and Inflammation categories  
 
 
Gene category 
Fold 
Change
(6 h) 
Fold 
Change 
(24 h) 
Skeletal & 
Muscle 
Development 
& Function 
Skeletal & 
Muscle 
Disorders 
Inflammatory 
Response 
Apoptosis genes  
Caspase 4 (CASP4) 2.8 4.3   X 
Engulfment adaptor 
PTB domain 
containing 1 
(GULP1)* 
2.3 2.1    
Tumor necrosis factor 
receptor superfamily 
member 6 (FAS) 
7.8 11.5  X X 
Cell cycle genes  
Cyclin D1   -3.1   X 
p16 2.0   X X  
p18* -2.0 -2.3    
p21 5.3   X X X 
Chemokines and cytokines  
CCL17 8.0 3.1  X X 
CCL2  17.6 20.7 X X X 
CCL3  3.3 40.0 X X X 
CCL5  9.0 86.8  X X 
CCL7 2.8 3.7 X X X 
CCL9 7.2 8.3 X X  
CX3CL1 10.6 4.7   X 
CXCL1 23.1 29.2  X X 
CXCL10 7.1 5.9  X X 
CXCL15  6.8  X X 
CXCL2  2.6 3.0  X X 
CXCL4   2.3   X 
CXCL5   112.0   X 
CXCL7   16.0   X 
CXCL9 10.5 35.0  X X 
Interleukin 1, alpha 
(IL-1α)  6.5 X X X 
Interleukin 15 (IL-15)   -2.3  X X 
Interleukin 6 (IL-6)  23.2 X X X 
Macrophage colony 
stimulating factor 1 
(M-CSF1) 
2.7   X X X 
Macrophage colony 
stimulating factor 2 
(M-CSF2) 
2.4   X X X 
Receptor activator of 
nuclear factor-κB 
ligand (RANKL) 
 1.9 X X X 
Tumor necrosis factor 
(ligand) superfamily, 
member 13b 
(TNFSF13B) 
  3.4  X X 
Extracellular matrix gene 
Matrix GLA protein 
(MGP)  -2.9 X   
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Gene category 
Fold 
Change
(6 h) 
Fold 
Change 
(24 h) 
Skeletal & 
Muscle 
Development 
& Function 
Skeletal & 
Muscle 
Disorders 
Inflammatory 
Response 
Growth factor genes 
Bone morphogenic 
protein 4 (BMP4) -2.2   X X  
Hepacyte growth 
factor (HGF)   2.3  X X 
Vascular endothelial 
growth factor (VEGF) 2.1 2.8 X X X 
Guanosine triphosphate enzymes (GTPase) genes 
GTP cyclohydrolase 1 
(GCH1) 9.0    X  
Guanylate binding 
protein 2 (GBP2) 4.4 16.3   X 
Inflammation genes 
Cyclooxygenase-2 
(COX-2) 3.2 2.3 X X X 
Haptoglobin (Hp) 2.6 7.5   X 
Hemopexin (Hpx)  7.0   X 
Lipocalin 2 (Lcn2) 33.6 354.8   X 
Lipolysaccharide 
binding protein (LBP)   2.4   X 
Myeloid 
differentiation protein-
2 (MD-2) 
-2.3     X 
Prostaglandin E 
synthase (PTGES) 3.2     X 
Serum amyloid A3 
(SAA3) 144.8 143.9  X X 
Superoxide dismutase 
2 (SOD2) 2.3 3.2 X X X 
Immune related genes  
Cathelicidin 
antimicrobial peptide 
(CAMP) 
  9.4   X 
Complement 
component 1s (C1s)  2.6 
 X X 
Complement 
component 3 (C3)   14.3 
 X X 
Complement 
component 4B (C4B)   2.3  X X 
Complement factor B 
(CFB)   19.9  X X 
DHX58   2.7   X 
Interferon gamma 
inducible protein 47 
(IFI47) 
3.1 2.9   X 
Interferon induced 
transmembrane protein 
3 (IFITM3) 
  3.2   X 
Interferon, alpha-
inducible protein 27 
(IFI27) 
  2.6   X 
Macrophage antigen 
CD68   2.0   X 
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Gene category 
Fold 
Change
(6 h) 
Fold 
Change 
(24 h) 
Skeletal & 
Muscle 
Development 
& Function 
Skeletal & 
Muscle 
Disorders 
Inflammatory 
Response 
Major 
histocompatibility 
complex, class I, C 
(HLA-C) 
  2.6  X X 
Major 
histocompatibility 
complex, class I, E 
(HLA-E) 
  2.8  X  
Major 
histocompatibility 
complex, class II, DM 
alpha (HLA-DMA) 
2.0    X X 
Major 
histocompatibility 
complex, class II, DQ 
beta 2 (HLA-DQβ2) 
  3.4  X X 
Pentraxin 3, long 
(PTX3) 11.9 32.0   X 
Retinoic acid-
inducible gene 1 
protein (RIG-1) 
  2.2   X 
S100 calcium binding 
protein A8 (S100A8)   3.4  X X 
Proteases and related genes 
A disintegrin and 
metalloproteinase 
domain 12 (ADAM12) 
-2.4    X 
A disintegrin-like and 
metalloproteinase with 
thrombospondin 
(ADAMTS7) 
 2.1  X  
Cathepsin L (CTSL) 2.2  X  X 
Elastase 1 (ELA1)* -2.4 -2.1    
Matrix 
metalloproteinase 12 
(MMP12) 
 2.9   X 
Matrix 
metalloproteinase 13 
(MMP13) 
9.3 8.4  X X 
Matrix 
metalloproteinase 13 
(MMP17) 
3.4   X X 
Matrix 
metalloproteinase 14 
(MMP14) 
-2.2   X X 
Matrix 
metalloproteinase 3 
(MMP3) 
 35.8  X X 
Matrix 
metalloproteinase 9 
(MMP9) 
 3.0  X X 
Proteasome subunit, 
beta type, 8 (PSMB8) 2.1    X 
Secretory leukocyte 
peptidase inhibitor 4.9 19.5   X 
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Gene category 
Fold 
Change
(6 h) 
Fold 
Change 
(24 h) 
Skeletal & 
Muscle 
Development 
& Function 
Skeletal & 
Muscle 
Disorders 
Inflammatory 
Response 
Serpina3f* 2.6 5.7   X 
Serpina3g* 6.3 7.0   X 
Serpinb6*   2.3   X 
Serpinb9*  8.7   X 
Tissue inhibitor of 
metalloproteinase 1 
(TIMP1) 
2.1   X  
Receptor genes 
CD44 2.2  X X X 
Cluster of 
differentiation 14 
(CD14) 
  2.1   X 
Interferon Receptor 2 
(IFNAR2)  2.7  X X 
Interleukin 1 receptor 
antagonist (IL1RN) -3.9  X X X 
Interleukin 10 
receptor, beta 
(IL10RB) 
 2.0   X 
Interleukin 13 
receptor, alpha 1 
(IL-13RA1) 
 4.1   X 
Interleukin 13 
receptor, alpha 2 
(IL-13RA2) 
 11.0   X 
Osteoprotegerin 
(OPG) -4.0  X X  
Toll like receptor 2 
(TLR-2) 3.7 12.6 X X X 
Tumor necrosis factor 
receptor superfamily, 
member 9 (TNFRSF9) 
 3.9  X X 
Structural genes 
Caveolin 1 (CAV1)  -2.1  X X 
Claudin 15 
(CLDN15)* -2.9 -3.2    
Vimentin (VIM)  -2.1  X  
Signal transduction genes 
B-cell lymphoma 3-
encoded protein 
(BCL3) 
 2.7   X 
Growth arrest and 
DNA-damage-
inducible, beta 
(GADD45B) 
  2.6  X  
Immediate early 
response 3 (IER3) 4.9 5.5   X 
Inhibitor of kappa 
light polypeptide gene 
enhancer in B-cells, 
kinase epsilon 
(IκBKE) 
 1.7   X 
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Gene category 
Fold 
Change
(6 h) 
Fold 
Change 
(24 h) 
Skeletal & 
Muscle 
Development 
& Function 
Skeletal & 
Muscle 
Disorders 
Inflammatory 
Response 
Inhibitor of kappa 
light polypeptide gene 
enhancer in B-cells, 
kinase gamma 
(IκBKG)  
 1.7   X 
Interleukin-1 receptor-
associated kinase 3 
(IRAK3) 
  2.3  X X 
Janus kinase 2 (JAK2)   6.9   X 
Mitogen-activated 
protein kinase kinase 
kinase 8 (MAP3K8)* 
2.6 4.2    
Myeloid 
differentiation primary 
response gene (88) 
(MYD88)  
 1.7 X X X 
Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor (NF-κBIA) 
4.6 5.7 X X X 
Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor (NF-κBIE)*  
3.1 5.5    
Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor (NF-κBIZ) 
11.2 9.6   X 
Receptor-interacting 
serine-threonine 
kinase 2 (RIPK2) 
2.4 2.9   X 
Suppressor of cytokine 
signalling 3 (SOCS3) 2.3 4.5 X X X 
TNFAIP3 interacting 
protein 1 (TNIP1) 2.7 5.9   X 
Tumor necrosis factor, 
alpha-induced protein 
3 (TNFAIP3) 
2.4 4.8 X X X 
WNT1 inducible 
signalling pathway 
protein 2 (WISP2) 
-2.6   X   
Transcription factor and inhibitor genes 
CCAAT/enhancer-
binding protein beta 
(CEBPβ) 
3.4 4.2 X X X 
FBJ murine 
osteosarcoma viral 
oncogene homolog 
(c-Fos) 
1.7 1.4 X X X 
Hairy-related 
transcription factor 1 
(HEY1) 
2.1    X 
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Gene category 
Fold 
Change
(6 h) 
Fold 
Change 
(24 h) 
Skeletal & 
Muscle 
Development 
& Function 
Skeletal & 
Muscle 
Disorders 
Inflammatory 
Response 
Jun B proto-oncogene 
(JUNB) 2.6 5.4 X  X 
Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 1 
(NF-κB1) 
 2.6 X  X 
Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 2 
(NF-κB2) 
 2.2   X 
Odd-skipped related 2 
(OSR2)*  -3.3  X  
Sex determining 
region Y box 9 (SOX-
9) 
 -3.1 X X X 
Signal transducer and 
activator of 
transcription 3 
(STAT3) 
2.6 2.6 X X X 
V-rel 
reticuloendotheliosis 
viral oncogene 
homolog A (avian) 
(REL-A) 
 1.5   X 
V-rel 
reticuloendotheliosis 
viral oncogene 
homolog B (REL-B) 
 4.0   X 
 
Table 4. Genes associated with Skeletal, Muscle and Inflammation categories with accompanied fold 
changes at 6 h and 24 h. Key bone metabolism genes RANKL, OPG and COX-2 are highlighted in peach. 
Genes marked with * were not linked to Skeletal, Muscle or Inflammation categories.  
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4.8.1 Confirmation of microarray results 
To interpret the results obtained from the microarray dataset, it was important to 
validate representative items of the data, using other mRNA detection assays, in this 
case qPCR. Therefore RANKL, OPG and COX-2 gene expressions were assayed, as 
these genes were the focus of earlier parts of this thesis. The microarray results 
determined that RANKL transcripts were upregulated at 24 h, OPG transcripts were 
downregulated at 6 h and COX-2 transcripts were upregulated at both 6 h and 24 h 
(Table 5A). This trend was indeed confirmed by qPCR (Table 5B).  
 
To further validate the data obtained by microarray analysis, the expression of 
inflammation-associated genes LCN2 and SAA3, which showed the greatest differential 
regulation in the microarray data, was also confirmed by qPCR. As indicated by the 
microarray data, LCN2 gene expression was increased at 6 h and 24 h (Table 5A), 
which was also confirmed using qPCR (Table 5B). SAA3 transcript levels were equal at 
6 h and 24 h in the microarray (Table 5A). This pattern of expression was confirmed by 
qPCR at 6 h, but at 24 h the magnitude of fold change was notably higher that in that 
obtained through microarray analysis (Table 5B). 
 120
Table 5. Validation of microarray data by qPCR analysis. 
 
A. Fold changes for genes from microarray 
 COX-2 LCN2 OPG RANKL SAA3 
Fold 
Change 
(6 h) 
3.2 *** 33.6 *** -4.0 *** ND 144.8 *** 
Fold 
Change  
(24 h) 
2.3 *** 354.8 *** < 2.0 1.9 *** 143.9 *** 
 
B. Fold changes for genes from qPCR 
 COX-2 LCN2 OPG RANKL SAA3 
Fold 
Change 
(6 h) 
10.1 ** 352.2*** -4.0 * 5.4** 4817.0*** 
Fold 
Change  
(24 h) 
5.7 *** 4097.0 *** -1.2 15.3 * 95296.4 *** 
 
Table 5. COX-2, LCN2, OPG, RANKL and SAA3 gene expression in W20-17 cells challenged with 5 
µg/ml of P. gingivalis W50 at 6 h and 24 h. (A) Fold changes are relative to control, by microarray 
analysis. (B) Fold changes are relative to control, by qPCR analysis. ND (transcripts were undetectable). 
The Student’s t test was used to compare differences between the P. gingivalis-challenged and control 
group in the QPCR assays. ** p < 0.01, ** p < 0.01, *** p <0.001. 
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Chapter 5. 
 
Discussion 
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5. Discussion 
This thesis comprises of a series of in vitro experimentations, which all have in common 
the investigation of the effects of P. gingivalis on bone marrow cells. The major part of 
the thesis investigates aspects related to the regulation of molecules that control bone 
resorption. Emphasis is placed on the regulation of the RANKL-OPG system, the 
potential inflammatory mediators and intracellular signaling events involved in this 
process, as well as the virulence factors of P. gingivalis responsible for triggering these 
events. The final part constitutes a global screening of transcriptomic events that take 
place in bone marrow stromal cells challenged with P. gingivalis, and when applicable, 
focus is placed on regulators of bone resorption and inflammation. 
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5.1 A model to study the effects of P. gingivalis on RANKL and OPG 
expression  
In these studies, an in vitro experimental system was established to investigate the 
effects of P. gingivalis on RANKL and OPG expression by W20-17 bone marrow 
stromal cells. It was demonstrated that P. gingivalis culture supernatant upregulated 
RANKL in a concentration- and time- dependent manner up to 48 h, but downregulated 
OPG expression in a concentration dependent fashion. Other studies corroborate these 
results, since viable P. gingivalis, its cell sonicates and culture supernatants have been 
shown to upregulate RANKL and downregulate OPG in cells of the calvariae (Choi, 
Moon et al. 2005), cementoblasts, human PDL cells, gingival fibroblasts and T cells 
(Yamamoto, Kita et al. 2006; Belibasakis, Bostanci et al. 2007; Belibasakis, Reddi et al. 
2011). It has been shown that primary osteoblasts, challenged with viable P. gingivalis, 
upregulated RANKL whereas OPG expression remained unchanged after a 6 h period 
(Okahashi, Inaba et al. 2004). In comparison, this study demonstrates that P. gingivalis 
culture supernatant upregulated RANKL and downregulated OPG expression from 24 h 
onwards. Different cell types, the use of viable bacteria opposed to culture supernatant, 
and the different strains of wild-type P. gingivalis used could explain the variation 
between the previous study and this one. Furthermore, exposure time to P. gingivalis 
may be a crucial factor, since the present work investigated the effects for longer time-
points (i.e. 48 h), in contrast to previous studies that have investigated up to 6 h. 
 
To determine the virulence factors responsible for the specific biological effects, it was 
decided to use P. gingivalis culture supernatant rather than viable P. gingivalis. In this 
way it is possible to determine the levels of endotoxin, gingipains and total bacterial 
protein present within a 6-day old bacterial culture supernatant. In this manner, a variety 
of defined and quantifiable virulence factors are used in combination to study the 
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specific cellular responses. Using viable bacterial cells, obtaining this information 
becomes more difficult and, furthermore, the phenotypic and growth characteristics of 
live bacteria present in the cell cultures may vary greatly, having profound effects on 
the cells. Adjusting the load of the bacterial challenge was also possible, by calibrating 
towards bacterial protein concentration. This was a suitable approach, since levels of 
endotoxin were similar between P. gingivalis W50, E8 and K1A strains.  
 
After investigating the effects of RANKL and OPG in W20-17 cells, the next step was 
to establish if another cell line would respond similarly to the bone marrow stromal 
cells. In a pilot experiment, the more differentiated murine pre-osteoblastic calvarial cell 
line, MC3T3-E1 was used where it was determined that 20 µg/ml of P. gingivalis 
concentration were toxic to the cells at 24 h and 48 h after challenge. Still, under sub-
toxic P. gingivalis concentrations, RANKL failed to be induced. Although OPG was 
expressed in abundance, the lack of RANKL induction would make this cell line less 
favourable to study the regulation of RANKL-OPG system by P. gingivalis although. 
Therefore, no further work on this cell line was pursued. On a clinical level it is 
worthwhile to mention that W20-17 cells are derived from endochrondral bone whereas 
MC3T3-E1 cells are derived from membrane derived bone. The MC3T3-E1 cells 
resemble more closely the alveolar bone which is also formed by intramembranous 
formation. The absence of RANKL and the constitutive expression of OPG by MC3T3-
E1 cells in response to P. gingivalis may be a protective measure from the cells against 
bone destruction and may have further implications in clinical periodontitis 
management, beyond the scope of this study. 
 
Porphyromonas gingivalis gingipains are known to degrade host proteins including the 
extracellular matrix components, such as collagen and fibrinogen (Yasuhara and 
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Miyamoto 2011) contributing to the destruction of periodontal connective tissue. P. 
gingivalis proteases have also been shown to degrade host cytokines such as monocyte 
chemotactic protein 1 and IL-8 (Kobayashi-Sakamoto, Isogai et al. 2003) and 
membrane TNF-α (Mężyk-Kopeć, Bzowska et al. 2005). Interestingly it has been shown 
that Lys-X gingipain can degrade OPG (Yasuhara and Miyamoto 2011). Therefore, it 
was of interest to further define the effect of P. gingivalis bacterial proteases on 
RANKL and OPG protein concentrations. This was investigated by incubating 
recombinant RANKL and OPG with P. gingivalis W50 wild-type culture supernatant. 
This incubation with P. gingivalis resulted in lower RANKL protein concentration, 
potentially indicating degradation. Regardless, in the experimental system used in this 
work, RANKL production was still increased as bacterial concentration and time 
increased. Surprisingly, the detected concentration of OPG, increased after incubation 
with P. gingivalis. One theory to explain this result could be that, due to gingipain 
activity, soluble OPG protein is cleaved in vitro, rendering more than one epitope in 
soluble form. When OPG protein is quantified by ELISA, the capture and detection 
monoclonal antibodies may recognise more than one epitopes. This may result in 
increased detection signal since an OPG concentration increase from a cellular source is 
not possible, as cells are not present in this system. Nevertheless, in the present 
experimental model, OPG expression by the cells still decreases with increasing 
concentrations of P. gingivalis. Based on these observations it can be concluded that a 
potential degradation of RANKL and OPG by P. gingivalis does not interfere with the 
general detection of RANKL and OPG protein expression in the cells as determined by 
ELISA. Moreover, the degradation of RANKL and OPG were tested using 
manufactured standards and this has not been tested in a cell culture model, so these 
results are only an indication of potential degradation by P. gingivalis.  
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It has been shown that P. gingivalis can upregulate RANKL and downregulate OPG in 
bone marrow stromal cells, effectively increasing the ratio between RANKL and OPG, 
thus favouring bone resorption. This is of clinical relevance since patients who suffer 
from aggressive and chronic periodontitis have been shown to have higher 
RANKL/OPG ratios compared to healthy controls (Liu, Xu et al. 2003; Mogi, Otogoto 
et al. 2004; Bostanci, Ilgenli et al. 2007). This highlights the importance of conducting 
research into key periodontal pathogens to further understand how they exert their 
virulence properties to elicit periodontal destruction. This study showed that using sub-
toxic concentrations of P. gingivalis and challenging bone marrow stromal cells, 
RANKL was profoundly induced, while OPG expression was downregulated. Therefore 
these conditions formed the foundation of further investigations, including the 
involvement of PGE2, a key inflammatory mediator, in RANKL and OPG regulation, 
putitative virulence factors and intracellular signalling pathways that may be 
participating in RANKL and OPG regulation.  
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5.2 The involvement of PGE2 in RANKL regulation 
It has been shown in a variety of cell types that PGE2 stimulates RANKL induction 
including bone marrow stromal cells, osteoblasts and cementoblasts (Kanematsu, Sato 
et al. 2000; Okahashi, Inaba et al. 2004; Oka, Miyauchi et al. 2007). Conversely, PGE2 
is also involved in the inhibition of OPG production in bone marrow stromal cells, 
human PDL cells and cementoblasts (Brändström, Jonsson et al. 1998; Sakata, Shiba et 
al. 2002; Oka, Miyauchi et al. 2007). In addition, it has been demonstrated that PGE2 is 
produced in response to P. gingivalis challenge and is partly responsible for RANKL 
induction and OPG downregulation (Okahashi, Inaba et al. 2004; Choi, Moon et al. 
2005). This is supported by the finding that P. gingivalis induced bone loss in healthy 
mice was mediated by prostaglandins (Zubery, Dunstan et al. 1998). These studies 
combined provide strong rationale to investigate PGE2 involvement in P. gingivalis-
induced RANKL upregulation and OPG downregulation in this work. 
 
The COX-2 enzyme is responsible for the breakdown of arachidonic acid into PGE2. In 
this study, the role of COX-2 and PGE2 in the induction of RANKL and OPG was 
investigated. It was found that, as expected, PGE2 followed COX-2 expression and that 
these were upregulated with increasing P. gingivalis concentrations and over time, 
similarly to RANKL. Next, it was determined whether PGE2 was involved in mediating 
RANKL induction or OPG upregulation. Indomethacin, a non-selective COX-1 and 
COX-2 inhibitor, partially blocked COX-2 expression and completely abolished PGE2 
synthesis. RANKL mRNA and protein were also significantly inhibited by 
indomethacin treatment, strongly suggesting that PGE2 is involved in RANKL 
induction by P. gingivalis. With regard to OPG, treatment with indomethacin did not 
affect the downregulation of mRNA and protein expression caused by P. gingivalis at 
24 h. However, after 48h, OPG mRNA downregulation by P. gingivalis was partly 
 128
rescued with the addition of indomethacin. Although OPG mRNA downregulation was 
partially rescued at 48 h, this was not followed by a significant change in protein 
expression. Therefore, there is no evidence to indicate that PGE2 is a mediator in OPG 
downregulation by P. gingivalis at early time-points. These results show that PGE2 is 
involved in the regulation of RANKL production in bone marrow stromal cells, induced 
by P. gingivalis. This is supported by previous findings indicating that P. gingivalis 
sonicates induced RANKL in primary murine osteoblasts with PGE2 being a key 
regulator (Choi, Moon et al. 2005). It has also been shown that PGE2 activates 
cementoclastogenesis, by inducing RANKL via a specific EP4 receptor pathway in 
murine bone marrow stromal cells (Oka, Miyauchi et al. 2007).  
 
Nitric oxide is an important signaling molecule that regulates bone formation, resorption 
and remodelling in physiological and pathological conditions. It has been reported that 
NO is able to induce OPG and downregulate RANKL in bone marrow stromal cells 
decreasing the RANKL/OPG ratio (Fan, Roy et al. 2004). Furthermore, evidence points 
to NO being a key mediator of PGE2 regulation in osteoblast cells (Hughes, Buttery et 
al. 1999). Based on this, and since it was shown that PGE2 contributes to P. gingivalis-
induced RANKL expression, the involvement of NO in the regulation of RANKL and 
OPG was investigated. There was an upregulation of iNOS mRNA in response to P. 
gingivalis challenge, but only after 48 h, which is later than the observed RANKL 
upregulation and OPG downregulation. Nitrite production was not detected at any time-
point, therefore NO does not appear to regulate RANKL and OPG expression in this 
experimental system. Based on the present findings, PGE2 is a key mediator in the 
induction of RANKL by P. gingivalis, but this does not involve the NO pathway. 
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5.3 Investigating putative P. gingivalis virulence factors on RANKL, 
OPG and PGE2 regulation 
The involvement of P. gingivalis virulence factors responsible for upregulating RANKL 
and downregulating OPG was further considered. Initially, the effects of bacterial 
proteases, such as gingipains, and other bacterial proteins were investigated through 
TLCK-treatment or heat-inactivation of P. gingivalis W50 culture supernatant. TLCK 
inhibits serine and cysteine proteases, whilst heat-treatment of the bacteria destroys all 
proteinaceous content of the culture supernatant. Arg-X and Lys-X gingipain activity 
was successfully inhibited in the TLCK-treated and heat-inactivated P. gingivalis 
culture supernatant. These treatments did not alter the capacity of P. gingivalis to 
upregulate RANKL and downregulate OPG expression by the cells. Although heat-
inactivation significantly downregulated COX-2 expression in comparison to untreated 
P. gingivalis, this was not followed by a change in PGE2 production. This indicates that 
the upregulation of RANKL and PGE2 and the downregulation of OPG are not 
dependent on P. gingivalis proteases or heat-affected proteins within the culture 
supernatant. 
 
Despite that heat inactivated P. gingivalis supernatant did not affect RANKL and OPG 
expression in the present study, there is evidence to suggest that heat denaturing 
complexes of P. gingivalis containing LPS can increase its biological effect (Takii, 
Kadowaki et al. 2005). In an extracted molecular complex consisting of gingipains, 
adhesins and LPS, heating resulted in dissociation of LPS from its bound proteins, thus 
unmasking it and allowing for its recognition by TLRs. When challenged with the heat-
denatured complex, macrophages produced significantly higher levels of NO, TNF-α 
and IL-6, compared to the native complex (Takii, Kadowaki et al. 2005). Accordingly, it 
is possible that by heat-inactivating of P. gingivalis supernatant, LPS becomes exposed, 
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inducing RANKL stronger than non-treated P. gingivalis. However, any protein that 
may potentially induce RANKL is also denatured by heating. Furthermore, although, 
heat-inactivation did not affect the ability of P. gingivalis to alter RANKL and OPG 
expression, it cannot be ruled out that it may affect the production of other cytokines or 
molecules that were not tested for in this study. 
 
Although heat inactivation and TLCK treatment suggest gingipain activity is not 
essential for the effects on RANKL and OPG, there is evidence to suggest that gingipain 
mutants are involved in RANKL upregulation by P. gingivalis in gingival fibroblasts 
(Belibasakis, Bostanci et al. 2007) and osteoblasts (Okahashi, Inaba et al. 2004). To 
specifically address this, two gingipain mutants P. gingivalis strains were employed. 
Interestingly, the E8 strain (Arg-gingipain knockout mutant) induced RANKL 
expression similar to the wild-type strain and downregulated OPG mRNA expression. 
In contrast, K1A strain (Lys-gingipain knockout mutant) exhibited a reduced capacity to 
induce RANKL compared to the wild-type strain, with OPG remaining unaffected. 
Finally, although E8 strain enhanced the expression of COX-2 and K1A strain 
downregulated COX-2 expression, PGE2 production was not significantly changed by 
either challenge.  
 
These results suggest that OPG downregulation by wild-type P. gingivalis remains 
largely unaffected by the removal of either of the gingipains. RANKL expression, on 
the other hand appears to be differentially regulated by E8 and K1A supernatants, since 
E8 upregulates RANKL, like the wild-type P. gingivalis strain, but K1A is unable to 
induce RANKL. This effect appears to be cell type specific since previous studies 
showed that gingival fibroblasts challenged with the E8 strain upregulated RANKL 
mRNA expression, compared to wild-type P. gingivalis strain (Belibasakis, Bostanci et 
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al. 2007). One important note when using these strains in the current study is that the 
culture supernatant from E8 has normal Lys-gingipain activity and abolished Arg-
gingipain activity, whereas K1A has abolished Lys-gingipain activity and only 19% of 
Arg-specific protease activity, compared to the wild-type P. gingivalis W50 strain. This 
may not be surprising, as when these mutants were constructed, Arg-specific protease 
activity in the K1A strain was reported to be reduced by 50% compared to the W50 
strain, in a 6 day old culture. It was therefore hypothesised that Lys-gingipains could 
contribute to the export of Arg-gingipain into the culture supernatant (Aduse-Opoku, 
Davies et al. 2000), possibly explaining the reduction of Arg-specific protease activity 
of K1A strain, in the present study. This could contribute to a decreased proteolytic 
activity on bacterial proteins and components within the 6 day culture period used in 
this study. In addition, Lys-gingipain may also be involved in the acquisition and 
storage of hemin, as the K1A strain exhibits a loss of the black pigmenting phenotype, 
when cultured on blood agar (Aduse-Opoku, Davies et al. 2000). This may be one 
reason why the RANKL-inducing capacity of the K1A strain is reduced. Of note, 
different levels of hemin can determine the types and levels of lipid A present in P. 
gingivalis LPS. For example, low hemin concentrations yield more penta-acylated 
structures, whereas high hemin concentrations yield more a mixture of tetra and penta-
acylated structures (Darveau, Pham et al. 2004; Al-Qutub, Braham et al. 2006; Reife, 
Coats et al. 2006). Different structures can have different biological effects, for instance 
RANKL mRNA expression was induced in murine cementoblasts upon stimulation with 
penta-acylated, but not tetra-acylated lipid A (Nemoto, Darveau et al. 2006). Therefore, 
the loss of RANKL-upregulating capacity may be due to global changes caused by 
gingipain loss, rather than the direct effect of a gingipain itself. 
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In a previous study demonstrating RANKL induction by P. gingivalis, the possibility of 
LPS involvement was eliminated, since heat-inactivation of bacteria caused loss of this 
capacity. A triple deficient mutant for three gingipains (Arg-gingipain A and –B and 
Lys-gingipain of strain ATCC 33277) was used in that study, and RANKL induction 
was significantly reduced in murine osteoblasts (Okahashi, Inaba et al. 2004). The 
reduced capacity of gingipain mutants to induce RANKL demonstrated in previous 
literature and in this thesis may also be attributed to the reduced proteolytic activity of 
the gingipains. When wild-type P. gingivalis W50 strain is grown for 6 days, the 
activity of the gingipains is intact, allowing for the opportunity to modify other P. 
gingivalis proteins. This could contribute to its increased virulence, and could explain 
the upregulation of RANKL expression in gingival fibroblasts and PDL cells 
(Belibasakis, Bostanci et al. 2007). When P. gingivalis W50 culture supernatant is 
treated with TLCK or is heat-inactivated, the protease activity from 6 days of growth is 
inactivated or destroyed, but any modifications that the gingipains may exert on other 
proteins or bacterial components, such as LPS, has not been prevented or inhibited over 
this period. The effect of the gingipains on RANKL may not be direct, but indirect by 
the proteases acting on other components present in the P. gingivalis W50 culture 
supernatants, increasing its virulence. This may explain the different effects of TLCK 
treatment, heat inactivation of bacterial supernatant, and the gingipain mutants to induce 
RANKL. 
 
Collectively, these findings indicate that the bacterial factor responsible for inducing 
RANKL and downregulating OPG in osteoprogenitor cells is a heat stable, non-
proteinaceous, non-proteolytic component, which may be modified by gingipains. The 
most likely candidate is LPS, and therefore this possibility was investigated further. 
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5.4 The involvement of P. gingivalis LPS in the regulation of RANKL, 
OPG and PGE2  
The role of LPS was investigated through the use of polymyxin B treatment, which 
removed lipid A from the P. gingivalis W50 culture supernatant. Upon treatment 89 % 
of endotoxin was removed from the culture supernatant. Polymyxin B treatment 
significantly reduced RANKL protein induction compared to wild type P. gingivalis 
supernatant, and also partly rescued OPG protein inhibition. COX-2 mRNA expression 
and PGE2 production was significantly reduced in cells challenged with polymyxin B 
treated, supernatant compared to untreated P. gingivalis supernatant. This is good 
evidence that LPS is a necessary bacterial component in RANKL, OPG and PGE2 
regulation. Nevertheless, it is still possible that the polymyxin B column is removing 
other proteins from W50 culture supernatant along with LPS that may be responsible for 
or contributing to the effect on RANKL, OPG and PGE2. In support of this theory, 
when gingipain protease activity was assayed for subsequent to polymyxin B treatment, 
Arg-specific and Lys-specific protease activities were reduced compared to the 
untreated P. gingivalis. There is evidence to suggest that membrane-associated forms of 
Arg-gingipains may be post-translationally modified by LPS (Curtis, Thickett et al. 
1999; Veith PD, Talbo GH et al. 2002). Furthermore, it has been reported that a 
complex composed of gingipains, adhesions and LPS was extracted from P. gingivalis. 
The complex consisted of LPS attached to the Hgp44 domains of RgpA and Kgp, and it 
is suggested that this post-translational modification of LPS may attach the complex to 
the outer membrane of the cell (Takii, Kadowaki et al. 2005). The polymyxin B 
treatment has either destroyed the gingipain activity within P. gingivalis culture 
supernatant, or it has been removed through its association with LPS. 
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To further investigate the involvement of P. gingivalis LPS in RANKL, OPG and PGE2 
regulation, cells were challenged with P. gingivalis LPS purified by phenol extraction. 
P. gingivalis LPS differs from other LPS species since it can be recognised by both 
TLR-2 and TLR-4 (Hajishengallis, Martin et al. 2002; Darveau, Pham et al. 2004; Zhou, 
Desta et al. 2005). To establish if bone marrow cells were responsive to purified P. 
gingivalis LPS in this study, the expression of TLR-2 and TLR-4 was assayed, in 
response to either P. gingivalis culture supernatant or P. gingivalis LPS alone. 
Ascending concentrations of P. gingivalis LPS, starting from 1250 EU/ml to 5000 
EU/ml were used. TLR-2, but not TLR-4, was significantly upregulated in response to 
P. gingivalis culture supernatant and P. gingivalis LPS. This data confirmed that bone 
marrow stromal cells respond to purified P. gingivalis LPS. The types of lipid A 
acylated structures present in the P. gingivalis culture supernatant and P. gingivalis LPS 
used in this study was undefined although a study using the same growth conditions and 
extraction procedures identified that the main lipid A structures that are present is non-
phosphorylated and mono-phosphorylated tetra-acylated structures (Curtis, Percival et 
al. 2011).  
 
A previous report in cementoblasts determined that tetra and penta-acylated P. 
gingivalis LPS activates the transcription factor NF-κB through TLR-2 (Nemoto, 
Darveau et al. 2006). Interestingly TLR-2 is also upregulated in response to P. 
gingivalis LPS in this work. It has been demonstrated that mono-phosphorylated tetra-
acylated lipid A can act as an antagonist for E. coli LPS dependent activation of TLR-4 
(Coats, Pham et al. 2005). Another group showed that growing P. gingivalis W50 at 
different temperatures can determine which types of lipid A structures are present, and 
that these structures interact differently with TLR-4. For instance, when P. gingivalis 
was grown at a normal body temperature of 37ºC, non-phosphorylated tetra-acylated 
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and mono-phosphorylated tetra-acylated structures were present which antagonised E. 
coli LPS dependent activation of TLR-4. P. gingivalis grown at 41ºC produced more 
mono-phosphorylated penta-acylated structures which were a potent activator of TLR-4 
activity (Curtis, Percival et al. 2011). These studies suggest that the LPS purified in the 
current work likely contained the non-phosphorylated tetra-acylated and mono-
phosphorylated tetra-acylated structures, which are capable of activating TLR-2 and 
opposing the activation of TLR-4. This is in line with findings reporting that TLR-2 can 
autoregulate itself and activation of TLR-2 leads to upregulation of TLR-2 itself (Liu, 
Wang et al. 2001).  
 
Since the cells were responsive to purified P. gingivalis LPS, the possible involvement 
of P. gingivalis LPS alone in regulating RANKL, OPG and PGE2 expression could be 
explored. P. gingivalis LPS failed to induce RANKL mRNA and PGE2 production 
although it did downregulate OPG mRNA expression, indicating that although this LPS 
alone is not sufficient to induce RANKL expression, it is the most likely the candidate 
in the downregulation of OPG by P. gingivalis.  
 
A series of experiments were performed to identify a virulence factor that may be 
responsible for the induction of RANKL. Firstly, protein and protease activity within 
the culture supernatant were eliminated as there was no alteration in RANKL induction, 
suggesting that the virulence factor was heat stable, non-proteolytic, non-proteinaceous 
component. Subsequently, experiments using gingipain mutants with the capacity to 
modify bacterial components within the 6 day culture period showed that K1A, a 
complete Lys-specific gingipain mutant with diminished Arg-specific gingipain activity, 
failed to induce RANKL expression. Also, COX-2 expression was downregulated in by 
the K1A strain, but PGE2 production did not follow this pattern. Taken together, this 
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data suggests that RANKL induction is a synergistic process dependent on gingipain 
activity, and mediated primarily, though not solely, through P. gingivalis LPS. It has 
been shown that purified P. gingivalis LPS can stimulate PGE2 production (Noguchi, 
Yanai et al. 2000) but this was not demonstrated in this work. Previous experiments 
showed that PGE2 is contributing to RANKL induction, but since P. gingivalis LPS 
alone was unable to induce PGE2, a heat stable protein must be required for this effect. 
In this model, the gingipains are involved in modifying a bacterial component within the 
culture period, either by altering the predominance of specific acylated P. gingivalis 
lipid A species by, in the case of K1A strain, possessing a reduced ability to 
acquire/store hemin, or altering the formation of LPS-protein complexes. As a further 
possibility the K1A strain may also be having a reduced proteolytic activity on an 
unidentified, heat-stable protein that is responsible for the induction of RANKL 
expression by the P. gingivalis wild-type strain. 
 
It has been demonstrated that cementoblasts behave differently in response to tetra- and 
penta-acylated P. gingivalis LPS stimulation, where penta-acylated LPS rapidly induced 
RANKL expression, but this was only slightly induced with tetra-acylated LPS 
(Nemoto, Darveau et al. 2006). This indicates that cementoblasts, one of the main cell 
types P. gingivalis encounters in vivo, possesses the ability to express RANKL in 
response to P. gingivalis lipid A and potentially contribute to osteoclastogenesis or 
cementoclastogenesis. Furthermore, this raises the possibility that the lack of RANKL 
induction in the present study was due to the type of LPS structures extracted. It has 
previously been reported that high concentrations of P. gingivalis LPS were necessary 
to induce RANKL mRNA expression and soluble RANKL in human PDL cells 
(Krajewski, Biessei et al. 2009). Although the same concentrations of P. gingivalis LPS 
were used as in wild-type P. gingivalis supernatant in this work, P. gingivalis LPS in 
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isolation may need higher concentrations to induce RANKL expression. So collectively 
it appears that multiple events may be occurring in the upregulation of RANKL. Firstly 
P. gingivalis LPS, although a good candidate, is not the sole RANKL inducing factor 
and other factors are required. Secondly, the gingipains have been demonstrated to be 
involved, at least indirectly, most likely by modifying LPS or other bacterial 
components involved in the induction of RANKL. 
 
The downregulation of OPG by P. gingivalis was regulated in a clearly different manner 
than RANKL. OPG downregulation was not affected by abolishing protease activity or 
bacterial proteins in the culture supernatant. In addition the gingipain mutants did not 
seem to have any profound effect on OPG downregulation. Interestingly, polymyxin B 
treatment partially rescued OPG downregulation indicating that P. gingivalis LPS or 
heat stable proteins are likely participating in the downregulation of OPG. It is possible 
that the partial downregulation of OPG observed after polymyxin B treatment is due to 
the remaining endotoxin present in the culture supernatant. Further evidence of P. 
gingivalis LPS involvement was demonstrated when purified P. gingivalis LPS alone 
downregulated OPG mRNA but was unable to upregulate PGE2 production like wild-
type P. gingivalis supernatant, suggesting that PGE2 is not involved in this process.  
 
It has been shown that the effect of LPS on OPG expression can vary in different cell 
types. When cementoblasts were challenged with tetra and penta-acylated lipid A from 
P. gingivalis LPS, OPG expression remained unchanged (Nemoto, Darveau et al. 2006). 
It was suggested that cementoblasts may have a protective effect in the periodontium 
against LPS challenge by constitutively expressing OPG (Nemoto, Darveau et al. 2006), 
since in osteoblast cells OPG is downregulated in response to E. coli LPS (Suda, 
Udagawa et al. 2004). Human gingival fibroblasts differ in their response to LPS 
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challenge compared to osteoblasts and cementoblasts. HGFs from patients with chronic 
periodontitis produced OPG when stimulated with E. coli LPS, suggesting a protective 
effect against LPS (Nagasawa, Kobayashi et al. 2002). However, one issue with this 
study is that P. gingivalis and E. coli LPS have different properties, and are capable of 
signalling through different TLRs. 
 
Further support for the protective effect of HGFs has been shown when P. gingivalis 
and A. actinomycetemcomitans LPS stimulated OPG production mediated by PGE2 
through EP1 and/or EP2 receptors (Kiji, Nagasawa et al. 2007). In addition it has been 
shown that, in human umbilical vein endothelial (HUVE) cells, OPG production is 
stimulated upon P. gingivalis LPS challenge, and therefore endothelial cells may slow 
down the process of bone resorption through the production of OPG (Kobayashi-
Sakamoto, Hirose et al. 2004). In contrast to these studies, this work demonstrates that 
P. gingivalis LPS downregulates OPG mRNA expression in bone marrow stromal cells, 
which would have a negative effect on the balance of bone resorption in vivo. 
 
In the current investigation, RANKL is induced and OPG is downregulated with P. 
gingivalis challenge in an established cell line of bone marrow stromal cells. It has been 
determined that P. gingivalis LPS and a heat stable component is most likely required 
for RANKL induction and LPS alone for OPG downregulation, with PGE2 being a key 
mediator of RANKL expression. The possible involvement of gingipains was 
investigated and it was shown that they were indirectly necessary for the induction of 
RANKL. Bone marrow stromal cells, although not osteoblasts, are early osteoprogenitor 
cells that have the potential to differentiate into osteoblasts. Therefore, in the present 
study using bone marrow stromal cells to investigate the effects of P. gingivalis 
virulence factors, has demonstrated that P. gingivalis can affect osteoprogenitor cells, 
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indicating that its virulence can also be exerted on cells with bone regenerative 
potential.  
5.5 The involvement of MAPK p38 in the regulation of RANKL and  
COX-2 
To better understand the mechanisms of pathogenesis for the discovery and 
development of therapeutic targets, it is important to investigate the intracellular 
signalling pathways that are regulated by pathogens. To this extent, P. gingivalis is 
shown to activate several intracellular mechanisms in host cells, including AP-1, MAPK 
and NF-κB pathways in osteoblasts, endothelial cells and gingival epithelial cells 
(Watanabe, Yilmaz et al. 2001; Okahashi, Inaba et al. 2004; Walter, Zahlten et al. 2004; 
Zhang, Zheng et al. 2011). Special focus is placed on MAPK signalling, as it is a known 
regulator of molecules involved in bone resorption, including RANKL, OPG and PGE2 
(Chen, Chen et al. 1999; Okahashi, Sakurai et al. 2003; Fukushima, Jimi et al. 2005; 
Rossa C, Ehmann K et al. 2006; Oikawa, Kobayashi et al. 2007). Therefore, this thesis 
also investigated the ability of P. gingivalis to activate MAPKs, with further potential 
involvement in the down-stream regulation of RANKL, OPG and PGE2 in bone marrow 
stromal cells.  
 
Using the previously established experimental system, the activation of the three MAPK 
signalling proteins p44/42 (also known as ERK), SAPK/JNK and p38 was investigated 
in response to P. gingivalis challenge. Phosphorylation of JNK and p38 increased after 
60 min of challenge with P. gingivalis challenge, whereas p44/42 phosphorylation did 
not appear to be affected, and was therefore not investigated further. Taken together 
these results indicate that MAPK p38 and JNK are activated by P. gingivalis in bone 
marrow stromal cells. 
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The next stage of this work was to investigate if MAPK pathways were involved in the 
regulation of RANKL, OPG and PGE2. Although the possible involvement of JNK 
cannot be disregarded, p38 was investigated further since this pathway showed a 
stronger induction by P. gingivalis challenge. It is well established that the p38 MAPK 
pathway is involved in regulating inflammatory mediators including IL-1β, TNF-α, 
RANKL and PGE2 (Chen, Chen et al. 1999; Mbalaviele, Anderson et al. 2006; Rossa C, 
Ehmann K et al. 2006). Therefore, its involvement in the present experimental system 
was investigated by means of chemical inhibition. Indeed the chemical synthetic 
inhibitor of p38 (SB203580) reduced P. gingivalis induction of RANKL and COX-2 
mRNA by 83% and 76%, respectively, but did not alter OPG mRNA expression. Since 
inhibition of p38 did not completely abolish COX-2 and RANKL mRNA to control 
levels, JNK or another signalling pathway may also be involved in the remaining part of 
COX-2 and RANKL induction. Alternatively, p38 MAPK activity may have been only 
partly inhibited by treatment. Together these results demonstrate that the p38 MAPK is 
being activated by P. gingivalis, and largely contributes to the induction of COX-2 and 
RANKL mRNA expression in this experimental system.  
 
RANKL induction occurring via the p38 MAPK pathway has also been observed when 
osteoblasts are challenged with Streptococcus pyogenes, a bacterial pathogen associated 
with bacterial arthritis (Okahashi, Sakurai et al. 2003). However, the same laboratory 
group reported that infection with live P. gingivalis induced RANKL transcription 
through the AP-1 pathway, minimising the possibility of p38 MAPK involvement 
(Okahashi, Inaba et al. 2004). This contradiction may be due to the strain of P. 
gingivalis used, use of viable bacteria instead of P. gingivalis secreted bacterial 
products, or the cell type studied. This also demonstrates the versatile nature of the 
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bacterium, to elicit its virulence potential using different intracellular signalling 
mechanisms in a range of cell types.  
 
This work has shown that firstly, PGE2 production follows COX-2 expression as 
expected and secondly, PGE2 is partly responsible for RANKL induction by P. 
gingivalis. In addition, throughout this work RANKL and OPG protein expression 
followed mRNA levels. Therefore, it was rational to investigate changes in the 
expression of these genes. 
 
In this work, p38 MAPK contributed to COX-2 induction by P. gingivalis. It has been 
reported that ERK, p38 and JNK MAPK pathways combined may induce RANKL 
expression after IL-1β stimulation in PDL cells, mediated by PGE2 synthesis (Oikawa, 
Kobayashi et al. 2007). Another study demonstrated alternatively that ERK-dependent 
PGE2 production was mainly responsible for the induction of RANKL and 
downregulation of OPG mRNA by IL-1α in the same cell type (Fukushima, Jimi et al. 
2005). In the present study, P. gingivalis induced RANKL is partially dependent on 
p38-dependent PGE2 production, since chemical inhibition of p38 significantly reduced 
RANKL and COX-2 mRNA expression. Nevertheless, it is difficult to collectively 
compare the results of all these studies, as the RANKL- or OPG-regulating stimuli are 
of different nature (bacteria versus pro-inflammatory cytokines).  
 
The P. gingivalis bacterial culture supernatant used to challenge cells contains several 
virulence factors that may be initiating intracellular events, such as LPS and gingipains. 
P. gingivalis LPS can activate p38 in human monocytes, but not in endothelial cells 
(Darveau, Arbabi et al. 2002). Interestingly, A. actinomycetemcomitans and E. coli LPS 
can induce RANKL by activating the p38 MAPK pathway in PDL cells (Rossa, Liu et 
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al. 2008). In contrast E. coli synthetic lipid A can induce RANKL in osteoblast like 
cells, mediated partly through the ERK pathway (Kikuchi, Matsuguchi et al. 2001). In 
this work, the removal of LPS from the P. gingivalis supernatants prevented RANKL 
and PGE2 induction, so it is possible that LPS may be the responsible factor activating 
p38. In addition, P. gingivalis fimbriae and gingipains can activate the p38 pathway in 
monocytes and macrophages respectively (Ogawa, Asai et al. 2002; Grenier and Tanabe 
2010). These studies combined accentuate that P. gingivalis is capable of using its 
virulence factors to activate various intracellular signalling pathways in a variety of cell 
types, contributing to inflammatory processes and the destructive nature of the disease.  
 
From a therapeutic angle, p38 inhibitors may be used to block the effects of bone 
resorption in periodontal disease. Several studies have shown that the use of p38 
inhibitors can reduce bone destruction in vivo (Mbalaviele, Anderson et al. 2006; 
Kirkwood, Li et al. 2007; Rogers, Li et al. 2007). The p38 MAPK pathway plays several 
roles in the control of the immune system and the production of inflammatory cytokines 
(Kirkwood and Rossa Jr 2009). Use of a p38 inhibitor could therefore be a double edged 
sword since the synthesis of some inflammatory cytokines may be blocked, leading to 
an improvement in disease outcome but a disruption of an anti-bacterial immune 
response. The finding in this work that RANKL, but not OPG, regulation was p38-
dependent suggests that therapeutic p38 inhibitors may be complemented by another 
therapy targeting OPG downregulation, to have the greatest effect on the RANKL/OPG 
ratio. 
 
Bacteria in the biofilm exert their effects on a multitude of cell types to cause 
periodontal disease. Work needs to be undertaken to investigate different bacterial 
virulence factors and their effects on the various cell types that are present within the 
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disease environment, in order to gain a better understanding of targeting intracellular 
pathways, such as p38. In any case, further studies in vivo are required to confirm the 
therapeutic use of inhibitors for p38 in periodontal disease. In conclusion, it has been 
demonstrated in this respect that P. gingivalis induced p38-dependent PGE2 production 
contributes to RANKL expression in bone marrow stromal cells, supporting the 
inhibition of p38 MAPK to be a promising target in the treatment of periodontal disease. 
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5.6 Summary of molecular mechanisms involved in P. gingivalis 
challenge  
Fig. 20. Summary of molecular mechanisms involved in P. gingivalis upregulating the 
RANKL/OPG ratio in bone marrow stromal cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P. gingivalis LPS 
PGE2 OPG
P. gingivalis LPS 
and unknown synergistic
factor
RANKL
RANKL induction 
by P. gingivalis
partially dependent 
on p38 MAPK-
dependent PGE2
production
Proposed molecular events following P. gingivalis culture supernatant challenge 
in W20-17 cells
RANKL/OPG 
ratio 
Fig. 20. Subsequent to P. gingivalis challenge in W20-17 bone marrow stromal cells it is proposed that P. 
gingivalis LPS and an unknown synergistic factor partly upregulates PGE2, which in turn contributes to 
RANKL induction by P. gingivalis. The activation of the intra-cellular p38 MAPK pathway by P. 
gingivalis is integral to PGE2 and RANKL induction. P. gingivalis LPS is a crucial factor in partly 
downregulating OPG expression. As a result, the normal balance of RANKL to OPG becomes altered 
resulting in an increased RANKL/OPG ratio favouring the process of bone resorption. 
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5.7 Array of genes affected by P. gingivalis and implications of this 
high-throughput information 
In this work, changes in gene expression in bone marrow stromal cells caused by P. 
gingivalis W50 culture supernatant were investigated using microarray technology. 
Bone marrow stromal cells are multi-potent and have the capacity to differentiate into a 
number of different cell types including osteoblasts, chondrocytes, myocytes and 
fibroblasts. Since bone marrow stromal cells possess the ability to differentiate into 
osteoblasts, these cells have osteogenic properties and are suitable for the investigation 
of the effects of P. gingivalis. However, these cells are multi-potent therefore genes 
discussed may overlap with functions for other cell types. Nevertheless, the emphasis of 
the discussion points will be placed on the virulence capacity of P. gingivalis and its 
effects on the pathogenesis of periodontitis. 
 
5.7.1 Confirmation of microarray gene expression through qPCR 
To validate the microarray results, specific genes related to bone metabolism that were 
previously investigated at transcript level were assessed in the microarray dataset were 
chosen, namely RANKL, OPG and COX-2. Further to this, the transcripts for two 
additional genes, LCN2 and SAA3, both encoding acute phase proteins, were strongly 
increased by P. gingivalis were also assayed using qPCR. The upregulation of RANKL, 
COX-2 and LCN2 transcription, as determined by qPCR, corresponded well with fold 
changes analysed from the microarray dataset. The downregulation of OPG gene 
expression obtained from the microarray data was also confirmed with qPCR. 
Regarding SAA3 gene expression, qPCR results followed the trends determined by 
microarray analysis but did not follow the same magnitude of transcription at 6 h and 24 
h. At 6 h and 24 h there was a 144.8- and 143.9-fold change respectively in SAA3 
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mRNA expression determined by microarray analysis whereas at 6 h and 24 h there was 
a 4817.0- and 95296.4-fold change respectively in SAA3 transcripts levels using qPCR 
This is likely because the dynamic range at which gene expression can be measured is 
relatively limited in a microarray. In contrast qPCR is a very sensitive method of 
detecting mRNA expression (Wong ML and JF 2005). SAA3 fold changes were among 
the highest measured, and were similar at each time point, supporting the explanation 
that the microarray analysis may have been measuring at the top of its dynamic range. 
This could explain the discrepancy between the fold changes observed between the two 
assays. In addition to these genes, transcripts for TLR-2 previously investigated in this 
project were upregulated in response to P. gingivalis and this increased gene expression 
was confirmed from results obtained by the microarray. Overall, the upregulation of 
RANKL and COX-2 and the downregulation of OPG expression by P. gingivalis 
supernatant demonstrated consistently throughout this work was supported by 
microarray analysis, supporting the notion that P. gingivalis is increasing the 
RANKL/OPG ratio favouring bone destruction. 
 
5.7.2 Gene expression profile of stromal cells challenged with P. gingivalis 
It was imperative to assay time periods of early and late responses to P. gingivalis, 
where initial synthesis of activation of cellular pathways and secondary responses could 
be observed in response to P. gingivalis challenge. A 6 h and 24 h period were chosen 
since P. gingivalis did not elicit significant cell death and more importantly, were 
crucial time periods for the expression of bone resorption molecules. Consequently, 
subsequent to challenge with P. gingivalis supernatant, the relative abundance of a wide 
array of genes linked to several categories including immune, inflammation and 
signalling related genes was affected. 
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5.7.3 Regulation of genes involved in apoptosis, proliferation and cellular 
structural integrity 
In the present experimental system, P. gingivalis upregulated genes related to apoptosis, 
including CASP4, GULP1 and FAS receptor, suggesting mechanisms by which P. 
gingivalis challenge may induce the apoptosis. P. gingivalis has been previously shown 
to induce apoptotic cell death in fibroblasts, endothelial cells and epithelial cells 
(Imatani, Kato et al. 2004; Roth, Ankersmit et al. 2007; Stathopoulou, Galicia et al. 
2009). It has been suggested that P. gingivalis gingipains may have a role in mediating 
apoptosis in gingival epithelial cells, since purified gingipains induced apoptosis whilst 
P. gingivalis gingipain mutant had no such effects (Stathopoulou, Galicia et al. 2009). 
These studies indicate that cell death and therefore tissue destruction by apoptosis is a 
key process in the progression of chronic periodontitis where the removal of damaged 
cells is part of the host response to infection by periodontal pathogens such as P. 
gingivalis.  
 
Gene transcripts that encode for cell cycle proteins were also affected upon P. gingivalis 
challenge. The genes encoding for p16 and p21, that arrest the cell cycle in G1 phase, 
were upregulated which was accompanied by the downregulation of cyclin D1 
transcripts, a protein that is crucial for the entry into the G1 phase of the cell cycle. One 
study demonstrated that the decreased expression of cyclin D1 and cyclin E by P. 
gingivalis infection causes G1 arrest of the cell cycle which was mainly attributed to the 
activity of the gingipains (Kato, Tsuda et al. 2008). It has also been shown that P. 
gingivalis infection reduced cyclin D1 levels and also upregulated p15, p16, p18 and 
p21, contributing to the inhibition of the cell cycle at the G1 phase in human 
trophoblasts (Inaba, Kuboniwa et al. 2009). This suggests that P. gingivalis may be 
abrogating the proliferation of cells that induce inflammatory responses, to aid its 
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survival within the host environment. Following P. gingivalis challenge, genes encoding 
for cellular structure were downregulated, including claudin 15 (a tight junction 
protein), caveolin 1 (an integral membrane scaffolding protein) and vimentin (a 
intermediate filament), indicating that. P. gingivalis is potentially disrupting the 
integrity of the cell structure through downregulating these related genes.  
 
5.7.4 P. gingivalis upregulates chemokine and cytokine expression 
Chemokines are cytokines that are involved in recruiting leukocytes to inflammatory 
sites. In this present study using microarray analysis, P. gingivalis upregulated 
chemokines CCL2, CCL3, CCL5, CXCL1, CXCL5 and CXCL9. These finding accords 
with a similar study where bone marrow stromal cells challenged with viable P. 
gingivalis elicited a similar chemokine gene profile. It was suggested that some of these 
responses may be attributed to P. gingivalis gingipains or LPS (Ohno, Okahashi et al. 
2006). In addition, P. gingivalis has also been shown to induce the expression of CCL2 
in endothelial cells (Kang and Kuramitsu 2002) and also CCL2 and CCL5 in bone 
marrow derived cells (Jiang and Graves 1999). CCL2 is highly expressed in inflamed 
human gingival tissue (Yu, Antoniades et al. 1993) and CCL2 and CCL5 mRNA is 
shown to be upregulated in gingival biopsies from aggressive and chronic periodontitis 
patients (Garlet, Martins et al. 2003). In this work, P. gingivalis stimulated the mRNA 
expression of chemokines responsible for recruiting leukocytes, such as monocytes, 
neutrophils and T cells. The recruitment of these immune cells protects the host against 
bacterial invasion but over-stimulation can conversely cause periodontal tissue and bone 
destruction.  
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Transcripts for cytokines, M-CSF1 and M-CSF2 that are required for survival, 
differentiation and proliferation of hematopoeitic cells was increased in response to P. 
gingivalis. Importantly, RANKL mRNA expression and is upregulated, whereas OPG is 
downregulated by P. gingivalis challenge. Activated B- and T- lymphocytes can express 
RANKL (Kawai, Matsuyama et al. 2006) and P. gingivalis bacterial supernatant is able 
to stimulate RANKL mRNA expression in T cells (Belibasakis, Reddi et al. 2011), 
which would support osteoclastogenesis. Therefore, multiple experimental approaches 
have shown that P. gingivalis is providing favourable conditions to enhance bone 
resorption in vivo.  
 
Transcripts for inflammatory cytokines IL-1α and IL-6 were also upregulated during P. 
gingivalis treatment. Interestingly, transcripts for IL1RN, an inhibitor of IL-1α was also 
downregulated, supporting the theory that IL-1α might be active in these cells. P. 
gingivalis has been previously shown to stimulate levels of IL-6 mRNA (Okahashi, 
Inaba et al. 2004; Zhou, Desta et al. 2005) and protein expression (Le XK, Laflamme C 
et al. 2009). Although IL-1α gene expression is increased, another study demonstrated 
that IL-1α production is only weakly induced by P. gingivalis in human monocytes 
(Bostanci, Allaker et al. 2007), this study shows weaker induction by P. gingivalis, 
compared to other bacterial species. Both IL-1α and IL-6 have been extensively studied 
and are involved in stimulating bone resorption contributing to the pathogenesis of 
periodontitis (Liu, Lerner et al. 2010).                               
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5.7.5 Regulation of growth factor gene expression by P. gingivalis 
BMP4 is involved in osteoblastic differentiation (Katagiri and Takahashi 2002). At the 
transcription level, this gene was downregulated by challenge with P. gingivalis, 
suggesting a potential inhibitory effect on the differentiation of mesenchymal cells into 
osteoblasts. On the contrary, the gene expression of VEGF, a potent inducer of 
angiogenesis and vascular permeability, was increased over the course of P. gingivalis 
challenge. Increased vascularisation, swelling and edema are characteristic of the 
progression of periodontal disease. Several studies implicate VEGF in the progression 
of periodontitis, since increased protein levels of VEGF were observed in diseased 
gingival tissue (Johnson, Serio et al. 1999) and GCF samples (Prapulla, Sujatha et al. 
2007), compared to healthy tissue. It has been shown that P. gingivalis vesicles and 
outer membrane proteins increased VEGF expression in HGFs (Suthin, Matsushita et al. 
2003). This suggests that P. gingivalis is potentially involved in promoting angiogenesis 
and vascular permeability in vivo, during periodontitis. In periodontitis, increased 
vascularisation can lead to increased hemin concentrations upon vascular ulceration, 
contributing to the growth of P. gingivalis. 
5.7.6 P. gingivalis increases the expression of genes encoding for inflammatory 
mediators 
As well as cytokines and growth factor transcripts, specific inflammatory genes were 
also altered by P. gingivalis challenge. Transcripts encoding for COX-2 and PTGES, 
enzymes involved in the synthesis of the inflammatory mediator PGE2, were 
upregulated in the current work. P. gingivalis have been shown to upregulate PGE2 
levels (Okahashi, Inaba et al. 2004; Choi, Moon et al. 2005; Belibasakis, Reddi et al. 
2011). It is well established that PGE2 is involved in the pathogenesis of periodontitis 
since higher levels of PGE2 have been found in periodontitis patients compared to 
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controls, and PGE2 has been shown to be involved in stimulating bone resorption 
(Noguchi and Ishikawa 2007). The effect of PGE2 in determining RANKL and OPG 
ratio has been investigated in this work where it was concluded that PGE2 has a role in 
RANKL induction stimulated by P. gingivalis. 
 
Transcript levels for LCN2 were dramatically upregulated during the course of P. 
gingivalis challenge and it was one of the highest differentially regulated genes 
encoding for acute phase proteins in the array. LCN genes encode for small 
glycoproteins, which form part of the acute phase response and are involved in the 
innate immune response to bacterial infection. LCN2 has been shown to possess 
antimicrobial effect, through sequestering bacterial siderophores and inhibiting the 
growth of iron-dependent bacteria (Flo, Smith et al. 2004). Interestingly, P. gingivalis 
does not use siderophores to sequester iron, therefore the huge upregulation of LCN2 
mRNA may be an aberrant cellular response to aim to limit bacterial growth. 
 
The SAA family of proteins are also involved in the acute phase response. In this study, 
the transcription of SAA3 was hugely upregulated by P. gingivalis, which is supported 
by work in stromal cells (Ohno, Okahashi et al. 2006). Four SAA isoforms exist in 
humans, with SAA1 and SAA2 comprising major active isoforms, SAA4 moderately 
induced during inflammation and SAA3 is a pseudogene in humans although it is an 
active isoform in mice (Kluve-Beckerman B, Drumm ML et al. 1991). In human 
mammary gland epithelia cells stimulated with E. coli LPS, SAA3 transcripts were 
detected and upregulated (Larson, Wei et al. 2003). In addition SAA3 mouse isoform 
has 70% amino acid sequence homology to human SAA1 and it is proposed that they 
may overlap in function (Reigstad and Bäckhed F 2010). It has been shown that 
sustained production of SAA proteins can lead to amyloidosis through fibril deposition 
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and occur in a small proportion of those who have chronic inflammatory conditions 
(Lachmann HJ, Goodman HJ et al. 2007). It has also been suggested that there may be a 
link between amyloidosis and periodontal disease, where one condition may predispose 
to, or aggravate, the other. This has been demonstrated in two patients, and may be 
caused by increasing systemic inflammatory mediators by either conditions  (Khoury, 
Dusek et al. 2004; Cengiz MI, Wang HL et al. 2010).  Since patients with periodontitis 
have higher blood serum levels of SAA than healthy individuals (Glurich, Grossi et al. 
2002), SAA protein levels could serve as a potential biomarker for periodontal disease 
progression, but this would require further investigations on the clinical level. 
 
Genes encoding for the acute phase proteins Hp and Hpx were upregulated by P. 
gingivalis. Hp binds hemoglobin in plasma and prevents heme-mediated oxidative 
damage to internal organs upon hemolysis during pathologic conditions such as 
bacterial infections (Tolosano, Fagoonee et al. 2002). Hp levels have been shown to be 
higher in individuals with periodontitis as opposed to those who are healthy (Ebersole 
JL, Machen RL et al. 1997). P. gingivalis utilizes hemin to receive iron for its growth, a 
process inhibited by host iron-sequestering (binding) proteins, including Hp and Hpx, 
which bind haemoglobin and heme respectively, thus forming complexes within blood 
plasma, thereby denying iron to bacteria. Interestingly, P. gingivalis is able to grow in 
the presence of these complexes and it has been suggested that it may possess a 
mechanism through which it is able to utilize iron from these complexes (Bramanti and 
Holt 1991). P. gingivalis Lys gingipain can degrade Hp and Hpx in vitro, releasing 
hemin from these complexes for bacterial growth (Sroka, Sztukowska et al. 2001). 
Therefore, like LCN2 mRNA upregulation previously described, the upregulation of Hp 
and Hpx may be a general host response to bacterial infection, and may be less effective 
as a specific anti-P. gingivalis response. 
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 There is circumstantial evidence to suggest that TLR-2 is activated by P. gingivalis in 
this work. Genes which encode for components of the TLR-2 complex (CD14, LBP and 
TLR-2) were uniformly upregulated by P. gingivalis challenge. Conversely, 
transcription of MD-2, the co-receptor for TLR-4 was downregulated in the current 
work. Transcripts for two signaling molecules involved in downstream TLR signaling 
were also changed. IRAK3 mRNA, which encodes a negative regulator of TLR 
signaling, was upregulated and MYD88, a critical signaling component of TLR 
signaling, was also increased. The activation of TLR pathways through the recognition 
of bacterial products, such as peptidoglycans or LPS, leads to the upregulation of 
inflammatory cytokines that can ultimately lead to tissue and bone destruction in 
periodontitis (Liu, Lerner et al. 2010). P. gingivalis fimbriae or, more commonly, LPS 
is recognised by either TLR-2 (Asai, Ohyama et al. 2001; Nociti, Foster et al. 2004; 
Nemoto, Darveau et al. 2006) or TLR-4 (Reife, Coats et al. 2006; Sawada, Ogawa et al. 
2007) in various cell types. This work previously showed that TLR-2 transcripts were 
upregulated by P. gingivalis and purified LPS, or heat killed P. gingivalis has also been 
demonstrated to induce TLR-2 expression (Brozovic, Sahoo et al. 2006). Interestingly, 
in TLR-2 deficient mice challenge with live P. gingivalis hugely reduced cytokine 
inflammatory response and alveolar bone loss, suggesting that TLR-2 activation is 
required to cause disease by P. gingivalis (Burns, Bachrach et al. 2006). Taken together, 
the results suggest that TLR-2 is a key signaling receptor in the recognition of P. 
gingivalis by host cells, and through this pathway may contribute to the overall 
inflammatory response. 
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5.7.7 Immune related genes are upregulated in response to P. gingivalis challenge 
In the current work, genes encoding members of the complement cascade C1s, C3, C4B 
and CFB were upregulated in response to P. gingivalis. The complement system is 
integral to innate immunity and has three main functions: the host defense against 
infection, assisting with antibody-antigen complexes and disposal of immune complexes 
and apoptotic cells. There are more than 30 complement proteins within plasma that 
participate in three main pathways when activated, named the classical, lectin and 
alternative pathway (Walport 2001). It has been shown that P. gingivalis is very 
resistant to bacteriocidal effects in normal human sera (Katarzyna Popadiak, Jan 
Potempa et al. 2007). It is proposed that P. gingivalis proteases are most likely 
responsible for this effect since Arg- and Lys-gingipain mutants have increased 
susceptibility to complement killing compared to wild-type P. gingivalis (Grenier, Roy 
et al. 2003). Interestingly, P. gingivalis is also able to degrade complement factors 
(Wingrove, DiScipio et al. 1992; Potempa, Banbula et al. 2000), and its gingipains can 
either degrade complement factors or, at low concentrations, activate them (Katarzyna 
Popadiak, Jan Potempa et al. 2007).  It is proposed that when P. gingivalis first 
colonises the host, the low concentration of gingipains would favour an inflammatory 
response which recruits nutrients needed for growth. Conversely, after a period of P. 
gingivalis growth, a higher gingipain concentration could degrade complement factors, 
inhibiting the innate immune response. Additionally surface polysaccharides of P. 
gingivalis has also been implicated in complement resistance (Slaney, Gallagher et al. 
2006). Inducing genes that encode complement proteins suggest that cells are mounting 
an immune response aimed at clearing bacterial infection.  
 
The expression of a number genes encoding for MHC class I and class II molecules 
were also increased over the course of P. gingivalis treatment of bone marrow stromal 
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cells. Transcripts for CD68, a macrophage marker, were also increased by P. gingivalis 
challenge. MHC class molecules are involved in presenting peptides to T cells. MHC 
class I are ubiquitously expressed and present intracellular peptides, whereas class II 
molecules are mainly expressed by antigen presenting cells such as macrophages and 
dendritic cells, and present exogenous peptides (Neefjes, Jongsma et al. 2011). 
Interestingly mesenchymal stromal cells have been documented to have suppressive 
effects on immune reactions (Abdi, Fiorina et al. 2008).  Alternately the expression of 
MHC class II molecules can be induced in response to IFN-γ in mesenchymal stromal 
cells (Romieu-Mourez, François et al. 2007). In addition, osteoblasts are capable of 
expressing MHC class II molecules in response to Gram-negative and Gram-positive 
bacteria (Schrum, Bost et al. 2003). Together this indicates that stromal cells are capable 
of behaving in an immunomodulatory manner. 
 
Transcripts for CAMP were upregulated by P. gingivalis challenge. CAMP is stored in 
granules within neutrophils and macrophages and upon phagocytosis it disrupts 
bacterial cell membrane integrity and can also binds to LPS, inhibiting its biological 
activity (Bals and Wilson 2003). Mesenchymal stromal cells can secrete CAMP in 
response to bacterial infection, which can inhibit the growth of gram negative bacteria 
in vitro (Krasnodembskaya, Song et al. 2010). CAMP inhibits pro-inflammatory 
responses elicited by killed P. gingivalis cells and its components LPS and fimbriae  
(Inomata, Into et al. 2010). It has been demonstrated that levels of CAMP are elevated 
in GCF from chronic periodontitis patients compared to healthy individuals (Puklo, 
Guentsch et al. 2008; Türkoğlu, Emingil et al. 2009). Of note, it has been reported that 
P. gingivalis is resistant to the microbial actions of CAMP in vitro (Altman, Steinberg 
et al. 2006; Bachrach, Altman et al. 2008). 
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The gene encoding for the acute phase protein PTX3 was notably upregulated in 
response to P. gingivalis. PTX3 protein is induced by LPS and inflammatory cytokines 
and is involved in a variety of cellular functions including innate immunity and 
inflammation (Ortega-Hernandez, Bassi et al. 2009). P. gingivalis LPS and fimbriae are 
all able to induce PTX3 transcripts in macrophage cells (Zhou and Amar 2007). PTX3 
levels has been found to be positively associated with severity of periodontitis (Pradeep, 
Kathariya et al. 2011). Moreover, PTX3 levels are higher in diseased sites compared to 
healthy sites in individuals with chronic periodontitis (Fujita, Ito et al. 2011). The 
upregulation of PTX3 transcripts seen in the microarray data therefore accords with the 
known literature on the regulation of this gene.  
5.7.8 P. gingivalis induces protease-encoding genes 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that are normally 
involved in tissue and ECM remodelling. Over-expression of MMPs can lead to 
degradation of ECM components such as collagen and fibronectin, contributing to 
periodontal tissue and bone destruction (Offenbacher 1996). In response to P. gingivalis 
challenge, a number of transcripts for MMPs were upregulated, specifically MMP3, 
MMP9, MMP12, MMP13, MMP13, MMP14 and MMP17. It has been demonstrated in 
several studies that whole P. gingivalis, its bacterial sonicates, or its supernatant are 
capable of simulating the production of MMPs in a variety of cell types including PDL, 
human dental pulp, and gingival fibroblast cells (Nakata, Yamasaki et al. 2000; Chang, 
Lai et al. 2002; Pattamapun, Tiranathanagul et al. 2003; Zhou and Windsor 2006).  
 
There is extensive evidence to suggest that elevated levels of MMPs are related to 
periodontal disease, since MMP levels are higher in periodontitis compared to health 
(Hernandez, Valenzuela et al. 2006; Hernández, Martínez et al. 2007; Rai, Kharb et al. 
2008; Balwant Rai, Jasdeep Kaur et al. 2010; Oyarzún, Arancibia et al. 2010) and 
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higher in active disease sites within periodontitis patients (Alpagot, Bell et al. 2001). 
Furthermore, there was positive correlation between the proportion of P. gingivalis 
detected in active sites and MMP13 levels (Silva, Dutzan et al. 2008)  
 
The mRNA expression of TIMP1, an inhibitor of MMPs, was upregulated by P. 
gingivalis in the current work. TIMP1 is increased in periodontitis (Alpagot, Bell et al. 
2001) and P. gingivalis is able to degrade TIMP1, with gingipains suggested as 
responsible for this effect (Grenier and Mayrand 2001; Zhou and Windsor 2006). 
 
Elastases are proteases capable of cleaving collagen and elastin (Dickinson 2002). There 
is substantial evidence to support ELA2 (a neutrophil elastase) in the pathogenesis of 
periodontitis (Palcanis, Lariava et al. 1992; Armitage, Jeffcoat et al. 1994; Jin, Söder et 
al. 1995). In this work, transcription of ELA1 is downregulated in response to P. 
gingivalis, but not ELA2, suggesting ELA1 may play a previously uncharacterised role 
in periodontal disease. Transcripts for CTSL, a lysosomal cysteine endopeptidase, were 
upregulated by P. gingivalis. CTSL is released from cells under different conditions and 
it can degrade components of the ECM (Dickinson 2002) and may be involved in the 
metabolic turnover of bone (Leto, Crescimanno et al. 2011). 
 
Several serpin family genes were upregulated in response to P. gingivalis challenge. 
Serpins inhibit serine proteases and some cysteine proteases such as elastase and 
cathepsin L (Silverman, Bird et al. 2001). P. gingivalis gingipains are cysteine proteases 
that could also potentially be inhibited by serpins.  
 
Secretory leukocyte peptidase inhibitor (SLPI) is a serine protease inhibitor of elastase 
and capthepsin G (Stetler, Brewer et al. 1986). After P. gingivalis challenge, transcripts 
of SLPI were notably induced. In one study, SLPI mRNA was similarly induced, but 
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secreted SLPI was reduced compared to controls. It was suggested that RgpA gingipain 
may be degrading SLPI (Into, Inomata et al. 2006; Yin, Swanson et al. 2010). In 
agreement with this, SLPI levels from periodontitis patients were found to be lower than 
healthy individuals (Laugisch, Schacht et al. 2011). Furthermore, in two out of five 
periodontitis patients SLPI levels were reduced in gingival tissue compared to healthy 
tissue, and this was correlated with the presence of P. gingivalis. Conversely another 
group demonstrated that regardless of the presence of P. gingivalis in periodontitis 
patients, SLPI levels were reduced, although generally it was shown that high levels of 
P. gingivalis were correlated with lower SLPI levels (Kretschmar, Yin et al. 2011). 
Overall, the increase in SLPI transcript levels is likely a host protective response against 
bacterial challenge to minimise protease-mediated tissue damage, but the evidence from 
the literature is that SLPI protein is a target of P. gingivalis protease activity which 
would contribute to the pathogenesis of periodontitis. Taken together, proteases are 
increased upon P. gingivalis challenge are able to destroy ECM components and cause 
periodontal damage unless this activity is counter balanced with appropriate protease 
inhibitors.  
5.7.9 Genes encoding for intracellular signaling and transcription factors are 
affected by P. gingivalis challenge 
The NF-κB pathway is involved in the expression of genes involved in immunity and 
inflammation. Dysregulation of these genes can lead to pathological conditions such as 
cancer and chronic inflammatory disorders (Hayden and Ghosh 2012). It has been 
demonstrated that NF-κB is activated at higher levels in chronic periodontitis patients 
compared to healthy subjects (Arabaci, Cicek et al. 2010).  Inducers of NF-κB include 
pro-inflammatory cytokines such as IL-1β, TNF-α and bacterial LPS (Sun and 
Andersson 2002). NF-κB complexes are normally inactive and are stabilised in the 
cytoplasm through the association of bound IκB proteins. When these IκB proteins are 
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phosphorylated by IκB kinases, IκB proteins dissociate from the NF-κB complex and 
degraded where NF-κB complexes are then free to translocate to the nucleus binding to 
κB sites and initiate gene transcription. (Hayden and Ghosh 2012).  
 
From the microarray data, it appears that P. gingivalis may modulate the activation of 
the NF- κB pathway. Genes for NF- κB family members NF- κB1/p50 subunit, NF- 
κB2/p52, REL-A/p65 and REL-B transcripts were increased. In addition, transcripts for 
the inhibitors of NF- κB complex BCL3, NF- κBIA (IκB-a), NF- κBIE (IκB-e), NF-
κBIZ (IκB-ε), TNFAIP3 and TNIP1 were all upregulated. Genes encoding for kinases 
that phosphorylate NF-κB inhibitors IκBKE and IκBKG were also upregulated. 
 
It has been demonstrated that live P. gingivalis can activate NF-κB in fibroblasts, 
stromal cells, osteoblasts and endothelial cells inducing inflammatory cytokines and 
MMPs (Choi, Park et al. 2005; Ohno, Okahashi et al. 2008). Heat killed P. gingivalis is 
also capable of activating NF-κB in HGE cells (Brozovic, Sahoo et al. 2006). 
Interestingly, it has been shown that P. gingivalis LPS is also able to activate NF-κB 
through TLR-2 in cementoblasts (Nemoto, Darveau et al. 2006), which may provide an 
explanation for the findings in this study. It has been demonstrated that live P. 
gingivalis is able to signal through multiple pathways including NF-κB, and p38 in 
endothelial cells (Walter, Zahlten et al. 2004; Zhang, Zheng et al. 2011).  
 
The JAK/STAT pathway is important in the expression of cytokines and growth factors 
(Rawlings, Rosler et al. 2004). In this work, there is evidence to suggest that activation 
of the JAK/STAT3 pathway may be altered by P. gingivalis as JAK2 and STAT3 
transcripts were upregulated in response to P. gingivalis challenge. In addition, 
transcripts for SOCS3, a negative regulator of the STAT pathway, were also 
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upregulated. The JAK/STAT pathway is activated when cytokines or growth factors 
bind to receptors already associated with JAK, which become transphorylated, starting a 
cascade. The phosphorylated JAKs in turn phosphorylate the cytokine/growth factor 
receptor, which allows STATs to be phosphorylated and translocate to the nucleus, 
binding to DNA and initiating gene transcription (O'Shea, Gadina et al. 2002). Live P. 
gingivalis has been shown to activate STAT3 and JAK1 in gingival epithelial cells 
(Mao, Park et al. 2007). Additionally, live P. gingivalis is able to induce transcripts for 
STAT1, STAT2 and SOCS1 in stromal cells (Ohno, Okahashi et al. 2006).  P. 
gingivalis Fim A upregulated STAT3 expression whereas LPS downregulated STAT3 
expression in macrophages (Zhou and Amar 2006), suggesting JAK/STAT regulation 
by P. gingivalis may be cell type dependent. Finally, STAT3 has been demonstrated to 
regulate RANKL expression in osteoblasts, which may hint at an underlying mechanism 
worthy of future experimental investigation (A. O’Brien, Gubrij et al. 1999; Bishop, 
Meyer et al. 2009; Mori, Miyamoto et al. 2011).  
 
It has been shown by several groups that P. gingivalis is able to activate the AP-1 
transcription factor in osteoblasts, HUVE and oral epidermoid cells (Okahashi, Inaba et 
al. 2004; Choi, Park et al. 2005; Yanti, Lee et al. 2009). In this study, genes that encode 
AP-1 components c-Fos and JUN-B were upregulated in response to P. gingivalis 
infection so it is possible that P. gingivalis may be activating the AP-1 pathway in this 
experimental system. 
  
Bone marrow stromal cells can differentiate into a number of cell types so it is perhaps 
not surprising that a broad array of transcription factors have been affected by P. 
gingivalis challenge. Other signaling or transcription factors affected that have 
relevance to bone include MAP3K8, HEY1, OSR2 and C/EBPβ. Transcripts for 
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MAP3K8/Cot/Tpl2, a serine threonine kinase that is able to activate the MEK1/2-
ERK1/2 pathway, was upregulated during the course of P. gingivalis infection. It has 
been shown that MAP3KB is an essential intracellular mediator for RANKL induction 
by synthetic E. coli lipid A in osteoblasts (Kikuchi, Yoshikai et al. 2003). Furthermore, 
when periodontitis was induced in MAP3K8 deficient mice, periodontal inflammation 
and bone loss was reduced and MAP3K8 positively regulated RANKL expression in 
vivo (Ohnishi, Okamoto et al. 2010). Therefore, MAP3K8 is a possible regulator of the 
RANKL induction observed in this thesis.  
 
C/EBPβ is a transcription factor involved in adipocyte and osteoblast differentiation and 
skeletal function in vivo (Zanotti, Stadmeyer et al. 2009). By microarray analysis, it was 
demonstrated that transcripts for C/EBPβ were upregulated in response to P. gingivalis. 
It has been shown that the transcription factor C/EBPβ can induce RANKL gene 
promoter activity in osteoblast-like cells (Ng, Tsui et al. 2010). The gene expression for 
HEY1 was increased in response to P. gingivalis. HEY1 is part of the Hairy and 
Enhancer of Split family of transcription factors and has been shown to negatively 
regulate osteoblastic differentiation (Zamurovic, Cappellen et al. 2004). HEY1 is 
involved in P. gingivalis LPS mediated inhibition of osteoblastic differentiation (Xing, 
Ye et al. 2010) and over-expression of HEY1 yields a osteopenic phenotype and 
chondrocyte hypertrophy (Salie, Kneissel et al. 2010). These investigations suggest that 
P. gingivalis is impairing osteoblast differentiation by inducing HEY1. OSR2 mRNA 
were downregulated by P. gingivalis challenge. It is thought that OSR2 has a role in 
osteoblast differentiation since in knockout mice there was a negative effect on 
osteoblast proliferation and formation of calvaria and long bones (Kawai, Yamauchi et 
al. 2007).  
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In summary, P. gingivalis is affecting an array of genes involved in protecting the host 
against bacterial invasion, by inducing genes involved in apoptosis, cellular 
proliferation, inflammation and immunity. From the literature, P. gingivalis and the host 
response indirectly elicits hyper-reactivity of the immune system and inflammation 
thereby initiating diverse events, for instance, apoptosis,  recruitment of phagocytic cells 
and upregulation of host MMPs, which can all lead to tissue destruction. In this work P. 
gingivalis favoured the regulation of genes involved in bone resorption. Based on the 
literature P. gingivalis has been shown to have developed virulence mechanisms to aid 
its growth and survival in the host environment. For example, P. gingivalis has evolved 
mechanisms to promote its growth through sequestering iron, and it is able to degrade 
complement factors and host proteinase inhibitors. Amongst several findings in this 
work, most promising is the involvement of TLR-2 and the possible activation of the 
NF-κB pathway by P. gingivalis which could be investigated as part of future work. 
 
In the current study the cellular response to P. gingivalis may also be taking into 
account that this pathogen is part of an oral biofilm and providing responses that would 
be suitable in vivo. In the present experimental system the intrinsic responses can be 
determined without the influence of extrinsic factors making this a very specific model. 
Overall the information regarding gene regulation in response to P. gingivalis largely 
concurs with existing literature both with in vitro and in vivo studies, which further 
supports the relevance of this model investigating P. gingivalis virulence.  
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Chapter 6. 
 
Final Discussion 
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6. Final Discussion  
Periodontitis is a bacterially induced inflammatory condition which results in soft 
periodontal tissue and alveolar bone destruction, ultimately leading to the loss of teeth. 
P. gingivalis is a major periodontal pathogen associated with chronic periodontitis. This 
work employed an experimental system whereby the effect of P. gingivalis was studied 
on molecules involved in bone resorption, namely RANKL and OPG, expressed by 
bone marrow stromal cells. P. gingivalis increased the RANKL/OPG ratio, which 
biologically suggests an increase in osteoclastogenesis, favouring bone destruction. It 
was determined that PGE2, an inflammatory mediator, is involved in the induction of 
RANKL by P. gingivalis. After characterisation of the effects on these major molecules 
involved in bone resorption, the studies then proceeded to identify virulence factors and 
intracellular signalling pathways involved in the observed effects. 
 
Porphyromonas gingivalis actively secretes, or passively releases upon cell lysis, a 
number of bacterial virulence factors including fimbriae, gingipains, LPS and outer 
membrane vesicles, which are contributing to the pathogenic effects associated with the 
development of the disease. P. gingivalis culture supernatant was used in this work as it 
contained a mixture of these factors and was thought to best mimic the in vivo 
environment. Through a series of investigations, it was determined that the virulence 
factor responsible for RANKL upregulation was likely P. gingivalis LPS, working 
synergistically with an unknown heat stable factor. LPS alone was the likely candidate 
for downregulating OPG expression. The direct involvement of gingipains in RANKL 
and OPG regulation was excluded, but there was evidence that they may have an 
indirect effect by modifying proteins or bacterial components of P. gingivalis during the 
culture period. 
 
 165
A further goal of this theme was to investigate the possible intracellular signalling 
pathways by which P. gingivalis may regulate RANKL and OPG. The demonstration 
that P. gingivalis induced p38-dependent PGE2 production, contributing to the 
induction of RANKL, reveals the intricate virulence mechanisms of this species.  
 
Collectively, the results of these studies provide mechanistic insights for the 
development of possible therapeutic strategies to intervene in the pathogenic regulation 
of the RANKL-OPG system by bacteria. For instance, it is possible that antibodies 
toward LPS-signalling receptors CD14 or TLRs may inhibit their interaction with LPS, 
thus preventing associated inflammatory events. Anti-LPS therapies may only abrogate 
one target but, conversely, another strategy would be to target intracellular signalling 
pathways involved in the pathogenesis of the disease, such as the use of p38 inhibitors. 
 
In vivo, P. gingivalis exists as part of an oral biofilm and may work synergistically with 
other bacteria to release virulence factors and penetrate into the tissues or invade a 
variety of cell types in the periodontium. This invokes an inflammatory response from 
cells that come into contact with P. gingivalis, including gingival epithelial, fibroblasts 
and PDL cells where there is molecular cross-talk between neighbouring cells, 
eventually leading to tissue and bone destruction. It is therefore important to conduct 
research into mechanisms of bacterial virulence and define intracellular signalling 
pathways that mediate these events. This in vitro project employed cells of bone marrow 
stroma origin which may be affected by the inflammatory response provoked by oral 
cells in response to P. gingivalis infection, further contributing to periodontal 
destruction. The fact that P. gingivalis is able to exert its virulence potential on bone 
marrow stromal cells, which may not normally be encountered in abundance, highlights 
the wide scope of the virulence potential of this bacterium against a multitude of cell 
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types in the periodontium. A large part of P. gingivalis influence also derives from its 
ability to elicit different cellular responses from various cell types with the same 
virulence factor, contributing to the destruction of the host environment.  
 
The last part of this thesis focussed on the changes caused in the global transcriptional 
profile by P. gingivalis using microarray technology. P. gingivalis challenge induced 
many genes that were involved in inflammatory, apoptotic and immune response 
categories, which would contribute to tissue and bone destruction and host protective 
measures to prevent or fight infection. Conversely key P. gingivalis induced-
downregulated genes were involved in inhibition of the cell cycle, disrupting the 
integrity of cell and increasing the RANKL/OPG ratio by decreasing the transcriptional 
expression of OPG. Taken together, the studies performed in the context of this thesis 
show that P. gingivalis regulates a number of genes involved in promoting 
inflammation and bone destruction. 
 
The information obtained from this work largely agreed with existing literature and is 
consistent with in vivo events/processes occurring in the disease. This further supports 
the reliability and the use of this specific in vitro model to study P. gingivalis virulence.  
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Overall conclusion  
Porphyromonas gingivalis is a pathogenic bacterium that is able to exert its virulence 
potential on bone marrow stromal cells and affect a host of genes involved with disease 
processes. It has been demonstrated that P. gingivalis increases the RANKL/OPG ratio 
favouring bone destruction. Bacterial virulence factors, host inflammatory mediators 
and intracellular signalling pathways have been investigated, whereby PGE2, LPS, and 
p38 MAPK have been instrumental in mediating these events. These findings provide 
potential candidate targets to be included in the development of adjunctive treatment 
modalities for P. gingivalis-associated periodontitis. 
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Chapter 7. 
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7. Future Work 
To extend the work in this thesis, several avenues can be investigated. All experiments 
performed were in an established continuous cell line. To further validate the findings in 
this study, primary bone marrow stromal cells could be used. To investigate whether the 
results obtained from this work are cell-type specific or to explore if this model of P. 
gingivalis challenge can be replicated in cells that face close contact with P. gingivalis 
in periodontitis: gingival epithelial cells, fibroblasts, cementoblasts and PDL fibroblasts 
can be used.  To relate this model to the in vivo environment, animal models of 
experimental P. gingivalis-induced periodontitis can also be employed (Oz and Puleo 
2011). 
 
In pilot work it was shown that MC3T3-E1 calvarial cells derived from 
intramembranous bone did not express RANKL and constitutively expressed OPG in 
response to P. gingivalis. This was in contrast to W20-17 bone marrow stromal cells 
derived from endochrondral bone where the RANKL/OPG was shown to be increased 
throughout the project upon P. gingivalis challenge. This highlights that the different 
responses from the cells could be due to the differences in bone biology from the two 
cell types. Within the microarray, P. gingivalis downregulated the transcriptional 
regulation of markers of osteoblast differentiation including the growth factor BMP4 
and the transcription factor OSR2 in W20-17 cells. It would be interesting to continue 
the investigation of RANKL and OPG in the more differentiated cell-line MC3T3-E1 
and also to explore the effect of P. gingivalis on markers of osteoblast differentiation in 
this cell type. 
 
The microarray data strongly indicates that TLR-2 is activated in response to P. 
gingivalis challenge, which is in line with the qPCR data confirming that P. gingivalis 
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culture supernatant and LPS upregulate TLR-2 mRNA. To go one step more and 
investigate LPS involvement in RANKL and OPG expression, TLR-2 activity could be 
inhibited by specific TLR-2 antibodies and the expression of RANKL, OPG, PGE2 and 
the involvement of p38 MAPK can be explored. This would provide a receptor link 
between the extracellular and intracellular signalling that leads to the regulation of the 
RANKL-OPG system and PGE2. In conjunction to experimental periodontitis in vivo 
models, these effects can be tested in TLR-2 knockout mice. 
  
Potential pathways activated by P. gingivalis indicated through micro-array analysis are 
the AP-1, JAK/STAT and NF-κβ pathways. Both AP-1 and NF-κβ binding-sites exist in 
the RANKL promoter regions (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=TNFSF11) so investigating these transcription factors and their 
ability to bind to promoter sites could be explored by electrophoretic mobility shift 
assays or chromatin immunoprecipitations which, may prove to be a worthy pursuit. 
 
It was shown that P. gingivalis induced p38-dependent PGE2 production contributes to 
RANKL expression, although the involvement of other pathways such as AP-1, 
JAK/STAT, NF-κβ pathways and also the SAPK/JNK MAPK pathway each may be 
involved in RANKL regulation. These pathways may be involved in the latter stages of 
RANKL induction, after p38 activation, and be integral to PGE2 mediated RANKL 
production.  
 
Transcripts for LCN2 and SAA3 mRNA were strongly upregulated after P. gingivalis 
challenge. The production of protein should be confirmed as also significantly 
upregulated, and if so, functional studies could be undertaken to determine the 
significance of these proteins to the pathology of periodontitis. This an interesting result 
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since the expression of these proteins in response to P. gingivalis challenge has not 
previously been studied and could also lead to investigation of correlating the presence 
of these proteins in periodontitis (either in gingival tissue or gingival crevicular fluid) 
and in relation to P. gingivalis. These could be worth investigating as potential 
biomarkers for periodontal disease occurrence and progression.  
 
Together these proposed lines of investigation can be pursued to expand this stream of 
work and open up new possibilities into identifying the virulence mechanisms of P. 
gingivalis. 
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9. Appendices 
Appendix 1: Buffers and Reagents 
Reagents to measure Arg-X and Lys-X protease activity 
 
 Assay buffer  
0.1M Tris–HCl (Sigma) 
(10mM L-cysteine (Sigma), 10mM CaCl2 (Sigma), pH 8.1, 30°C)  
 
 Substrate for Lys-X protease activity 
25mg of N-α-acetyl-L-lysine-p-nitroanilide (Ac-LyspNA) (BACHEM) dissolved 
in 5% methanol, to this 25ml 
of dH20 was added 
 
 Substrate for Arg-X protease activity 
25 mg of N-α-benzoyl-DL-arginine-p-nitroanilide (BRpNA) (Sigma) dissolved 
in 5% DMSO, to this 25ml of dH20 was added 
 
Protein extraction 
 
 RIPA buffer 
150mM Sodium dodecyl sulphate (Fisher scientific) 
50mM TRIS pH 7.3 (Invitrogen) 
2.5 % Sodium chloride (BDH) 
1 % NP-40 (Fluka) 
 
 
RANKL and OPG ELISAs (R n D systems) 
 
 Wash buffer 
0.05 % Tween 20 (Sigma) diluted in 1 x PBS, pH 7.4 
 
 Reagent Diluent 
1% of bovine serum albumin (PAA, the cell culture company) diluted in  
1 x PBS 
 
Griess Reaction 
 
 Nitrite standard 
0.1 M Sodium Nitrite (Sigma) dissolved in dH20 
 
 Sulfanilamide sol. 
1% sulfanilamide (Sigma) in 5% phosphoric acid (Sigma) 
 
 N-1-napthylethylenediamine dihydrochloride (NED) sol.  
0.1% N-1-napthylethylenediamine dihydrochloride (Sigma) diluted in dH20 
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Appendix 2. Gene transcription at 6 h in response to P. gingivalis 
Genes upregulated more than two-fold at 6 h
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Gene symbol Fold change 
Saa3 144.7943
Lcn2 33.58387
Cxcl1 23.13512
Ccl2 17.62608
Ptx3 11.93013
Ptx3 11.52533
Nfkbiz 11.212
Cx3cl1 10.57374
Cxcl9 10.49606
Mmp13 9.319547
Gch1 9.005278
Ccl5 8.939191
Ch25h 8.355517
Ccl17 7.965845
Mmp13 7.810667
Fas 7.78019
Ccl9 7.167534
Cxcl10 7.142059
Fas 6.517889
Serpina3g 6.313765
Cd74 6.176455
Ankrd47 5.427477
Cdkn1a 5.263454
Cd74 5.025454
Slpi 4.940808
Rem2 4.937027
Ier3 4.916338
Slc2a6 4.719902
Nfkbia 4.609359
Zc3h12a 4.56093
Gbp2 4.374025
Slc24a6 4.008769
Tmem25 3.955971
TLR-2 3.744937
Syngr3 3.478439
Mmp17 3.405849
Cebpb 3.373075
Insl6 3.370797
Ccl3 3.34252
6430548M08Rik 3.331163
Hrbl 3.295758
Chac1 3.280644
Plk2 3.266554
Ptgs2 3.236976
4930572J05Rik 3.235112
Ehd3 3.222709
Hap1 3.221821
Grtp1 3.203551
LOC100044177 3.197671
Ptges 3.183894
Ifi47 3.119106
Mycl1 3.085585
Syn1 3.078951
Gene symbol Fold change 
Nfkbie 3.056928 
Sc4mol 3.045707 
1810015C04Rik 2.994005 
LOC100047651 2.981218 
Sqle 2.92861 
Reep6 2.916075 
LOC100043986 2.910129 
Spsb1 2.872737 
Ttll1 2.869438 
Csdc2 2.855875 
H1f0 2.843256 
Ccl7 2.832705 
Mapk8ip1 2.829642 
Dcxr 2.803246 
Rasl11b 2.801031 
Ccrn4l 2.799202 
Pfkp 2.797755 
Egr2 2.793851 
Hsd17b7 2.786798 
Stac2 2.784077 
Hr 2.772023 
Gcnt2 2.771199 
Casp4 2.766445 
Ncald 2.766394 
Pbx4 2.764175 
Nfkbie 2.73773 
Wfdc3 2.73354 
Ckb 2.718222 
Tnfaip2 2.716493 
Casp4 2.698254 
Tnip1 2.697194 
Csf1 2.68803 
Lrig1 2.687697 
Syn1 2.687652 
Tnip1 2.677298 
Stx6 2.673198 
Rasl11b 2.666019 
Stx6 2.664597 
Plvap 2.660739 
Eno2 2.650579 
Smox 2.648488 
Map3k8 2.633911 
Hp 2.633588 
Junb 2.630128 
Smox 2.625651 
Irf1 2.623241 
Eif4e3 2.617205 
Sema6b 2.611151 
Stat3 2.609693 
9130213B05Rik 2.609548 
1700088E04Rik 2.608456 
Irf1 2.596547 
Serpina3f 2.59493 
Genes upregulated more than two-fold at 6 h continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene symbol Fold change 
Cxcl2 2.593425
Hp 2.583361
Egln3 2.579902
Tmod1 2.564519
Mfsd7 2.564324
Dcxr 2.545471
Slc45a4 2.543356
Hook2 2.542683
Usp2 2.541824
Ccrn4l 2.540355
Mapk8ip1 2.538546
Por 2.534494
Plscr1 2.524827
Irf1 2.50094
Prss35 2.497494
Plscr1 2.497336
C630004H02Rik 2.490863
2810003C17Rik 2.490143
Chst8 2.480563
Nab1 2.478614
Snapc1 2.43859
Tnfaip3 2.435512
Lmcd1 2.434751
Mapkapk3 2.432875
Ttll1 2.430195
Slc11a2 2.426307
Nab1 2.423758
Por 2.404097
Tgoln1 2.402764
Tubb2b 2.400274
Cmbl 2.397074
Csf2 2.39652
Tmem66 2.396075
Ripk2 2.390463
Kank3 2.38627
Lmcd1 2.385232
Acss2 2.374224
Cd248 2.371193
Add3 2.370945
Zc3h12a 2.36987
Hp 2.36574
Smox 2.359704
Stat3 2.359676
Ptges 2.355503
Sod2 2.347944
Tubb2b 2.338117
Lmcd1 2.331752
Capn5 2.328319
Rab3a 2.319274
Brp17 2.304231
Axud1 2.302903
Crip2 2.300811
Idi1 2.298137
Gene symbol Fold change 
Socs3 2.297671 
Ifi30 2.290553 
Gnb5 2.289578 
BC046404 2.289485 
Rab3d 2.276528 
Gchfr 2.27334 
Id1 2.266497 
Skil 2.265962 
Gca 2.265059 
Slc9a3r1 2.263847 
Mtap 2.261651 
Tnfaip2 2.255719 
Neu1 2.249049 
Arhgef3 2.248939 
Tnfaip2 2.247883 
Ctsl 2.240973 
Cd44 2.235742 
Fbxo31 2.234761 
Igsf9 2.224286 
Cox7a1 2.220156 
Pdxp 2.215614 
Asl 2.212557 
Ccdc92 2.208948 
Limk1 2.204789 
Eif4e3 2.201129 
Slc25a33 2.200031 
Arrb2 2.198583 
Sqle 2.188847 
BC004044 2.188441 
Tapbp 2.188329 
Dhcr7 2.18483 
Rbm38 2.183763 
P4ha2 2.180856 
Atp6v1a 2.176066 
Smox 2.173456 
Itpka 2.171723 
Agrn 2.17011 
Gch1 2.168017 
Irf1 2.165895 
Prkcd 2.165097 
Rbm38 2.162089 
Micall2 2.161063 
Rasl12 2.160551 
LOC100045343 2.159308 
Smox 2.155073 
Ubd 2.151097 
Efna3 2.145273 
Hs2st1 2.144169 
Ptpn1 2.142118 
3010026O09Rik 2.140865 
Ifi30 2.134852 
Pcyt2 2.130996 
Hif1a 2.128772 
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Genes upregulated more than two-fold at 6 h continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene symbol Fold change 
Gprc5a 2.128504
Ddit4 2.128387
St3gal5 2.127805
1200002N14Rik 2.127507
Fkbp5 2.126505
Rac3 2.125568
Bckdhb 2.123221
Aldh4a1 2.12188
Pcyt2 2.118279
Lrrc15 2.117019
Apol9b 2.115069
Kif5c 2.112051
Mtap 2.106985
Gdf15 2.106466
Pcyt2 2.106435
Gdpd5 2.10298
Napa 2.09413
A330021E22Rik 2.092574
LOC100046457 2.091888
VEGF 2.091474
Cbara1 2.083462
Phlda1 2.080142
Tmem50b 2.079821
Metrn 2.073238
Mfap3l 2.073099
Psmb8 2.07089
Snx18 2.070212
Hey1 2.064908
Fbxo31 2.064848
Ttll1 2.06149
Tubb2b 2.059472
Tec 2.059405
Stat3 2.059314
VEGF 2.055166
Cdk2ap2 2.050331
Hagh 2.04793
LOC100048436 2.0459
Gnb5 2.042187
Rab3il1 2.041382
H2-DMa 2.040253
Tsc22d1 2.039001
Cdkn2a 2.036461
H2-M3 2.032903
Hrb 2.030487
Atp6v0b 2.027443
Dok4 2.024406
Syt13 2.020575
Col18a1 2.01886
Dos 2.018582
Rab3ip 2.017181
Igsf3 2.016906
Arntl 2.01374
Rpo2tc1 2.01185
Gene symbol Fold change 
Xpr1 2.010442 
Siat9 2.01002 
Asl 2.008372 
Plxdc1 2.002261 
Bex2 2.000896 
Tnnc1 2.000369 
Xpr1 2.010442 
Siat9 2.01002 
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Genes downregulated more than two-fold at 6 h  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene symbol Fold change 
Cc2d2a -4.68022
Sema3a -4.51999
Foxg1 -4.19903
Zfp532 -4.1979
Tnfrsf11b -4.01238
LOC100044776 -3.95499
Il1rn -3.93934
Ppapdc1 -3.67174
Zfp532 -3.65987
Dbp -3.45868
S3-12 -3.42361
Zfh4 -3.40096
Pik3ip1 -3.38379
Dis3l -3.29722
Rasl11a -3.23969
Pet112l -3.23761
Pet112l -3.2306
Rspo2 -3.17911
Tgf-b1i1 -3.16534
0610037L13Rik -3.16189
Mylk -3.14287
LOC100046883 -3.11348
Tgf-b1i1 -3.07427
1700034H14Rik -3.06422
Mylk -3.06158
Trp63 -3.03827
Cdc20 -2.9623
Htra3 -2.91864
Cldn15 -2.91821
AW061290 -2.90252
Avpr1a -2.86738
Il1rn -2.86103
Zfp521 -2.85519
Cdc20 -2.84092
Suv420h1 -2.81633
LOC100046044 -2.76721
Fbxo4 -2.7586
Hcfc1 -2.68577
Tbc1d5 -2.67593
1700030K09Rik -2.67589
Brd9 -2.6697
1700034H14Rik -2.65959
N4bp2 -2.65808
A930025D01Rik -2.65799
Fes -2.65303
Rpe -2.64386
4833442J19Rik -2.6403
Wisp2 -2.6395
Cul7 -2.63742
Gtf2ird2 -2.62073
Mfap5 -2.61579
Setd1b -2.59592
Gper -2.5917
Gene symbol Fold change 
Kctd12b -2.58695 
Ap4s1 -2.55583 
1700034H14Rik -2.52236 
D14Ertd449e -2.52112 
Fbxo6 -2.51656 
Efna5 -2.51226 
Aven -2.49702 
Myl4 -2.49125 
N6amt1 -2.48415 
Figf -2.47872 
Tnfrsf12a -2.47506 
Epc1 -2.47061 
1500012F01Rik -2.46481 
Pet112l -2.46465 
Ap4m1 -2.45563 
Pank1 -2.44759 
A930025D01Rik -2.44651 
Tor1aip1 -2.4448 
Runx1t1 -2.43824 
Lgr5 -2.43648 
Prrg2 -2.42328 
BC067068 -2.41687 
Ela1 -2.40697 
Irx5 -2.39742 
Adam12 -2.39657 
Mcph1 -2.39006 
Gpr176 -2.38935 
Pet112l -2.38924 
Ulk2 -2.38357 
Epc1 -2.38284 
Trub1 -2.37871 
Taf9b -2.37527 
Tmco4 -2.37516 
2410016F19Rik -2.37425 
Pus3 -2.37366 
Smo -2.36099 
Trub1 -2.35949 
Accs -2.35649 
Npr3 -2.35556 
Tceal8 -2.35316 
Mtrf1 -2.35131 
Nr1h3 -2.34465 
Rpap1 -2.32809 
Nr1d2 -2.3242 
Md-2 -2.32219 
Snx33 -2.31425 
Evi2a -2.30309 
Brd9 -2.30293 
Pkig -2.30141 
Suv420h1 -2.29587 
Mc5r -2.29446 
D030070L09Rik -2.29126 
Jmjd5 -2.29075 
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Genes downregulated more than two fold at 6 h continued
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene symbol Fold change 
Traf3ip2 -2.28773
Gulp1 -2.28493
6720458F09Rik -2.28161
Ccdc91 -2.28075
Gtf2ird2 -2.27295
Lrrk1 -2.2724
1110001A07Rik -2.26965
Sspn -2.26937
Ndufaf1 -2.26834
Gtf3c3 -2.26806
Nr2f2 -2.25612
Cul1 -2.24492
Txnl4b -2.24427
Slc39a10 -2.23987
Scmh1 -2.23846
1700025K23Rik -2.23689
Bmp4 -2.23541
Tsga14 -2.23052
Plk1 -2.22812
Rcbtb2 -2.22794
Elf1 -2.22759
Mcrs1 -2.22164
Tmem42 -2.22163
2010321M09Rik -2.22041
Qrsl1 -2.2171
Hirip3 -2.20834
Arsj -2.20612
Nrn1 -2.20592
Acsf3 -2.20041
Tpk1 -2.19297
Spag7 -2.18816
Stag1 -2.18815
Epdr1 -2.18706
Spon2 -2.18274
D030070L09Rik -2.17048
Mmp14 -2.16416
Pik3c3 -2.16369
Avpr1a -2.16249
C87436 -2.16006
Pcdhb22 -2.15989
Thnsl2 -2.15669
Il1rl1l -2.15075
Nsmaf -2.14731
Tmed1 -2.14439
Zfp236 -2.13389
Tarbp2 -2.13156
Gpx7 -2.12866
Fntb -2.12605
Aurka -2.12591
6530404N21Rik -2.12043
2610524A10Rik -2.11754
1500010J02Rik -2.11563
Gbl -2.10685
Gene symbol Fold change 
Thtpa -2.10438 
Rnf103 -2.10268 
Nt5m -2.0996 
Ing4 -2.09917 
Gtrgeo22 -2.09713 
Krt10 -2.09708 
Hbp1 -2.09662 
1810009N02Rik -2.09599 
Gnpda2 -2.08813 
Rhobtb3 -2.08728 
Tead2 -2.07968 
Tgf-b3 -2.07954 
Lrba -2.07926 
Sdpr -2.07774 
2010321M09Rik -2.07661 
Ubtf -2.07384 
Ppa2 -2.07209 
Tapbpl -2.07173 
Tmem17 -2.07136 
Mbd3 -2.0694 
Htra3 -2.06737 
Zfp710 -2.06636 
Rab11b -2.0636 
Hsd3b7 -2.06044 
BC029169 -2.05888 
Hmgb2 -2.05529 
Frk -2.0525 
2610002M06Rik -2.05154 
Npepl1 -2.04865 
2700062C07Rik -2.04637 
Zfp236 -2.04508 
Tmem209 -2.04433 
Acy3 -2.0413 
Mrpl48 -2.04005 
BC039093 -2.03696 
Eif5 -2.03329 
Acp2 -2.03292 
Cdkn2c -2.02853 
Gbl -2.02591 
Pbk -2.02301 
Kcnk2 -2.02158 
Gtf2h4 -2.02099 
Nusap1 -2.02019 
5430435G22Rik -2.02017 
Cenpa -2.01976 
Pdgfra -2.0154 
C87436 -2.01401 
2610044O15Rik -2.01325 
Prkcbp1 -2.00829 
N6amt1 -2.00617 
Thtpa -2.10438 
Rnf103 -2.10268 
Nt5m -2.0996 
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Appendix 3. Gene transcription at 24 h in response to P. gingivalis 
Genes upregulated more than two-fold at 24 h 
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Gene symbol Fold change 
Lcn2 354.7951
Saa3 143.8862
LOC100044702 111.9489
Ccl5 86.75045
Mmp3 35.80779
Cxcl9 34.95269
Ptx3 31.98103
Cxcl1 29.22046
Ptx3 27.63012
Ch25h 24.79245
Il-6 23.2266
Ccl2 20.68476
Cfb 19.94681
Slpi 19.45854
Mmp3 16.91814
Gbp2 16.32286
Ppbp 15.96733
Ppbp 14.37349
C3 14.32161
Cd74 13.14656
TLR-2 12.6473
Fas 11.48997
Il13ra2 10.90555
Cbr2 10.71476
Gbp3 10.23904
Cd74 9.774575
Nfkbiz 9.56099
Camp 9.350696
Mmp3 9.128228
Fas 8.878448
Serpinb9g 8.687324
Mmp13 8.439232
Ccl9 8.268634
Plk2 7.582802
Hp 7.483097
Zc3h12a 7.326866
Mmp13 7.29968
Hpx 7.023619
Hp 7.001449
Slc2a6 7.001397
Serpina3g 6.977099
Jak2 6.904497
Rac3 6.876009
Cxcl15 6.772895
Mt2 6.511619
IL-1α 6.450745
Slc15a3 6.305687
Gbp3 6.190493
Dnmt3l 6.156311
Osmr 6.077178
Rac3 6.024558
Tnip1 5.939297
Cxcl10 5.90929
1100001G20Rik 5.837463
Gene symbol Fold change 
Usp18 5.75763 
Nfkbia 5.736463 
LOC435337 5.705378 
Serpina3f 5.664974 
Oasl2 5.629959 
Dnmt3l 5.62634 
Nfkbie 5.53638 
Jak2 5.533565 
LOC100048346 5.50133 
Ier3 5.477968 
Vnn3 5.447197 
Junb 5.356735 
Ly6c1 4.924612 
Tnfaip3 4.751849 
Cx3cl1 4.690369 
Tnip1 4.524131 
LOC100038882 4.50169 
Socs3 4.454419 
Hp 4.341765 
Vnn3 4.326532 
Casp4 4.313249 
Il13ra1 4.126325 
1200002N14Rik 4.182948 
Cebpb 4.180982 
Zc3h12a 4.167035 
Map3k8 4.150677 
RELB 3.998608 
Dcxr 3.978684 
Casp4 3.941854 
Tnfrsf9 3.874082 
Bst2 3.779415 
Mfsd7 3.752104 
Slc7a2 3.699996 
Ccl7 3.693088 
Gbp2 3.676518 
Rcan1 3.586354 
Usp18 3.521841 
Rcl1 3.51005 
Nfkbie 3.484758 
Angptl4 3.465131 
Dcxr 3.454607 
H2-Ab1 3.43524 
Tnfsf13b 3.387728 
S100a8 3.381834 
Ereg 3.370088 
Actc1 3.352229 
Abcc3 3.27527 
Ubd 3.230891 
Sod2 3.22047 
Iigp2 3.201707 
Wfdc12 3.183889 
Ifitm3 3.178828 
Gja8 3.178367 
Tnfsf13b 3.169215 
Genes upregulated more than two-fold at 24 h continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene symbol Fold change 
4933426M11Rik 3.147578
AU018778 3.142585
Ccl17 3.136138
4930583H14Rik 3.120409
LOC100048710 3.117704
Serping1 3.113135
Ppp1r15b 3.073311
Cxcl2 3.024402
Ifi27 2.988571
Slc7a2 2.981963
Trib3 2.97513
Rcl1 2.961909
Mmp9 2.95792
Enpp2 2.938036
Ripk2 2.914385
Matn4 2.91226
Ifi47 2.909141
Mmp12 2.89754
Dgat2 2.893499
Igtp 2.854418
Cox7a1 2.826698
Rcl1 2.814322
Riok3 2.792285
Egfl7 2.787763
Plscr1 2.783824
H2-T23 2.783414
Orm2 2.76792
Csgalnact1 2.758847
Ube2l6 2.756154
VEGF 2.752308
H2-Q7 2.740188
Hif1a 2.74015
Ly6a 2.733837
Dcn 2.722417
EG630499 2.715031
Casp4 2.714532
Insl6 2.698915
Arhgdib 2.696723
Dhx58 2.690421
H2-Ab1 2.684702
Ets2 2.677864
Dcn 2.67034
Clip1 2.663725
Bcl3 2.655449
Prrx1 2.654502
Ifnar2 2.653588
Tmem176b 2.640099
Chac1 2.639009
LOC547343 2.638172
Stat3 2.622056
D14Ertd668e 2.603786
Clip1 2.601327
Hapln4 2.598229
A4galt 2.598076
C1s 2.596423
Gene symbol Fold change 
Rsn 2.591058 
LOC100046232 2.586748 
Nfkb1 2.567591 
Plscr1 2.565908 
Gadd45b 2.564189 
D12Ertd647e 2.549963 
Ifnar2 2.547994 
Ifnar2 2.542844 
Snx18 2.531356 
Gp38 2.522789 
Slco1a5 2.516495 
P2rx4 2.514034 
Tnip1 2.512111 
C1s 2.509864 
LOC626578 2.508939 
9130213B05Rik 2.50837 
P2rx4 2.500625 
Gdnf 2.49757 
VEGF 2.480708 
Plscr2 2.464677 
Irf1 2.463881 
Parp14 2.447776 
Skil 2.439202 
Prrx1 2.436542 
Gstt1 2.431473 
Lbp 2.41984 
Stat3 2.411036 
Irf9 2.404343 
Susd2 2.395802 
Adora2b 2.385239 
D12Ertd647e 2.383773 
Slc11a2 2.365842 
Stat3 2.359274 
Irf1 2.344791 
Ctps 2.33914 
Ifit3 2.336982 
Irf1 2.331641 
F13a1 2.329826 
H2-T23 2.325076 
Riok3 2.324276 
Hgf 2.321185 
LOC667370 2.308213 
Irf1 2.306419 
Npy1r 2.305056 
Cxcl4 2.30002 
Ddt 2.300006 
Tnfrsf9 2.285822 
Irak3 2.283404 
Rasl12 2.28032 
C4b 2.276476 
Ptgs2 2.276068 
Prrx1 2.269099 
Macrod1 2.264048 
Serpinb6b 2.263698 
Gypc 2.262248 
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Genes upregulated more than two-fold at 24 h continued 
 
 
 
 
Gene symbol Fold change 
Lrrc8 2.246792
Mmp13 2.245348
Col18a1 2.234789
Ddx58 2.209375
Trim47 2.20855
Cdc42ep3 2.201048
Sars 2.199899
Asns 2.189598
Ctps 2.179705
Nfkb2 2.173142
Sbno2 2.165198
LOC56628 2.163463
Nadk 2.149603
Tmod1 2.1477
Rrbp1 2.134948
Ctps 2.12349
Cd14 2.121116
D14Ertd668e 2.120823
Ifit3 2.119507
Akp2 2.115837
Sphk1 2.103179
Asns 2.100091
Pla1a 2.097374
Rffl 2.097132
Psmd10 2.088839
Tcp10a 2.084519
Timp1 2.07527
LOC100044190 2.067314
Slit2 2.061944
Adamts7 2.055568
Dusp16 2.052084
Rhou 2.049477
Il10rb 2.048616
A630077B13Rik 2.041595
EG317677 2.040942
H2-M3 2.035108
Bckdhb 2.032184
1110008P14Rik 2.030749
Gstt3 2.030136
Cyp4f14 2.025628
Dtwd1 2.018756
Nab1 2.015766
Lmo4 2.012415
2010002N04Rik 2.009882
CD68 2.001726
Lxn 2.00117
 199
Genes downregulated more than two-fold at 24 h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene symbol Fold change 
Sult1a1 -4.62267
Krt13 -4.41691
Gper -4.38766
Aldh3a1 -3.41507
Osr2 -3.31904
Cldn15 -3.19474
Slc40a1 -3.163
Inmt -3.13242
Ccnd1 -3.12871
Sox9 -3.06391
Il17rd -3.01461
Efnb2 -2.99538
Ctnnal1 -2.95605
Ptprv -2.94636
Ermp1 -2.93965
Mgp -2.92179
Spon2 -2.84905
Htra3 -2.82317
Ppl -2.75327
Fdxr -2.7242
Sep-06 -2.66337
Efnb1 -2.64868
Abca9 -2.60776
Ppp1r3c -2.59233
Lbh -2.56834
Ccnd1 -2.56352
Cldn15 -2.5557
Pdk4 -2.52822
Hist1h2ah -2.49804
Hist1h2an -2.47889
Tgf-b3 -2.47749
Fdxr -2.46582
Ndrg1 -2.46309
Rin2 -2.44748
Tgm5 -2.44181
Sep-06 -2.43941
Hist1h2af -2.41087
Pacs2 -2.39414
Nxph2 -2.39089
Hist1h2ak -2.38737
Rarb -2.38412
Ccnd1 -2.38366
Cldn15 -2.38091
Aqp1 -2.37443
Emp1 -2.36062
Centg2 -2.34688
Hist1h2ad -2.34156
Pxmp4 -2.33454
Il15 -2.33392
Rin2 -2.33246
Il15 -2.33114
Hist1h2ao -2.32076
Pdlim2 -2.31868
 200
10. Supplementary Material 
Supplementary material consists of attached publications derived from work in this 
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